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ABSTRACT 
 
BLOCKING IMMUNOSUPPRESSIVE FACTORS AND TAKING ADVANTAGE OF THE 
NUTRIENT SUPPLY WITHIN THE TUMOR MICROENVIRONMENT: PATHWAYS TO ACHIEVE 
IMPROVED CANCER IMMUNOTHERAPEUTIC EFFICACY FOR PATIENTS WITH 
METASTATIC MELANOMA 
Ying Zhang 
Hildegund C.J. Ertl 
 
The incidence of melanoma is increasing. Immunotherapy commonly fails due to the 
immunosuppressive tumor microenvironment (TME). The aim of my dissertation is to develop 
strategies that dampen the TME’s immunosuppressive capacity and improve the antitumor 
performance of vaccine-induced melanoma-associated antigen (MAA)-specific CD8+T cells. I 
pursued this goal using three approaches. First, interactions between co-inhibitors on CD8+ 
tumor-infiltrating lymphocytes (TILs) with immunoinhibitory ligands within the TME impair T cells’ 
effector functions.  I assessed whether blocking immunoinhibitory signaling during T cell priming 
augments their antitumor activity. I designed a melanoma vaccine expressing MAAs within 
herpes simplex virus (HSV) glycoprotein D (gD), which blocks the inhibitory BTLA/CD160-HVEM 
pathway. Compared to a non-gD vaccine, the gD-adjuvanted vaccine enhances CD8+T cells to 
low avidity epitopes and prolongs survival of tumor-bearing mice. gD renders MAA-specific 
CD8+TILs more resistant to functional impairment within TME,  which increases their ability to 
limit tumor progression. Second, the stroma of solid tumors is crucial for tumorigenesis and 
suppresses the CD8+TILs’ effector functions. To determine whether destroying tumor stroma 
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could improve the MAA-specific CD8+T cells’ tumoricidal capacity, I designed a vaccine targeting 
the fibroblast activation protein (FAP), which is expressed at high levels on tumor-stromal 
fibroblasts. Combining the vaccines to FAP and MAAs significantly improves the survival of 
tumor-bearing mice.  This is caused by destruction of FAP+ cells, which reduces frequencies and 
inhibitory functions of immunosuppressive cells. It also decreases the MAA-specific CD8+TILs’ 
metabolic stress and delays their progression towards functional exhaustion. Finally, the TME 
commonly lacks nutrients and oxygen needed for the CD8+TILs’ energy production. My data 
demonstrate that these metabolic challenges profoundly contribute to the CD8+TILs' functional 
impairment. Using 13C-stable isotope tracing in vivo, I show that metabolically stressed CD8+TILs 
in late stage tumors increasingly depend on fatty acids (FAs) catabolism for energy production. 
Promoting FA catabolism by CD8+TILs improves their effector functions and capacity to delay 
tumor growth. Overall, my studies show that blocking inhibitory factors while taking advantage of 
the available nutrients within the TME could improve the performance of vaccine- or adoptive 
transfer-induced CD8+TILs. These strategies provide new avenues for cancer immunotherapy 
that may benefit cancer patients.  
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Chapter 1 
 
INTRODUCTION 
 
 
 
1.1 Melanoma: discovery, development and epidemiology 
	
      Melanoma, the most aggressive and lethal form of skin cancer, is an impending 
health problem with a long history. Hippocrates was the first to record the disease as melas 
(dark), and oma (tumor) in the 5th century BC. Samuel Cooper in 1844 formally acknowledged the 
untreatable nature of melanoma and stated that “ the only chance for benefit depends on early 
removal of the disease” (1). This statement still holds true today even with advances in our 
scientific knowledge. The study of melanoma development and treatment in the 19th and early 
20th century progressed slowly and were mainly descriptive in nature. In 1956, Henry Lancaster 
for the first time pointed out the direct link between ultraviolet (UV) radiation exposure and 
melanoma incidences. Further work by Lancaster and Nelson identified the association between 
pale skin/hair color and melanoma development. This was confirmed by recent work, which 
identified the UV-mediated activation of a highly polymorphic protein called melanocortin receptor 
1 (MC1R)(2). MC1R variants associated with pale skin phenotype are linked to deficiency of 
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melanin production in the skin upon UV exposure and compromised photoprotection. Other early 
genetic studies based on “melanoma families” identified mutations associated with CDKN2A 
gene, which regulates cell cycle entry at G1 checkpoint and p53 stabilization, conveys enhanced 
risk of melanoma formation(3). These works identify melanoma as a genetic disease and provide 
some mechanistic insights into the pathogenesis of this highly malignant lesion.  
     Today we know that metastatic melanoma arises from transformed melanocytes in 
75% of the cases and from nevus in 25% of the situations (4-6). Melanoma pathogenesis is a 
complicated process that requires the interplay of environmental and host factors. It is a 
genetically and phenotypically heterogeneous disease; each tumor bears its unique combinations 
of epigenetic and genetic mutations and occurs at different body locations. Cancer genome deep 
sequencing has revealed that, with a median number of >10 mutations per megabase of DNA, 
melanomas carry the highest mutational load of all human tumors and harbor an overwhelming 
number of UV-signature mutations (7). Besides the commonly mutated genes BRAF, NRAS, 
PTEN, TP53, and p16, new candidate genes such as PPP6C, RAC1, STK19, PREX2 have been 
identified through large-scale melanoma exome sequencing (7-9). In most cases melanoma 
development is a multistep process regulated by a key set of genes. Cells must acquire 
sequential genetic alterations, including constitutive oncogenic pathway activation and loss of 
functions for tumor suppressor genes in order to form tumors and metastases (Figure 1-1). Since 
melanomas from a certain location and with different UV exposure histories often bear unique 
genetic mutation signatures, it was proposed that melanoma could be molecularly classified 
based on these factors (10). For example, the well-known BRAFV600E mutation occurs in up to 
80% of nevus-derived cancers and is more common in melanomas arising on intermittent sun-
exposed areas, while sun exposure-induced or mucosal and acral melanomas usually have no 
BRAF mutation but have higher rates of KIT alterations (11).  
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Figure 1-1: Hypothetical model of melanoma development from a pre-existing nevus following a 
cascade of genetic mutations that leads to tumor formation and metastasis. Figure is adapted from 
Bertolotto, 2013(6). 
     Although melanoma represents less than 5% of all skin cancers, it is responsible for 
over 75% of skin cancer-related deaths. Despite intensive research, public campaigns and 
screenings programs, the incidence of melanoma has been increasing at a steady rate over the 
last 8 decades, and its death rate continues to rise (5). In the early stages melanoma can be 
cured by surgical resection. However, the deeper melanoma invades into the skin, the worse the 
prognosis becomes due to increased chance that cancer cells metastasize to lymph nodes and 
visceral organs. Once it has progressed to the metastatic stage, melanoma is extremely hard to 
treat and largely refractory to current therapies (12). The median survival of patients with stage IV 
melanoma is less than 1 year (13).  
1.2 Current treatment strategies 
	
     For patients with primary cutaneous melanoma with negative (localized) or positive 
(locoregional) regional lymph node invasion, surgery is the gold standard treatment. However, for 
the majority of patients with distant metastatic disease, the benefit from surgery is quite limited 
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and can only be curative in rare cases (9). Instead, systemic treatment strategies such as 
chemotherapy and immunotherapy play a major role in treating these advanced stage 
melanomas.  
     Prior to 2011 when I proposed my doctoral thesis, systemic therapy was limited to 
chemotherapy with agents such as dacarbazine, temozolomide and fotemustine; high-dose 
interleukin (IL)-2 or interferon alpha-2b administration and combination biochemotherapy. 
Adoptive cell transfer and cancer vaccines studies were in preclinical or Phase I-III clinical trials. 
Although promising clinical responses have been seen in some patients, none of these methods 
demonstrated an improvement in median progression-free survival (PFS) or overall survival (OS) 
based on randomized phase III clinical trial (14,15). However, since 2011 with the improved 
understanding of the BRAF-MEK-ERK mitogen-activated protein kinase (MAPK) pathway and 
breakthrough findings in the cancer immunotherapy field, the landscape of systemic therapeutic 
approaches has dramatically advanced. Four new agents, after demonstrating significant 
advantages in response and survival compared to traditional chemotherapy, have been approved 
by FDA. These include the MEK inhibitor trametinib (MekinistTM, 2013), the RAF inhibitors 
vemurafenib (ZelborafTM, 2012) and dabrafenib (TafinlarTM, 2013), the anti-programmed cell death 
protein (PD)-1 monoclonal antibody nivolumab (OpdivoTM, 2014) and pembrolizumab (2014) and 
the anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) monoclonal antibody ipilimumab 
(YervoyTM, 2011).  
1.2.1 Oncogene-targeted small molecule drugs 
    Stratton and colleagues reported the seminal discovery of oncogenic BRAF mutations 
in 2002(16). The most common BRAF valine-to-glutamic acid alteration at codon 600 has been 
characterized in more than 50% of human melanomas (17,18) and to a lesser extent in some 
other cancers(19). BRAFV600E mutation occurs early during melanomagenesis, which produces a 
senescence-like state in melanocytes that is insufficient to transform these cells by itself(20). 
However as BRAF is upstream of the MAPK pathway, studies have shown that the presence of 
mutated BRAF confers a stringent tumor dependency on MAPK signaling. RAF enzymes could 
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form “side-to-side” dimers between two RAF enzymes or heterodimers with RAF-related pseudo-
kinase KSR (kinase suppressor of Ras), which can catalytically trigger the constitutive 
phosphorylation and activation of MEK (21). Knocking down mutated BRAF or its inhibition by 
selective small inhibitors can significantly suppress the growth of melanoma cells (22,23). The 
FDA-approved RAF inhibitors have modest preference for the mutated form of B-RAF compared 
to wild-type B-RAF. In addition, the inhibitors have differential ability to inhibit the activity of over 
200 kinases and could potently suppress ERK phosphorylation and tumor cell proliferation in 
BRAFV600E cell lines (24).   
    Although both RAF and MEK inhibitors achieve potent antitumor activity in melanoma 
patients with BRAFV600E mutation, resistance develops at a median time of 6-7 months (25,26). 
Several models have been proposed that could explain the mutant cell drug resistance, including 
overexpression of the mutated BRAF, acquisition of NRAS or MEK1 mutations and post-
transcriptional splice variant of the mutated BRAF with enhanced dimerization capacity (11). The 
bottom line is that BRAF or MEK inhibitors create high selection pressure for melanoma cells 
survival, and cells with any new mechanism to reactivate or bypass the MAPK signaling will likely 
lead to resistance. Combining the BRAF and MEK signaling pathway inhibitors is a strategy that 
can suppress the MAPK pathway more effectively. In three phase III clinical trial, patients with 
BrafV600E-metastatic melanoma showed significantly improved response rate with this combination 
therapy compared to those receiving monotherapy and had a longer median PFS (27-29). The 
FDA has granted approval to the combined therapeutic strategy of dabrafenib and trametinib in 
2014.  Although BRAF and MEK inhibitors have achieved groundbreaking success in prolonging 
melanoma patient survival, there is the caveat that this strategy only works in ~50% of the 
patients with BRAFV600E mutation. In addition, one clinically untenable situation is the occurrence 
of multiple distinct resistances within different metastatic sites in one patient. Therefore, other, 
more universal and efficient therapeutic strategies are still urgently needed.  
1.2.2 Immunotherapy 
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    Immunotherapies rely on taking advantage of the host immune system to induce an 
anti-tumor immune response. Melanoma is highly immunogenic, with naturally occurred immune 
responses that could control melanoma growth or even lead to spontaneous tumor 
regression(30). Cellular inflammation, mainly tumor-infiltrating CD4+ and CD8+ T lymphocytes 
have been detected in regressing melanomas(31). In addition, tumor-associated antigens (TAAs) 
that could induce tumor-specific B and T cell responses were identified in melanoma earlier than 
in other cancer types(32,33). These advantages make melanoma an ideal cancer type for 
immunotherapy study.  
1.2.2.1 Immune checkpoint inhibitors: 
    Immune checkpoints are a plethora of immunoinhibitory molecules expressed on T 
lymphocytes, which could bind to their receptor ligands on antigen-presenting cells (APCs) or 
tumor cells. Under physiological conditions, immunoinhibitory molecules are upregulated upon T 
cell activation, which put ‘breaks’ on T cells to prevent their overactivation. These are crucial 
molecules for maintaining self-tolerance and adjusting the duration and amplitude of physiological 
immune responses in peripheral tissue to minimize damage (34). Tumor cells or stromal cells 
within the tumor microenvironment (TME) usually overexpress inhibitory ligands, which dampen 
antitumor T cell responses. Antibodies that block the T cell-tumor cell inhibitory interaction can 
dramatically enhance the antitumor T cell responses and have achieved remarkable successes in 
the clinic.  
     Ipillimumab: CTLA-4 is the first immunoinhibitory molecule that was used clinically. It 
regulates the amplitude of immune response early after T cell activation and is exclusively 
expressed on T cells (34). CTLA-4 outcompetes T cell costimulatory receptor CD28 in binding 
CD80/CD86 ligands on APCs or tumor cells; therefore it dampens the activation of T cells (35). 
Several studies suggest that CTLA-4-CD80/CD86 ligation activates the protein phosphatases 
SHP2 and PP2A, which counteracts the kinase signals induced by T cell receptor (TCR) ligation 
and CD28 co-stimulation (36). Other studies show that CTLA-4 could sequester or remove 
CD80/CD86 ligands on APCs, therefore blocking their interaction with CD28 (37). CTLA-4 is also 
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expressed on helper T cells and regulatory T cells (Tregs). Blockade of CTLA-4 leads to markedly 
higher immune responses that are dependent on helper T cells and reduces the 
immunosuppressive activity of Tregs (38,39). Humanized anti-CTLA-4 antibody ipilimumab, which 
boosts the endogenous antitumor immune response if given alone, was the first immunotherapy 
that showed improved survival for patients with metastatic melanoma. In phase III clinical trial, 
nearly double the rates of patients treated with ipilimumab combined with dacarbazine showed 
durable responses and 3-year overall survival compared to patients treated with dacarbazine 
alone (40).  
        Anti-PD-1/PD-L1 antibodies: PD-1 is another potent immunoinhibitory molecule 
upregulated on activated T cells. Unlike CTLA-4 ligation that inhibits T cell activation, PD-1 mainly 
inhibits T cell effector responses at the site of inflammation or within tumor through binding to 
PD1 ligand 1 (PD-L1) or PD-L2 (41). The activation of PD-1 signaling dampens TCR ligation 
induced kinase activity through phosphatase SHP2 (42). PD-1 is one of the signature co-
inhibitors that is upregulated early on ‘exhausted’ T cells during chronic infection and cancer (43). 
Blockade of PD-1 signaling on these cells may partially reverse the functional exhaustion of 
effector T cells and therefore improve their antitumor efficacy (44). Moreover, unlike CTLA-4, PD-
1 expression is also detected on B-lymphocytes and nature killer (NK) cells, where it restricts their 
lytic functions (45,46). Anti-PD-1 antibody therefore can also improve tumor-killing efficacy 
through enhanced NK cell activities. In phase III clinical trial, PD-1 blocker nivolumab was 
associated with significantly enhanced PFS and OS compared with dacarbazine for patients with 
metastatic melanoma without BRAF mutation (47). Furthermore, another phase III trial showed 
that pembrolizumab could prolong PFS and OS and exhibit endless toxicity compared to 
ipilimumab in patients with advanced melanoma (48). Besides PD-1 inhibition, PD-L1 inhibitors 
received similar attention due to their high expression on tumor cells and tumor stroma cells in 
many types of cancers, including metastatic melanoma (49). In addition, PD-L1 is expressed on 
myeloid cells in the TME (50). There are two major pathways that promoted enhanced PD-L1 
expression on tumor cells, either through oncogenic signaling (innate immune resistance) (51,52) 
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or the production of IFN-γ via T cells interacting with tumors by PD-1-PD-L1 ligation (adaptive 
immune resistance) (53). Anti-PD-L1 antibodies are under development and have shown 
promising results.  
    In 2015 FDA approved the combined usage of nivolumab with ipilimumab for patients 
with metastatic melanoma, as the combined treatment showed markedly improved PFS than 
single agent treatment(54). The study dictates future applications of combined therapies targeting 
multiple factors within TME to achieve enhanced antitumor efficacy. 
        
1.2.2.3 Cancer vaccines 
    Cancer vaccines aim to harness the patients’ own immune system to recognize tumor 
cells as ‘foreign. Their goal is to generate or boost effective immune responses to destroy tumor 
cells.  This is a difficult task due to the high mutation rates of melanoma antigens, unique 
combinations of mutations and diversified haplotypes in each melanoma patients and the 
complex and immunoinhibitory nature of the TME.  
   Melanoma antigens  
     One major factor that determines the efficacy of cancer vaccines is the set of antigens 
they express. The identification of large number of melanoma-associated antigens (MAAs) has 
facilitated vaccine design. MAAs can be characterized into several categories:  
(i) Neo-antigens are tumor-specific antigens (TSAs) that are the results of numerous nucleotide 
point mutations, alternative transcripts or products from cryptic start sites, alternative reading-
frames, pseudo-genes or antisense strands of DNA(33,55,56) generated during melanoma 
development. Novel T cell epitopes can be processed and presented depending on the HLA 
species in individual patients, and are recognized by CD8+ and CD4+ T cells. In addition, many 
proteins during melanoma transformation become phosphorylated, i.e. phosphorylated β-catenin, 
IRS2, generating unique phosphorylated epitopes(57).  
(ii) Cancer testis antigens are a family of antigens that are only expressed in spermatozoa, some 
ovarian tissues and trophoblasts; they are normally silenced in somatic cells. These antigens can 
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re-emerge on tumor cells, often due to hypomethylation or histone acetylation of the genes(58). 
Proteins such as MAGE-1 and NY-ESO-1 belong to this category.  
(iii) Melanoma-differentiation antigens are tissue-specific antigens expressed on normal 
melanocytes, which are usually overexpressed on melanoma cells. Carbohydrate antigens, 
particularly gangliosides and melanosome membrane glycoproteins, i.e., tyrosinase-related 
protein (Trp)-1, Trp-2, gp100, tyrosinase and MART-1, belong to this subset(59). Although high-
avidity T cells against self-antigens are deleted during thymic selection, low-avidity T cells remain 
which could mount immune responses with enhanced antigen load and tumor-associated 
inflammation(60). This is confirmed as spontaneous T cell responses to melanoma-differentiation 
antigens can be detected in cancer patients(61).  
  
Current approaches 
     Thus far melanoma vaccines have taken a variety of shapes and forms, ranging from 
whole-cell tumor preparations to recombinant viral vectors and exhibited different antitumor 
efficacies in preclinical models and patients with advanced melanoma. 
(i) Peptide vaccines: Early vaccine trials using MAA-derived peptides showed low response rates 
and no indication of efficacy(15,62). This could be due to low avidity of the available T cell 
repertoire in patients. Further studies using modified peptides with enhanced HLA binding 
capacity enhanced the MAA-specific CD8+T cell responses elicited in patients, although they still 
showed only limited clinical benefit(63). These paradoxical outcomes may result from the 
suboptimal induction of T cell responses by dysfunctional tumor-influenced APCs, downregulation 
of antigen-presenting molecules on tumor cells, mutations of tumor antigens under selection 
pressure and the immunoinhibitory factors within TME(64).  To circumvent the outgrowth of 
antigen-loss variants, multipeptide immunization studies have been carried out. Some patients 
upon receiving this vaccine regimen showed prolonged PFS, which encourages more studies to 
understand factors that contribute to the success of these vaccine with the hope that their clinical 
potential can be maximized to benefit patients with advanced stage melanoma(65).  
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(ii) DNA/viral vector based vaccines: Naked DNA vaccines with electroporation are capable of 
inducing T cell responses in advanced melanoma patients, although similar as peptide vaccines 
they have thus far shown little to no antitumor efficacy(66,67). Other vectors as tumor-antigen 
delivery vehicles, such as attenuated bacteria S. typhimurium, alphavirus, coronavirus, vaccinia 
virus or adenovirus-based vaccines were shown to trigger inflammation and anti-viral danger 
signals that could enhance immune response to transgene(68,69). In some of the trials viral 
vector mediated gene delivery induced high avidity effector CD8+T cell responses, and achieved 
regression of melanoma metastases and stable disease in a small proportions of melanoma 
patients(70,71). The differences in clinical outcomes highlight the importance to conduct more 
detailed studies to optimize the vectors, transgenes, vaccine regimens and other factors to 
improve the antitumor immune responses of the vaccines.  
  Adenovirus as vaccine carrier: For my thesis project the chimpanzee-derived adenoviral 
(Ad) vector of serotype 68 (AdC68) was selected as the vaccine backbone. Adenovirus contains 
26-45kb pairs long linear, double stranded DNA genome that is surrounded by a non-enveloped 
icosahedral capsid. Ad can be modified into early (E)1 gene deleted replication-defective 
vectors(72) This deletion furthermore increases the space within the viral genome for insertion of 
transgenes(73). Importantly, Ad vectors are powerful vaccine delivery vehicles as they can induce 
innate immune responses in mammalian hosts and therefore exert adjuvant effects needed to 
elicit strong and sustained transgene product-specific immune responses upon a single dose 
injection(74,75). Moreover, Ad vectors have a broad tropism; they can transduce a series of 
different cell types(76). Ad vectors persist. After clearance of Ad-transduced cells at the site of 
vaccination, Ad vectors remain transcriptionally active at very low levels within muscles at 
injection site, livers and T cells including those directed to Ad vector encoded antigens(77). The 
continued presence of low amount of tumor antigens expressed by Ad vectors helps to maintain a 
fairly high population of effector and effector memory T cells against melanoma cells, which can 
be highly advantageous in suppressing cancer progression. One potential caveat of using Ad 
vectors as vaccine delivery vehicles is the high prevalence of neutralizing antibodies to human Ad 
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vectors, which may dampen T cell responses to Ad-delivered transgenes. To circumvent this 
problem, both serologically rare human Ads, such HAdV-26 and HAdV-35, and Ads that naturally 
infect non-human primates, such as chimpanzee-derived serotypes AdC6, AdC7 and AdC68 can 
be used as vaccine carriers(78). Vaccines based on these Ad vectors have achieved promising 
results in preventing or treating infectious disease and cancer in both preclinical and clinical 
studies.  
(iii) Dendritic cell (DCs) based vaccines: One reason for the poorly activated CD8+T cell 
responses by cancer vaccines in melanoma patients may be explained by the insufficient antigen-
presentation by DCs. This could be due to tumor-derived factors, including inhibitory cytokines 
and Tregs, which dampen the functions of DCs. To overcome this problem, exogenous DCs can 
be pulsed with different forms of tumor-antigens (TAs), in the form of whole proteins, peptides, 
messenger RNAs or transgenes of viral vectors and be utilized as vaccines. These DCs have 
been matured and activated in vitro, thereby bypassing the processing and presenting of TA-
derived epitopes by endogenous functionally compromised DCs in cancer patients. Various 
strategies have been studied to optimize exogenous DC-based vaccination protocols(79-81). A 
recent study has shown that a peptide-loaded DC vaccine targeting both helper CD4+ and CD8+T 
cells could enhance antitumor CD8+T cell responses and lead to improved clinical outcome in 
melanoma patients(82). In a study reviewing 32 clinical trials on DC-based vaccines, clinical 
responses were significantly correlated with the selection of antigens, the use of helper antigen or 
adjuvant and the induction of TA-specific T cells(83). Despite the success in many melanoma 
patients, the CD8+T cell responses induced are usually transient and there are still significant 
portions of patients who show little responses to this vaccine approach. Modulating other factors 
within DCs or effector T cells, i.e. different maturation stimuli, subsets of DCs used and route of 
vaccination, the mechanism of antigen delivery or blocking immunoinhibitory signals on CD8+T 
cells or Tregs may enhance the clinical success of this immunotherapy(84-88).  
 
1.2.2.3 Adoptive Cell Therapy 
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     Adoptive cell therapy (ACT) has achieved very promising clinical results in a good 
proportion of patients with advanced metastatic melanoma. ACT works by transferring T cells with 
direct antitumor capacities into cancer patients.  This approach bypasses the necessity of eliciting 
TA-specific T cell responses by cancer vaccines in the immunoinhibitory environment of cancer 
patients. Instead it could introduce large numbers of antitumor T cells with selected tumor 
reactivity, avidity, proliferation potential and effector functions(89). Moreover, the TME of cancer 
patients can be modified to create a better niche for the performance of TA-specific T cells prior 
to cell transfer.  
Autologous tumor-infiltrating lymphocytes (TILs) with lymphodepletion 
    The first clinical trial with ACT was conducted in metastatic melanoma patients using 
autologous TILs expanded in IL-2 in vitro(90). Although 34% of the patients showed objective 
regression of cancer, the responses did not last long and the transferred T cells disappeared fast 
in circulation after the cell transfer. To overcome these limitations, in a later study the isolated 
autologous TILs were screened for their antitumor activity and TILs populations with high reactive 
potentials were expanded. In addition, ACT was conducted immediately after a nonmyeloablative 
lymphodepleting chemotherapy, which led to markedly improved clinical responses and complete 
tumor regression was achieved in some patients(91). Lymphodepletion contributes significantly to 
the positive outcome of ACT, which may result from the depletion of Tregs and myeloid-derived 
suppressor cells (MDSCs) that inhibit effector T cell functions(92). Other studies show that 
lymphodepletion increases the T cell growth factor IL-15 in blood in patients, which facilitates the 
expansion of transferred cells(93).  
 
TILs targeting mutated melanoma-specific antigens 
    Besides the use of autologous TILs for ACT, recent studies show that transfer of T 
cells that recognize a specific mutated melanoma-specific antigen may achieve better antitumor 
efficacies. Melanoma is characterized by high mutation rates. One exomic mutation rates study 
show that melanomas and non-small cell lung cancers have 100 mutations/Mb, which are much 
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higher than those of other cancer types(94). Studies using other immunotherapeutic regimens 
suggest that T cells recognizing some mutated TAs naturally exist in the TME of melanoma 
patients. Dr. Linettes’s group and Dr. Rosenberg’s group have developed new methods to 
produce T cells targeting mutated melanoma antigens that could mediate complete cancer 
regression(89,95).  
    In order to determine which mutated antigens are immunogenic, polypeptides 
containing the mutated amino acid (AA) flanked by 10-12 unmutated AAs were linked and 
predicted with high binding capacity to the patient’s HLAs. Those with the most promising binding 
potential (scores) were pulsed onto autologous APCs and cocultured with TILs. T cells with high 
reactivity and effector functions, which showed enhanced activation markers, could be expanded 
and infused back into cancer patients(96). As the prediction of peptide binding with some HLA 
molecules is not accurate, a minigene approach can be used(97). Minigenes containing the 
mutated genes flanked by normal sequences on each side were linked and transduced into 
patient’s autologous APCs, in order to be processed and presented for recognition by TILs. 
These study show that each mutation recognized by TILs was from a distinct protein, and each 
melanoma sample possesses its unique immunogenic mutated proteins. TILs with antitumor 
capacity in these patients were reactive to random somatic mutations of melanoma cells. Clinical 
trials using expanded TILs or engineered chimeric antigen receptor (CAR) T cells targeting 
immunogenic mutated melanoma antigens led to dramatic regression of metastatic melanoma 
and significantly improved clinical outcomes, suggesting future studies with cancer vaccines or 
CAR T cells designed to target cancer-specific mutated antigens instead of overexpressed self 
antigens may achieve better therapeutic efficacy.  
 
CAR T cells 
    To apply ACT to non-immunogenic cancers with limited T lymphocytes infiltration, CAR 
T cells were developed in which T cells isolated from the circulation are transduced with retroviral 
vectors. The vectors express variable regions of antibody heavy and light chains recognizing a 
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surface molecule on tumor cells, which are further linked to the intracellular signaling domains of 
T cell receptors (TCRs), including CD3-zeta chain together with costimulatory domains. CAR T 
cells recognize antigens expressed on target tumor cells without MHC restriction, and send T cell 
activation signals that could trigger their antitumor effector functions. Since 2010, CAR T cells 
have achieved great successes in treating CD19+ lymphoma and leukemia (ALL and CLL) 
(98,99). One major limitation of CAR T cells, however, is that they may recognize antigens not 
only expressed on tumor cells but also within normal tissues.  
   Further development of ACT for immunotherapy of melanoma and other non-
immunogenic solid tumors depends on selecting the ideal T cell population with higher 
proliferation potential and survival advantage in the TME, as well as searching for suitable targets 
for transferred TCRs or CAR T cells. Preclinical studies have implied that less differentiated 
central memory T cells would be more potent at mediating tumor regression compared to effector 
memory T cells or effector T cells(100,101). Moreover, many studies have suggested that CD4+T 
cells also play an important role in the antitumor immune responses(102), therefore the transfer 
of TCRs or CAR CD4+T cells alone or in combination with CD8+T cell populations may provide 
survival advantage for patients with metastatic cancer. Finally, ACT usually targets a single ‘self’ 
or ‘mutated’ antigen, which may enhance the selection pressure against that antigen and lead to 
antigen-loss or further mutations. It would be worthwhile to combine several TCRs or CAR T cells 
subsets with different antigen specificities for ACT and investigate its impact on suppressing 
tumor growth.  
 
1.3 Challenges within the TME and their impacts on T cells 
	
     Although novel melanoma treatment strategies, especially immunotherapy have 
achieved significant progresses in suppressing tumor growth and have markedly benefited a 
portion of patients with metastatic melanoma, the overall response rate is still low and more 
studies have to be conducted to further improve the efficiency of melanoma immunotherapy. 
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1.3.1 T cell exhaustion 
 1.3.1.1 Characteristics of exhausted T cells 
    One major barrier that blocks the efficiency of antitumor T cells is their ‘functional 
exhaustion’ they experience over time within the TME. T cell exhaustion was first described 
during chronic LCMV infection in mice, and was subsequently identified in human with HIV, HBV 
or HCV infection and cancer. T cell exhaustion is a hyporesponsive status of T cells characterized 
by sequential upregulation of co-inhibitory molecules on T cells and loss of effector T cell 
functions in a hierarchical manner. Exhausted T cells usually express enhanced levels of PD-1, 
lymphocyte activation gene 3 protein (LAG-3), CD244 (2B4), CD160, CTLA-4, T-cell 
immunoglobulin domain and mucin domain protein 3 (TIM-3) and so on(103). Functions such as 
IL-2 production and cytotoxic capacity are lost first, while production of tumor necrosis factor 
(TNF)-α and proliferation potentials are lost in the middle stage; IFN-γ production is lost at the 
advanced phase of exhaustion(43).  
     Both functionally exhausted CD8+ and CD4+ T cells possess unique transcriptional 
signatures that distinguish them from effector or memory T cells. Genes involved in co-stimulatory 
and co-inhibitory molecules expression, T cell signaling pathways, cytokines productions and 
various metabolism pathways are all significantly affected(104,105). Transcriptional factors T-bet 
and Eomes are well studied in exhausted T cells; they define the lineage of these cells and have 
crucial functions in maintaining the pool of exhausted T cells with certain antigen specificity. They 
mediate exhaustion-specific functions that are different from their functions in effector T cells. 
During acute infection, T-bet plays an important role in the formation of terminally differentiated 
cells while Eomes is involved in maintaining the homeostatic proliferation of central memory T 
cells(106,107). However in the case of chronic infection, T-bet suppresses the expression of PD-
1 and maintains the proliferative potential of a fraction of exhausted T cells while Eomes is 
associated with the terminal differentiation of exhausted T cells(108). The T-bethiPD-1int cell 
population maintains a pool of exhausted antigen-specific T cells with weak effector functions, 
while a larger EomeshiPD-1hi cell subset is more terminally differentiated but has better cytotoxic 
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function. Both factors are crucial for the long-term maintenance of the exhausted T cells, 
depleting either factor will result in the disruption of immune system-pathogen/cancer balance 
and lead to accelerated disease progression. These findings have been observed in human HCV 
and HIV infection(108,109). In addition, many other transcription factors, such as Blimp1, NFAT, 
FoxO1 have special functions in regulating exhausted CD8+T cells. More recently, it was found 
that co-inhibitors expression during T cell exhaustion is also regulated at the epigenetic level, 
suggesting another important layer of gene regulation in exhausted T cells that may imprint the 
exhaustion in the epigenome(110).  
1.3.1.2 Mechanisms that contribute to T cell exhaustion within TME 
    Continuous antigen stimulation is traditionally viewed as the cardinal cause of T cell 
exhaustion. The level of antigen persistence during mouse LCMV infection or human HIV 
infection positively correlates with the severity of exhaustion (111,112). TME possess abundant 
tumor antigens, which combine with the inflammation in the microenvironment may contribute to 
the formation of exhausted antigen-specific TILs. In addition, TME contains various 
immunoinhibitory factors, such as inhibitory ligands, tumor stromal cells, immunosuppressive 
cells, inhibitory cytokines and deprivation of key nutrients, which form a dense network that may 
directly or indirectly promote T cell exhaustion.  
Inhibitory ligands: Tumor cells, tumor stromal cells and other cells within TME usually show 
enhanced expression of different inhibitory molecule binding ligands, which through binding with 
co-inhibitory molecules overexpressed on TILs could send non-redundant signals that adjust the 
magnitude of T cell exhaustion. One of the most prevalent pathways in melanoma TME is the PD-
L1-PD-1 interaction. Melanoma cells with enhance PD-L1 expression are mainly found in 
proximity to IFN-γ producing TILs, suggesting that immune response within melanoma TME 
contributes to PD-L1 expression, a phenomena termed “adaptive immune resistance”(113). The 
mechanism through which this pathway leads to T cell dysfunction is not well understood. Some 
studies suggest that PD-1 may modulate the activity of signaling networks downstream of the 
TCR by recruiting phosphatases SHP-1 and SHP-2 to its immunoreceptor tyrosine-based 
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inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM), which 
dephosphorylates the TCR signaling intermediaries and suppress downstream pathways 
including PI3K/ AKT/mTOR and RAS signaling(114). 
Immunosuppressive cells: The presence of Tregs, MDSCs, tumor-associated macrophages 
(TAMs), tumor stromal cells and dysfunctional dendritic cells may contribute to T cell exhaustion 
through different pathways. Tregs express ectoenzymes CD39 and CD73, which may generate 
pericellular adenosine that dampen the function of effector T cells(115). In addition, Tregs have 
high expression of CD25, which could deplete IL-2 within the local microenvironment and impair T 
cell function(116). The production of inhibitory cytokines by Tregs, such as transforming growth 
factor β (TGF-β) and IL-10, could also suppress the functions of effector T cells and contribute to 
their exhaustion(117,118). MDSCs and TAMs may induce T cell exhaustion through PD-L1 and 
PD-1 interactions(119). Their abnormal activities of arginase 1 and nitric oxide synthase deplete 
local L-arginine, which inhibits T cell proliferation and functions. Tumor tissues also contain 
plasmacytoid dendritic cells, which express decreased co-stimulatory molecules such as CD86 
and CD40 but increased levels of PD-L1 and indoleamine 2,3-dioxygenase (IDO)(120). IDO 
depletes the essential amino acid L-tryptophan, which will inhibit T cell functions.  
Soluble mediators: These molecules include immunoinhibitory cytokines such as IL-10 and 
TGF-β, as well as inflammatory factors including IL-4, IL-6, IL-13 and type I interferons (IFNs). All 
factors may accelerate T cell exhaustion within the TME either directly or through regulating the 
functions of other cell types. Blocking the activities of these cytokines have the capacity to 
partially restore T cell functions and slow tumor progression(121). A summary of different 
pathways that contribute to T cell exhaustion is shown below (Figure 1-2). Finally, it is important 
to note that exhausted T cells still possess suboptimal but crucial functions that keep tumor 
progression in check. T cell exhaustion is also reversible; therefore immunotherapeutic strategies 
that recover the functions of exhausted T cells, such as the application of anti-PD-1/PD-L1 
checkpoint inhibitors, could substantially prolong the survival of patients with metastatic 
melanoma.  
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Figure 1-2: Overview of the mechanisms that contribute to T cell exhaustion. Inner circle: Three major 
factors may play impo tant roles in riving T cell exhaustion: c ll-c ll contact including antigen 
overstimulation through TCR ligation, and the interaction of inhibitory receptors; the presence of suppressive 
cytokines; tissue and microenvironment factors such as local nutrients and oxygen depletion, altered pH, 
and dysregulation of lymp oid organ zations. The out r circle hows different types of cells that may 
contributes to the changes in TME that affect T cell functions. Figure is adapted from Wherry and Kurachi, 
2015(121).  
 
1.3.2 Tumor stroma and ance -associated fibroblasts (CAFs) 
        Tumor cells themselves are not fully responsible for the immunosuppressive 
microenvironment. Most epithelial-derived cancers require the support of mesenchymal-derived 
stromal cells, which play a pivotal role in the complicated communication network with cancer 
cells and immune cells to provide the appropriate TME for neoplastic cell expansion and 
metastasis. Tumor stroma promotes tumorigenesis by suppressing the immune control of tumor 
growth, providing nutritional support required for tumor mass maintenance, stimulating 
angiogenesis, cancer cell proliferation and invasion(122-124). Tumor cells and the tumor stroma 
exist in a dynamic network of interactions through the secretion of a plethora of growth factors 
and cytokines, including TGF-β, VEGF, IL-4 etc (123). The reactive tumor stroma constantly 
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modifies the ECM and induces neoangiogenesis, therefore creates a TME that is conductive to 
growth and metastasis of the tumors(125). The induction of reactive tumor stroma blocks immune 
cell infiltration and impairs T cell responses in the TME, and is linked to poor prognosis in various 
cancers.  
       The supporting stroma of melanoma contains an abundance of connective tissue, 
blood vessels, inflammatory cells such as lymphocytes and myeloid cells, extracellular matrix 
(ECM) components and cancer-associated fibroblasts (CAFs). CAFs are present in aberrantly 
high frequencies in the tumor. They are phenotypically and functionally distinct from normal 
fibroblasts in normal tissues by increased proliferation rate and differential expression of ECM 
components and growth factors(123,126).  CAFs are activated by growth factors and cytokines in 
the TME and contribute to tumorigenesis in all stages of tumor progression. In addition, CAFs 
promotes angiogenesis through VEGF production, and enhance the metastatic potential of 
cancer cells through production of proinflammatory factors. Moreover, CAFs represent a major 
source of inhibitory cytokines such as IL-10 and TGF-β; they therefore contribute to the local 
immunosuppressive environment(123,127) and dampen antitumor T cell responses induced by 
immunotherapy. The functions of CAFs during tumorigenesis are shown below (Figure 1-3).  
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Figure 1-3: Illustration of the mechanisms utilized by CAFs to promote tumor development. CAFs are 
originated from endothelial cells, malignant epithelial cells through epithelial-to-mesenchymal transition 
(EMT) or are transformed from normal fibroblasts. CAFs enhance cancer cell proliferation, invasion, modify 
ECM composition, promote angiogenesis while inhibit immune cell functions. These effects are mediated 
through the secretion of numerous growth factors, cytokines and proteases as illustrated. CAFs also affect 
functions of adipocytes and inflammatory cells within TME, which indirectly promote tumor growth. Ac, 
acetyl; AFC, 7-amino-4-(trifluoromethyl) coumarin;bFGF, basic fibroblast growth factor; CCL2, chemokine 
(C-C motif) ligand 2;Col, collagen; DPP-II (IV, 6, 7, 8, 9, 10), dipeptidyl peptidase-II (IV, 6, 7, 8, 9, 10); FN, 
fibronectin; GM-CSF, granulocyte macrophage colony-stimulating factor; HGF, hepatocyte growth factor; 
IGF2, insulin-like growth factor 2; LOX, lysyl oxidase; SDF-1, stromal cell-derived factor 1; SFRP-1, secreted 
frizzled-related protein 1; SPARC, secreted protein, acidic and rich in cysteine; TNC, tenascin-c.	
Figure is adapted from Brennen et al., 2012(127).   
 
      One key feature of transformed CAFs is that they express the highly selective 
fibroblast activation protein (FAP). FAP is a type II membrane-bound glycoprotein and a member 
of the serine protease family that has dipeptidyl peptidase and collagenase activities. FAP is not 
present at high levels on tumor cell, normal fibroblasts or in normal adult tissues(126). FAP+ 
stromal fibroblasts are required for maintenance of the tumor microenvironment(126). They 
suppress the immune response to tumors by producing stromal cell-derived factor-1 (SDF-
1/CXCL12), which can attract regulatory T cells, MDSCs and TAMs into the tumor(128,129). They 
also induce random movement of effector T cells, which interferes with T cell-tumor cell 
interactions and hinders tumor destruction(130). Genetic FAP depletion can lead to profound 
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tumor growth inhibition, through a mechanism that was shown to be dependent on host immunity, 
in particular on IFN-γ and TNF-α production(124).  Vaccines targeting FAP or T cells with a FAP-
specific chimeric antigen receptor (CAR) inhibit tumor growth in part by enhancing tumor-specific 
immune responses and they increase tumor mice survival(131-133). A key advantage of FAP+ 
CAFs over tumor cells is that they are genetically stable, they thus represent an ideal therapeutic 
target with reduced risk of development of resistance. Strategies that depleting the 
immunosuppressive CAFs or re-educating them to become normal fibroblasts have the potential 
to significantly improve the overall efficacy of melanoma immunotherapy in patients.  
 
1.3.3 Immunosuppressive cells  
      As mentioned above, there are various immunosuppressive cell populations within 
the TME, all of them can promote tumorigenesis and suppress functions of TILs through different 
mechanisms.  
      Tumor-associated macrophages (TAMs): Macrophages are usually viewed as 
effector cells that enhance immune defense against cancer at the onset of tumor initiation. 
However during tumor development, macrophages are educated to become immunosuppressive 
and promote tumorigenesis(134). This transition is partially mediated by the change of the 
cytokine and growth factor milieu within TME, from a Th1 type inflammatory environment 
consisting of IFN-γ, GM-CSF etc. to a Th2-type anti-inflammatory setting containing TGF-β, IL-4, 
Il-10, IL-13 and M-CSF, with the former setting promoting ‘classic activated’ M1-macrophages 
formation while the latter facilitating the polarization of ‘alternatively activated’ M2-
macrophages(135-137). In addition, it is suggested that other conditions such as lack of oxygen 
supply within the TME could induce this functional switch of macrophages(138). Within 
established melanoma, most of the TAMs bear a M2 phenotype, with enhanced secretion of IL-10 
and TGF-β{Quatromoni:2012wp}.  One major function of TAMs is to drive the tumor cell invasion 
through the colony-stimulating factor 1 (CSF-1)-epidermal growth factor (EGF) interaction loop. 
Tumor cells secrete CSF-1, which works as chemoattractant to recruit TAMs. TAMs produce EGF 
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and works in a paracrine manner to promote the invasive phenotype of cancer cells(139,140). In 
addition, TAMs secrete CCL22 and proteases such as cathepsin, which recruit Tregs to TME and 
promote tumor growth, angiogenesis and invasion(141,142). All of these conditions will suppress 
functions of TILs.  
     Myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs): 
MDSCs are a heterogeneous population of cells of myeloid origin, which consist of myeloid 
progenitor cells and immature myeloid cells (IMCs) that are originated from the bone marrow.  In 
conditions such as infectious diseases and tumor development, IMCs can not fully differentiate 
into mature macrophages, dendritic cells or granulocytes and this immature cell subset with 
immunosuppressive activities will expand in different tissues(143). In mice, MDSCs are 
characterized by their expression of surface antigens Gr-1 and CD11b. They contain two subsets 
with distinct functions to suppress T cell activities, i.e., monocytic (MO) MDSCs, which are 
phenotypically Gr-1intCD11b+, and granulocytic (polymorphonuclear, PMN) MDSCs, which are Gr-
1hiCD11b+(144).  
    The expansion and activation of MDSCs is induced by factors secreted by tumor cells, 
tumor stromal cells and activated T cells, i.e. VEGF, GM-CSF, G-CSF, IFN-γ, TGF-β, IL-4, IL-6, 
IL-10, IL-13, CCL2, CXCL5, CXCL12 etc., all of which stimulate myelopoiesis and inhibit the 
differentiation of IMCs(145-153). Most of these factors induce MDSCs expansion and inhibitory 
functions through activation of Janus kinase (JAK) family members and signal transducer and 
activator of transcription (STAT) pathway(143,154). MDSCs suppress T cell functions through the 
secretion of soluble factors including arginase 1(Arg1), inducible nitric oxide synthase (iNOS), 
reactive oxygen species (ROS) and peroxynitrite, which require direct cell-cell contact and 
suppress T cell activities through different mechanisms. For example, both Arg1 and iNOS 
catabolize L-arginine, an important amino acid that is required for T cell proliferation. Depleting its 
availability within TME limits T cell proliferation. In addition, the catabolism of L-arginine by iNOS 
produces nitric oxide (NO), which suppresses T cell function by inhibiting the JAK3-STAT5 
pathway in T cells and inducing cell apoptosis(155,156). Peroxynitrite induces the nitration and 
	
	
23	
nitrosylation of amino acids such as cysteine, tryptophan and tyrosine(157,158). Studies have 
shown that during direct MDSC-T cell interaction, the production of peroxynitrite by MDSCs can 
lead to nitration of the TCR and CD8 molecules, which decrease the binding capacity of MHC-
peptide complex to the TCR and reduce T cell effector functions in an antigen-specific 
manner(159,160). Moreover, it has been shown that MDSCs could promote the de novo 
generation of Treg cells through the production of cytokines such as IL-10(146,161). Tregs 
promote tumorigenesis and inhibit T cell functions through different mechanisms, such as by 
suppressing antigen presentation within the TME and inhibiting the cytolytic granule releases by 
effector CD8+T cells(162).  
    Successful cancer immunotherapy depends on the inhibition or removal of 
immunoinhibitory factors and cell populations. Therefore, strategies that could promote MDSCs 
differentiation, or could inhibit their proliferation and functions will effectively improve the efficacy 
of cancer vaccines or adoptive T cell transfer in melanoma patients.  
1.3.4 Metabolic defects  
 
      (This section is adapted from my review article: Zhang Y, Ertl HC. Starved and asphyxiated: how can 
CD8+ T cells within a tumor microenvironment prevent tumor progression. Frontiers in Immunology 2016; 
7(32).) 
 
 
       The etiology of T cell exhaustion within the TME warrants further discussion. High 
levels of antigen as found during chronic viral infections may not be solely responsible. The 
amount of antigens within a tumor would not be expected to be overwhelming, especially as 
tumor cells commonly down-regulate MHC class I expression (163), which makes their antigens 
virtually invisible to CD8+T cells. Instead I hypothesize that CD8+T cell exhaustion may be 
triggered by metabolic stress within the TME.   
        Following antigenic stimulation, differentiation of naïve CD8+T cells into effector cells 
is accompanied by metabolic reprogramming to accommodate their increased demand for energy 
and biomass formation. Resting CD8+T cells primarily gain energy through oxidative 
phosphorylation (OXPHOS), the mitochondrial pathway of energy production (164). The 
tricarboxylic acid (TCA) cycle, which is linked to OXPHOS, oxidizes acetyl-CoA. This metabolite 
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can be derived from carbohydrates, amino acids or FAs.  Upon CD8+T cell activation, T cell 
receptor (TCR) and co-stimulator CD28 ligation activates the phosphatidylinositol 3-kinase (PI3K) 
/ protein kinase B (Akt) / mammalian target of rapamycin (mTOR) pathways, which in turn 
increase the activity of hypoxia-inducible factor (HIF)-1α and Myc (165). HIF-1α augments 
surface expression of Glut1 and thereby allows for increased uptake of glucose, while Akt and 
Myc increase the activity of several glycolytic enzymes (166-168). All of these signals drive 
activated CD8+T cells to rely increasingly on glycolysis after activation. The activity of the 
mitochondrial OXPHOS pathway is also enhanced (169). Cancer cells also ferociously consume 
glucose to fuel energy production through glycolysis, which can lead to hypoglycemia within 
tumors. In addition, angiogenesis often lags behind expansion of solid tumors, leading to hypoxia 
in some areas of the TME. T cells that infiltrate solid tumors thus face dual metabolic jeopardy; 
lack of glucose prohibits energy production through glycolysis while lack of O2 prevents energy 
production through OXPHOS. How tumor-specific CD8+TILs cope with these challenges and how 
metabolic reprograming of CD8+TILs will affect their antitumor performance require further 
investigations, in order to improve the efficacy of cancer immunotherapy.   
1.3.4.1 Effects of hypoxia on CD8+TIL metabolism and functions 
    Solid tumors commonly have areas of hypoxia. This can be caused by lack of 
perfusion due to structural and functional abnormalities of the tumor microvasculature, general 
anemia of the patient or insufficient diffusion due to lack of angiogenesis. The latter affects cells 
once they are more than 70 µM away from a blood vessel. Studies have shown that up to 50-60% 
of solid tumors of a variety of different types possess unevenly distributed areas of hypoxia (170).  
     Tumor-infiltrating CD8+T cells are initially activated under physiological O2 tension in 
peripheral lymphatic tissues. Upon tumor entry, CD8+T cells will be subjected to increasingly 
severe hypoxia once they leave areas close to blood vessels; this will activate HIF-1α. HIF-
1α signaling adjusts the cells’ metabolism to allow for energy production when O2 is limiting. HIF-
1α enhances glycolysis by CD8+T cells mainly by promoting the activity of lactate dehydrogenase 
A (LDHa), while inhibits OXHPOS by increasing expression of pyruvate dehydrogenase kinase 
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1(PDK1), which prevents the oxidation of pyruvate to acetyl-CoA (171,172). CD8+TILs under 
hypoxia therefore must increase glucose consumption to fuel glycolysis.  
     A series of in vitro and in vivo studies in the past two decades show that hypoxia 
dampens lymphocyte activation, diminishes their proliferation, and reduces the ability of activated 
T cells to produce cytokines or lytic enzymes (173-179). T cell activation causes release of Ca2+ 
from intracellular stores followed by sustained Ca2+ influx, which is inhibited by increased HIF-
1α activity (180). Whole body hypoxia dampens inflammation and T cell functions in mice and 
humans (181,182). These data show that hypoxia is immunosuppressive and metabolic 
reprograming due to increased activity of HIF-1α may contribute to reductions of immune 
responses. This could be caused by reduced ATP production due to impaired OXPHOS under 
hypoxia. Additionally, hypoxia is known to increase accumulation of reactive oxygen species 
(ROS), which may induce apoptosis of activated T cells (183,184). Vice versa, activated CD8+T 
cells with a partial deficiency in HIF-1α  show enhanced production of cytokines (185,186). One 
study has shown that under hypoxia or with increased HIF-1a activity T cells increase expression 
of co-inhibitors including CTLA-4, CD244 and LAG-3 and decrease levels of T-bet (187), a key 
transcription factor that controls many of the T cells’ functions, again indicating that hypoxia is 
immunosuppressive. 
     Conversely, two recent reports show that hypoxia and increases in HIF-1α activity 
promote effector T cell functions, especially production of the lytic enzymes granzyme B and 
perforin (187,188). There is a caveat with these studies; both used a protocol in which after an 
initial 48 hours of activation, CD8+T cells were rested for several days in IL-2-supplemented 
medium before being subjected to hypoxia. Unlike highly activated CD8+T cells, resting CD8+T 
cells rely more on FAO and OXPHOS for energy production. This metabolic reprogramming and 
their decreased energy demand may allow CD8+T cells to improve some functions upon hypoxia. 
In real life CD8+T cells induced by a cancer vaccine or tumor antigens that leaked into lymphatic 
tissues are unlikely to rest before they infiltrate a tumor, where they may receive additional 
activation signals. Results obtained with resting cells are thus not pertinent to TILs exposed to 
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hypoxia. The same papers showed that genetic depletion of HIF-1α reduces CD8+ T cell 
functions while its constitutive overexpression through functional depletion of the Von Hippel-
Lindau (VHL) factor improves functions. During the initial phase of T cell activation, HIF-1α is 
essential to allow T cells to use glycolysis. The effects of its complete absence or increased 
expression during this critical phase of differentiation may differ from changes in HIF-1α activity 
during later phases of activation. These studies thus give limited insights into the effect of hypoxia 
or HIF-1α on CD8+TILs, which encounter limited O2 after activation in the periphery once they 
penetrate into the tumor.  
      Hypoxia and increased HIF-1α activity in tumor tissues in general correlate with poor 
prognosis of cancer patients (34, 35). Hypoxia not only affects protective immune responses but 
also promotes tumorigenesis by enhancing proliferation of cancer cells and increasing their PD-
L1 surface expression (189). The latter in turn may further dampen functions and survival of PD-
1+TILs. Hypoxia may also increase the suppressive activity of tumor-infiltrating myeloid 
suppressor cells and tumor-associated macrophages, which will lead to further impairments of 
CD8+TIL functions (190,191). Overall, all of these studies strongly suggest that lack of O2 
negatively affects metabolism and functions of CD8+TILs.  
1.3.4.2 Effects of hypoglycemia on metabolism and functions of TILs 
       Glucose is crucial during the initial stages of CD8+ T cell activation. Naïve CD8+T 
cells can differentiate into effectors in absence of glucose but then become functionally impaired 
(192). Lack of glucose also dampens effector functions of fully activated CD8+T cells both in vitro 
and in vivo (192-197).  
       Attracted by chemokines, activated CD8+T cells regardless of their antigen-specificity 
infiltrate solid tumors. Here they encounter an environment where key nutrients such as glucose 
may be limiting due to its consumption by tumor cells (198).  Although activated CD8+T cells 
express increased levels of the glucose transporter Glut1, in vitro studies show that their effort to 
take up glucose is thwarted by tumor cells, which are simply more effective at consuming this key 
nutrient (192). CD8+T cell glycolysis within TME may further be reduced by accumulating 
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concentrations of tumor cell-derived lactate, which prevents the monocarboxylate transporter-1-
mediated, gradient-dependent export of lactate from CD8+T cells. Increasing concentration of 
lactate within CD8+T cells in turn causes a fall in pH, which inhibits the activity of 
phosphofructokinase, a key enzyme of glycolysis (199). In addition, glucose deprivation increases 
co-inhibitor PD-1 expression on activated CD8+T cells (200), which can further reduce glycolysis 
but enhance FA metabolism. Blockade of PD-1 has been shown to lessen the CD8+TILs’ 
metabolic stress by augmenting their glycolytic capacity through increased mTOR signaling (192).     
        It has been reported that FAO can maintain the survival of cancer cells when 
glucose is not available (201). T cells may also be able to cope with lack of glucose by enhancing 
other metabolic pathways. Sudden deprivation of glucose can lead to drops in ATP with 
enhanced AMP in activated CD8+T cells. The increased AMP: ATP ratio activates the energy 
sensor AMP-activated protein kinase (AMPK). AMPK is a key regulator that reduces the T cells’ 
energy expenditure by blocking production of cytokines (202). Furthermore, AMPK maintains T 
cell viability by decreasing glycolysis and anabolic processes through inhibition of the mTOR 
pathway, while enhancing OXPHOS fueled by FAs and glutamine (203,204). In agreement the 
studies showed that knockout of AMPK increases apoptosis of T cells activated with limited 
access to glucose (202).  
        To what degree CD8+TILs’ functions are impaired by lack of glucose within the TME 
may depend on the T cells’ differentiation status, or, in other words on their metabolic 
programming prior to entering the tumors. Recently activated CD8+ effector T cells conditioned to 
use glycolysis are likely most susceptible to sudden loss of exogenous glucose (205,206), as 
compensatory endogenous production of glucose through gluconeogenesis or glycogen 
degradation are not sustainable (207). In contrast, CD8+T cells programmed to use other 
nutrients may cope better with restricted glucose access (208). This in turn invites the testing of 
metabolic drugs that reprogram T cell metabolism as adjuvant treatments for active cancer 
immunotherapy or adoptively transferred TA-specific T cells.  
1.3.4.3 Effect of hypoxia combined with hypoglycemia on CD8+TIL functions and metabolism 
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      Hypoxia inhibits OXPHOS but allows cells to gain energy through glycolysis. 
Hypoglycemia on the other hand reduces glycolysis but cells can switch to OXPHOS by burning 
other nutrients. The problem is that many tumors have low levels of glucose combined with areas 
of hypoxia, which foils both pathways of energy production.   
       Malignant cancer cells increase lipogenesis, lipolysis, FA secretion and recruit 
adipose progenitors to the TME (209-211). In addition, dying tumor cells may release FAs.  FAs 
provide ample energy through peroxisomal or mitochondrial FAO, which may be used by 
CD8+TILs. FAO is preferred by some effector T cells such as those participating in graft versus 
host disease (212) and it is suggested that FAO may be preferred by T cells that encounter large 
quantities of antigens (213).  Energy production through FAs requires more O2 than energy 
production through glucose to generate equivalent amounts of ATP. OXPHOS fueled by glucose 
yields 36 molecules of ATP and consumes 6 molecules of O2. In contrast, OXPHOS fueled by 
palmitate, a 16-carbon FA, results in a net yield of 129 ATP and requires 31 molecules of O2. FAs 
thus require 1.44 times more O2 than glucose to provide the same amount of energy, which 
makes it an inefficient fuel within an O2-deprived TME.  
       Ketone bodies, i.e., acetoacetate, acetone and b-hydroxybutyrate, are produced 
during FA catabolism when the amount of acetyl-CoA produced by FAO overwhelms the 
processing capacity of the TCA cycle. When acetyl-CoA declines, ketone bodies can be 
converted back to acetyl-CoA providing a ready source of energy that requires less O2 than 
catabolism of FAs (214). Previous studies showed that under conditions of hypoxia and 
hypoglycemia, cells of the nervous system maintain their energy balance through the use of 
ketone bodies (215). We propose that CD8+TILs may do the same. T cells may take up ketone 
bodies from the surrounding or they could synthesis them directly (214,216,217).  
        CD8+TILs are not stationary; they migrate throughout the TME (218) and we 
assume that their environment changes accordingly. When T cells are close to vessels and O2 is 
readily available, FAs may fuel the TCA cycle and excess FA-derived acetyl-CoA can be 
converted into ketone bodies. When T cells penetrate deeply into the tumor and O2 becomes 
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scarce, T cells may burn ketone bodies to sustain their energy requirement. As has been shown 
during heart ischemia, lack of O2 results in increases in AMPK, which decreases the activity of 
acetyl-CoA carboxylase (ACC) that converts acetyl-CoA to malonyl-CoA.  Once cells have access 
to O2, such upon reperfusion of an ischemic heart or migration of TILs to areas close to 
vasculature, lack of malonyl-CoA will cause a surge in FAO (219). Lipid metabolism has been 
shown to correlated with long-term survival in many different cell types (220,221). It has been 
suggested that PD-1 ligation, which prevents terminal differentiation of effector CD8+T cells (222), 
promotes survival by enhancing the cells’ FA metabolism (223). Ketone body metabolism also 
promotes metabolic fitness and longevity of cells by regulating histone deacetylase (HDAC) 
activities (214). Catabolism of these carbon sources may allow T cells to survive under 
hypoglycemia and intermittent hypoxia. The potential metabolic pathways utilized by naive or 
activated T cells under normal or different metabolically stressed conditions are illustrated 
(Figure 1-4). 
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Figure 1-4: Energy production by activated CD8+T cells under physiological or metabolically 
challenging conditions. The potential signaling pathways after T cell activation under different conditions 
and how they affect the metabolic pathways of activated CD8+T cells are illustrated. Blue: activity goes 
down; Red: activity goes up; Bold: increased activity; Dashed: decreased activity; Italic with double strikes: 
limited access. Glu: Glucose; FA: Fatty acid; PI3K: Phosphoinositide 3-kinase; Akt: Protein kinase B; mTOR: 
Mechanistic target of rapamycin; HIF: Hypoxia-inducible factors; O2: Oxygen; OXPHOS; Oxidative 
phosphorylation: NFAT: Nuclear factor of activated T cells; T-bet: T-box transcription factor TBX21; PD-1: 
Program Cell Death-1; LAG-3: Lymphocyte-activation gene 3. 
 
1.3.4.4 Exploring metabolic manipulations to improve T cell-mediated immunotherapy of cancer 
        Adoptive transfer of ex vivo expanded TILs has achieved some successes in 
treatment of melanomas (224). Alternatively, T cells from peripheral blood can be modified to 
express chimeric antigen receptors (CARs) that recognize cell surface expressed tumor antigens 
independent of major histocompatibility antigens (225). Transfer of such CAR-T cells has been 
remarkably successful in treatment of acute lymphatic leukemia or B cell lymphoma but in general 
yielded disappointing results in patients with solid tumors (226-230). This has been blamed on the 
immunosuppressive nature of the TME (231,232). Treatments that reduce numbers or functions 
of regulatory T cells, myeloid suppressor cells, tumor-associated macrophages or that block 
	
	
31	
immune checkpoints have improved the efficacy of adoptive cell transfer for cancer therapy 
(233,234).  
       As already mentioned, the metabolic profile of CD8+T cells prior to their tumor 
infiltration has significant impacts on their longevity and performance within TME. In addition, the 
metabolic profiles of the tumor cells will influence what nutrients are available to T cells. Some 
studies show that drugs, which inhibit glycolysis by tumor cells such as Glut1 inhibitors cause 
tumor regression and increase glucose supply within the TME (235,236). Its use prior to cell 
transfer could increase the efficacy of cell immunotherapy.  Others have shown that reducing 
glucose consumption by tumor cells through blockade of PD-L1 signaling allows for increased 
glycolytic energy production by CD8+TILs, which is accompanied by improvements of their 
functions (192). A recent study shows that glucose limitation leads to reduction of the glycolysis 
metabolite phosphoenoylpruvate (PEP), which is essential for Ca2+-NFAT signaling in CD8+TILs. 
Overexpressing phosphoenolpyruvate carboxykinase (PCK) 1, which converts the TCA cycle 
intermediate oxaloacetate to PEP, was shown to improve NFAT signaling and function of TILs 
(197). 
        However, glycolysis may accelerate terminal differentiation of CD8+T cells and 
thereby shorten T cell survival (237); thereby, limiting glycolysis by CD8+TILs may yield better 
therapeutic effects. One study showed that inhibition of glycolysis by 2-deoxyglucose during in 
vitro expansion of TA-specific CD8+T cells increases their efficacy in a mouse melanoma model 
(205). A similar effect was seen when TILs were treated prior to adoptive transfer with an Akt 
inhibitor, which reduces their use of glycolysis and increases OXPHOS (208). Along the same 
line, when CD8+T cells were cultured in vitro with IL-7 or IL-15, which drives their differentiation 
towards memory, their antitumor efficacies in vivo significantly improved (238-240). Further 
studies showed that adoptive transfer of central memory CD8+ T cells confers better eradication 
of solid tumor masses than transfer of equal numbers of effector CD8+ T cells (241,242), which 
led the authors to conclude that the T cell differentiation status, which dictates potential for 
proliferation, is crucial to ensure optimal efficacy of adoptive T cell transfer. I think that the 
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metabolic reprogramming towards preferential use of FAO and OXPHOS as naturally occurs 
during differentiation from effector to memory cells, may allow for the superior performance of the 
transferred T cells within TME. 
       Immunotherapy of cancer is still in its infancy. T cells are able to stop an infection by 
rapidly killing millions of infected cells but they clearly need additional help to eliminate tumors. In 
recent years exciting new studies have started to illuminate the metabolism of T cells under 
different conditions and its impact on T differentiation and functions. A better understanding of the 
metabolic programs utilized by CD8+TILs and how they affect the TILs’ antitumor performance is 
crucial to find new therapeutic targets for cancer immunotherapy. Metabolic manipulations that 
could prepare TA-specific T cells, which are either induced by cancer vaccines or expanded ex 
vivo in form of TILs or CAR-T cells, to optimally cope with the metabolic constrains within the 
TME may significantly improve the overall antitumor efficacy. Undoubtedly the type of cancer and 
peculiarities of its TME will dictate the most suited metabolic treatment. 
 
1.4 Objectives Of The Study 
	
      Metastatic melanoma is largely refractory to existing therapies and has a very poor 
prognosis. Despite the significant progresses made in the cancer immunotherapy field in recent 
years, only a small proportion of melanoma patients show positive clinical responses. There are 
several major barriers to improve the efficacy of immunotherapy for solid tumors. First, the 
specific CD8+ T cell responses against tumor antigens can be severely dampened by the 
prevalence of immunosuppressive ligands expressed within TME. Second, the immune control of 
tumor growth can be directly suppressed by tumor stromal fibroblasts, which suppress immune 
responses through different mechanisms. Third, tumor cells are capable of evading the immune 
pressure exerted by vaccine- or T cell transfer-induced immune responses due to the 
advantageous growth of non-targeted subpopulations, further impairing the efficacy of 
immunotherapy. In addition, T cells become functionally exhausted within the TME during tumor 
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progression, which is traditionally viewed as a result of chronic exposure to cancer antigens. Our 
preliminary data suggest that the metabolic stresses, including glucose and oxygen limitation in 
late stage tumors, may lead to the metabolic alteration and functional impairment of TILs.  
        The overall goal of my thesis project is to develop novel immunotherapeutic 
strategies against melanoma that can overcome the immunosuppressiveness of the TME, reduce 
the exhaustion of TILs and thus achieve sustained tumor regression. The vaccines I designed 
against melanoma are based on chimpanzee-derived adenoviral vector AdC68, which is known to 
induce potent CD8+ T cell responses. I hypothesize that the melanoma cell targeting vaccine not 
only has to express multiple melanoma antigens in an immunogenic form but also has to 
overcome the low responsiveness of TA-specific CD8+T cells. Furthermore, the novel cancer 
treatment strategies have to contain components that directly reduce the TME’s ability to 
suppress tumor-specific immune responses. In my thesis I addressed this hypothesis through the 
following aims:  
 
Specific Aim 1: To determine whether blocking prevalent immunoinhibitory pathway 
during T cell priming could reduce the exhaustion of melanoma-associated antigens 
(MAAs)-specific CD8+T cells in the TME and improve the antitumor efficacy of cancer 
vaccine. 
    Co-expression of several different immunogenic antigens in one vaccine can minimize 
the frequent immune escape of tumor cells. In addition, studies by our lab have shown that 
vaccines expressing antigens as fusion proteins within herpes simplex virus glycoprotein D (gD) 
can induce markedly enhanced antigen-specific T cell responses through disruption of the 
immunosuppressive B-and T-lymphocyte attenuator (BTLA)-herpesvirus entry mediator (HVEM) 
signaling pathway in the TME(243,244). I hypothesized that the Ad vaccine expressing multiple 
immunogenic MAA epitopes fused within gD can induce high frequencies of CD8+T cells targeting 
melanoma cells for destruction. Blocking the immunosuppressive signaling in activated T cells 
may also reduce their exhaustion in tumors. To address this hypothesis, I compared the functions 
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and exhaustion status of MAA-specific T cells induced by melanoma vaccine expressing multiple 
MAA epitopes fused within gD to those of T cells elicited by a vaccine expressing MAA epitopes 
without gD in melanoma-bearing mice.  
 
Specific Aim 2: To determine whether depleting tumor stromal fibroblasts through 
vaccination could enhance the antitumor efficacy of melanoma cell targeting vaccine.  
    Tumor stromal fibroblasts express selectively the fibroblast activation protein (FAP), 
which is not expressed by normal fibroblasts or normal adult tissues. FAP+ stromal fibroblasts 
suppress the immune response to tumors by attracting regulatory T cells into the tumor and 
interfering with T cell-tumor cell interaction. I hypothesized that combining an Ad-based vaccine 
directly targeting tumor stromal fibroblasts for destruction will enhance the efficacy of the 
melanoma antigen-expressing vaccine by reducing immunosuppression within TME. The 
frequencies and functions of immunosuppressive cells may change upon FAP+ stromal cell 
depletion, which may also reduce the exhaustion of MAA-specific TILs. To study the effect of 
FAP+ stromal cell depletion, I designed an AdC68-based vaccine targeting murine full-length FAP 
protein. The effects of the vaccine given either alone or in combination with the MAA targeting 
vaccine were tested in both a B16 transplantable tumor model and a clinically relevant inducible 
transgenic melanoma mouse model.  
 
Specific Aim 3: To determine whether metabolic challenges within TME contribute to T cell 
functional exhaustion and to explore novel strategies to alter the metabolism of TILs in 
order to improve their functions. 
     The TME poses significant metabolic challenges to TILs due to disorganized 
vascularization, presence of toxic products derived from tumor and stromal cells and lack of 
nutrients and oxygen (O2)(245). TILs require energy to eliminate tumor cells. Upon activation T 
cells enhance energy production through glycolysis(246), which is less efficient than OXPHOS 
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but provides building blocks for biomass formation and cell proliferation. Tumor cells also use 
glycolysis(247), which may lead to Glu depletion within the TME(192,197). T cells with limited 
access to Glu have to rely on OXPHOS to produce energy. Although many substances including 
FAs can fuel OXPHOS, it requires O2, which can become limiting within tumors due to insufficient 
blood supply(248). TILs therefore face dual metabolic jeopardy, which I hypothesize drives their 
functional exhaustion and thereby impairs the efficacy of cancer immunotherapy. I studied the 
effects of metabolic stress within the TME on differentiation and effector functions of CD8+TILs in 
a B16 melanoma mouse model. Melanoma-bearing mice were immunized with a mixture of 
vaccines that induce CD8+T cells specific for MAAs and an unrelated tumor antigen (TA), i.e. E7 
of human papilloma virus (HPV)-16. I analyzed the metabolism, differentiation and functions of 
both MAA- and E7-specific TILs in spleens, small tumors or late stage tumors using a series of 
transcriptional profile, flow and metabolomics analysis. The impact of metabolic challenges on the 
tumoricidal functions of effector T cells was studied both in vitro and in vivo. Moreover, I explored 
strategies to manipulate the metabolism of TILs in order to improve their tumor-killing capacity in 
the TME.  
 
 
 
 
 
 
	
	
36	
Chapter 2 
 
 
The effect of adjuvanting cancer vaccines with herpes 
simplex virus glycoprotein D on melanoma-driven 
CD8+T cell exhaustion 
 
 
 
 
 
ABSTRACT 
	
Immunoinhibitory ligands within the tumor microenvironment (TME) represent a major barrier for 
vaccine-induced tumor antigen-specific CD8+T cells to exert effector functions. To determine if 
blocking immunoinhibitory pathways could enhance the efficacy of cancer vaccine, I compared 
two chimpanzee-derived replication-defective AdC68 vectors expressing CD4+ and CD8+ T cell 
epitopes of melanoma-associated antigens (MAAs) in a mouse model of melanoma. In one 
vaccine, termed AdC68-gDMelapoly, the epitopes were expressed as a fusion protein within 
HSV-1 gD, which blocks immunoinhibitory signaling through the HVEM pathway. The other 
vaccine, termed AdC68-Melapoly only expressed the MAA epitopes. AdC68-gDMelapoly induced 
more potent MAA-specific CD8+T cell responses especially to the subdominant MAA epitopes. 
Upon prophylactic vaccination, mice that developed CD8+ T cell responses to the two vaccines 
that were comparable in magnitude showed equal protection against tumor challenge. When mice 
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were first challenged with tumor cells and then vaccinated results differed. In animals with 
comparable CD8+T cell responses, the AdC68-gDMelapoly vaccine was more efficacious 
compared to the AdC68-Melapoly vaccine in delaying tumor growth. This effect was linked to 
reduced expression of 2B4, LAG-3 and PD-1 on tumor-infiltrating MAA-specific CD8+ T cells 
elicited by the gD-adjuvanted vaccine, suggesting that CD8+ T cells induced in presence of gD 
are less susceptible to tumor-driven exhaustion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter were adapted from: 
Zhang Y, Ertl HC. The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on     
Melanoma-Driven CD8+ T cell exhaustion. Journal of immunology 2014; 193(4): 1836-1846. 
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INTRODUCTION 
	
      Even cancer vaccines that are highly immunogenic in animal models commonly fail to 
provide benefits to patients with advanced cancers(249,250). This has partially been linked to the 
highly immunosuppressive tumor microenvironment, which expresses immunoinhibitory ligands 
(251), recruits suppressive cell subsets such as regulatory T cells (252) and myeloid suppressor 
cells (253) and provides a metabolically stressed milieu (254). Biologicals that block 
immunoinhibitory pathways such as antibodies to PD-1 (34,255) or CTLA-4 (256) or both 
(257,258) are being tested alone or in combination with active immunotherapy in cancer patients 
and have yielded promising results.  
     My focus has been on the herpes virus entry mediator (HVEM) pathway. HVEM, which 
was first identified as a receptor for HSV-1 glycoprotein D (gD)(259), is a bimodal switch 
expressed on many cells including antigen presenting cells that can interact with the 
immunoregulatory molecules on lymphocytes (260). Binding of HVEM to LIGHT or lymphotoxin 
provides stimulatory signals; binding to the B and T lymphocyte attenuator (BTLA) or CD160 
activates inhibitory pathways (261). Co-activators and co-inhibitors bind to different domains of 
HVEM and can form a trimolar complex, in which signaling through co-inhibitors dominates (261). 
The N-terminus of HSV-1 gD binds to a site on HVEM that is close to the BTLA/CD160 binding 
site and thereby blocks immunoinhibitory but not co-stimulatory HVEM signaling (262).  
     As I have shown previously, vaccines that express antigens fused into the C-terminus 
of gD elicit enhanced T cell responses, which is linked to blockade of the immunoinhibitory HVEM 
pathway (243). Adjuvanting vaccine antigens with gD is especially effective to augment CD8+ T 
cell responses in aging mice (263) and in mice with advanced cancers (244). My previous cancer 
studies were based on human papilloma virus type 16 (HPV-16)-associated tumors, which 
express viral antigens that are foreign to the immune system. The current study was conducted to 
assess if expressing ‘self’’ antigens from non-viral tumors within gD would enhance the 
immunogenicity and efficacy of a cancer vaccine. Experiments were conducted in a 
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transplantable melanoma model, based on B16F10 cells that were stably transfected to express 
BrafV600E (B16BrafV600E). The vaccine antigen, termed Melapoly, was designed to express CD4+ 
and CD8+ T cell epitopes of melanoma-associated antigens (MAAs) including tyrosinase-related 
protein (Trp)-1, Trp-2, gp100 and mutated BrafV600E linked to the universal T helper cell epitope 
PADRE and an endoplasmic reticulum targeting signal sequence. To test for the gD adjuvant 
effect, the Melapoly encoding sequence was fused into the C terminal domain of HSV-1 gD 
(gDMelapoly). The Melapoly and the gDMelapoly fusion proteins were expressed by a simian E1-
deleted adenovirus vector of serotype 68 (AdC68).  
    As expected, the AdC68-gDMelapoly vector induced more potent MAA-specific CD8+ T 
cell responses, especially to subdominant epitopes, compared to the AdC68-Melapoly vector and 
provided superior protection if given before tumor challenge. In the same token, in a therapeutic 
vaccination model, the AdC68-gDMelapoly vector was superior in delaying tumor progression 
compared to the AdC68-Melapoly vector. To assess if the improved efficacy of the gD-adjuvanted 
vaccine solely reflected differences in the magnitude of MAA-specific T cell responses, I 
vaccinated mice with different doses of the AdC68 vectors and selected subgroups with 
comparable frequencies of MAA-specific CD8+ T cells. In a pre-challenge vaccination model, 
vaccine efficacy was shown to depend on frequencies of MAA-specific CD8+ T cells. In contrast in 
a post-challenge vaccination model, AdC68-gDMelapoly vaccinated mice that had MAA-specific T 
cell frequencies comparable to those of AdC68-Melapoly vaccinated mice survived significantly 
longer. This was not caused by differences in production of mediators by AdC68-gDMelapoly-
induced T cells but rather by their increased resistance against differentiation towards exhaustion.  
 
RESULTS 
	
The gD adjuvant enhances CD8+ T cell responses to dominant and subdominant epitopes 
    Levels of transgene expression can affect the immunogenicity of viral vectors. I 
therefore tested the levels of transgene product expression in transfected cells and showed by 
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real-time PCR that both vectors expressed comparable levels of transgene-derived mRNA  (data 
not shown). 
    I compared the magnitude of MAA-specific CD8+ T cell responses induced by the 
vaccines in young female C57BL/6 mice. Each group (n=5) of mice received either the AdC68-
Melapoly or the AdC68-gDMelapoly vector given i.m. at doses of 1010 or 1011 vp. Two and four 
weeks after vaccination, I measured CD8+ T cell responses to two MAA epitopes, i.e. Trp-1455 
and Trp-2180, by staining T cells with the corresponding MHC class I tetramers (Figure 2-1).  
           
Figure 2-1: Gating 
scheme for 
tetramer+CD8+T cells. 
Samples were initially 
gated on lymphoid cells 
(A) and then singlets (B) 
using forwards and side 
scatters. Singlets were 
further gated on live cells 
(C). Live cells were 
gated on cells positive 
for CD8 (D). CD8+ cells 
were blotted into CD44low 
and CD44hi cells (E) with 
the former serving as 
intrinsic controls. Using 
the CD44 gate CD44low 
(F,H) and CD44hi  (G,I) 
cells were gated over the 
Trp-1 (F,G) and Trp-2 
(H,I) tetramer. Counts for 
live CD8+ cells as well as 
CD44lowtetramer+ and 
CD44hitetramer+ cells 
were recorded and used 
to calculate frequencies 
of tetramer+ cells over all 
CD8+ cells. 
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Both vaccines induced stronger CD8+ T cell responses to Trp-1455 than Trp-2180 (mean 
frequencies of positive CD44+CD8+ cells for Trp-1455 vs. Trp-2180: 1010 vp: week 2: Melapoly: 5.1% 
vs. 0.56%, gDMelapoly: 5.8% vs. 0.58%; week 4: Melapoly: 2.5% vs. 0.25%, gDMelapoly: 5.3% 
vs. 0.42%; 1011 vp: week 2: Melapoly: 8.7% vs. 0.86%, gDMelapoly: 14.7% vs. 0.51%; week 4:  
Melapoly: 7.8% vs. 0.18%, gDMelapoly: 8.5% vs. 0.56%; naive CD44- T cells: 0.043% vs. 0.056% 
and 0.043% vs. 0.078% for weeks 2 and 4, respectively, Figure 2-2A-B). All groups mounted 
significant responses to the Trp-1455 and Trp-2180 tetramer compared to the internal CD44-CD8+ T 
cell controls (adjusted p-values are listed in legend to Fig. 1) or to naïve mice (data not shown). 
At the 1011 vp dose at week 2 and the 1010 vp dose at week 4 Trp-1455-specific CD8+ T cell 
responses were significantly higher in AdC68-gDMelapoly vaccinated animals than in AdC68-
Melapoly vaccinated mice. Responses to Trp-2180 were significantly higher in mice vaccinated 
with 1011 vp AdC68-gDMelapoly at both weeks 2 and 4. At the 1010 vp dose at week 4 Trp-2180 
responses were significantly higher in Melapoly vaccinated mice. 
 Figure 2-2: Induction of MAA-specific CD8+T cells by different vector doses 
 
 
Figure 2-2: Induction of MAA-specific CD8+ T cells by different vector doses: Groups (n=5/group) of 
C57BL/6 mice were vaccinated i.m. with 1010 vp or 1011 vp of either AdC68-Melapoly (open squares) or 
AdC68-gDMelapoly (closed squares) vector. PBMCs were collected 2 and 4 weeks later, (A) Trp-1455- and 
(B) Trp-2180-specific CD8+ T cell responses were compared. The graphs show responses in individual 
animals, the lines indicate means ± standard errors. * indicates significant differences between groups 
connected by lines (* p = 0.01-0.05, ** p = 0.001-0.01, *** p = 0.0001-0.001, ****p<0.0001). The following 
differences had significant p-values: all groups Trp-1455 compared to CD44-CD8+ controls: p < 0.0001; Trp-
1455: Melapoly vs. gDMelapoly: 1011 vp, wk 2: p = 0.012, 1010 vp, wk 4: p <0.0001; Trp-2180 compared to 
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controls: Melapoly, 1010 vp: wk 2: p < 0.0001,wk 4: p = 0.016; 1011 vp: wk 2: p < 0.0001, wk 4: p = 0.034; 
gDMelapoly: both doses and both time points: p < 0.0001; Trp-2180: Melapoly vs. gDMelapoly: 1011 vp: wk 2: 
p = 0.027, 1010 vp: wk 2: p = 0.036, wk 4: p < 0.0001. 
 
  To further assess differences, I immunized mice (n=7-8) with 1011 vp of the AdC68-
Melapoly vector or 1010 vp of the AdC68-gDMelapoly vector. I collected blood at different time 
points after vaccination and measured the CD8+ T cells to individual MAA epitopes by intracellular 
cytokine staining (ICS) for production of IFN-γ, TNF-α and IL-2 (Figure 2-3, Figure 2-4). For 
these experiments, blood had to be pooled to allow for testing the PBMC samples stimulated with 
the eight different peptides carrying CD8+ T cell epitopes expressed by the vaccines. Both vectors 
induced significantly higher tumor-antigen specific CD8+ T cell responses to both dominant and 
subdominant epitopes compared to naive controls (CD44-CD8+ T cells).  In spite of the lower 
dose, there was a clear trend of the AdC68-gDMelapoly vaccine to induce higher responses 
mainly to the subdominant epitopes (Trp-1455 epitope: mean frequencies averaging all time points: 
1.9 % and 2.9 % for Melapoly and gDMelapoly, respectively, Figure 2-3A; subdominant epitopes: 
mean frequencies of the sum of responses averaging all time points 1.3% and 3.0% for Melapoly 
and gDMelapoly, respectively, Figure 2-3B). The preferential increase of responses to 
subdominant epitopes by gD was confirmed by comparing responses to the dominant Trp-1455 
epitope to those against the subdominant Trp-2180 epitope by tetramer staining at 4 and 26 weeks 
after vaccination with 1011 vp of AdC68-Melapoly or 1010 vp of AdC68-gDMelapoly (Figure 2-3C-
D). At both early and late time points the responses to Trp-1455 epitope were comparable, while 
the responses to Trp-2180 epitope were significantly higher in mice immunized with AdC68-
gDMelapoly  (wk 4, mean tetramer frequencies for Trp-1455: Melapoly vs gDMelapoly: 7.8% vs 
5.3%; Trp-2180: 0.18% vs 0.42%, p = 0.0053; wk26, Trp-1455: Melapoly vs gDMelapoly: 4% vs 
5.9%, Trp-2180: 0.35% vs 0.66%, p = 0.033).  
   I selected three time points (weeks 6, 12 and 24) to compare the overall response 
pattern (Figure 2-3E-J). Responses to the subdominant epitopes developed with a delay as 
compared to Trp-1455-specific responses. At all three time points the gD-adjuvanted vector 
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induced a more prominent CD8+ T cell response to the subdominant epitopes compared to the 
AdC68-Melapoly vector (sum of frequencies to Melapoly and gD-Melapoly, respectively: wk 6: 
3.8%, 4.4%, wk 12: 2%, 6.7%, wk 24: 4.5 %, 6.6%). 
Figure 2-3: MAA-specific CD8+ T cell responses to individual epitopes 
In a pretumor challenge vaccination model, gD adjuvant
efficacy is solely linked to magnitude of the MAA-specific
CD8+ T cell responses
To determine whehter vaccination with the AdC68-gDMelapoly
vector resulted in superior protection against tumor growth than
vaccination with the AdC68-Melapoly vector, we immunized
groups of mice (n = 5–18) with 1010 vp AdC68-gDMelapoly, 1011
vp AdC68-Melapoly or 1011 vp AdC68-gD, the latter as a control
for nonspecific effects of the vector or gD. Fourteen days later,
mice were challenged with B16BrafV600E cells given s.c. Total
cytokine+CD8+ T cell responses to the eight CD8+ T cell epitopes
were measured before tumor challenge. As shown in Fig. 3A, both
vaccines induced significantly higher responses when compared
with background stains of naive T cells (mean frequencies 4.5 and
FIGURE 2. MAA-specific CD8+ T cell responses to individual epitopes. Groups of C57BL/6 mice (n = 7–8) were vaccinated i.m. with 1011vp AdC68-
Melapoly or 1010vp AdC68-gDMelapoly. (A and B) CD8+ T cell responses to individual epitopes were measured by ICS for IFN-g, TNF-a, and IL-2 upon
stimulation of cells with peptides representing the T cell epitopes expressed by the vaccines over a course of 24–26 wk. Graphs show the sum of cytokine
responses. (A) shows responses to the dominant Trp-1455 peptides. (B) shows the sum of responses over time for the other peptide; responses to individual
peptides (but for Trp-1455) were totaled. (C) and (D) shows Trp-1-teramer
+ and Trp-2 tetramer+CD8+ T cell responses 4 and 26 wk after vaccination in
tumors of vaccinated mice. Differences between the two vaccines were not significant for Trp-1–specific CD8+ T cells (p = 0.12 and 0.18, respectively) but
significant for Trp-2–specific CD8+ T cells (p = 0.0053 and 0.035, respectively). (E–J) The patterns of the sum of cytokine responses to the eight CD8+ T
cell epitopes at three time points [i.e., week 6 (E, F), 12 (G, H) and 24 (I, J)] after vaccination.
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Figure 2-3: MAA-specific CD8+ T cell responses to individual epitopes. Groups of C57BL/6 mice (n=7-
8) were vaccinated i.m. with 1011vp AdC68-Melapoly or 1010vp AdC68-gDMelapoly. (A-B) CD8+ T cell 
responses to individual epitopes were measured by ICS for IFN-γ, TNF-α and IL-2 upon stimulation of cells 
with peptides representing the T cell epitopes expressed by the vaccines over a course of 24-26 weeks. 
Graphs show the sum of cytokine responses. (A) shows responses to the dominant Trp-1455 peptides. (B) 
shows the sum of responses over time for the other peptide; responses to individual peptides (but for Trp-
1455) were totaled. (C-D) shows Trp-1-teramer+ and Trp-2 tetramer+ CD8+ T cell responses 4 weeks and 26 
weeks after vaccination in tumors of vaccinated mice. Differences between the two vaccines were not 
significant for Trp-1-specific CD8+ T cells (p = 0.12 and 0.18, respectively) but significant for Trp-2-specific 
CD8+ T cells (p = 0.0053 and 0.035, respectively). (E-J) The patterns of the sum of cytokine responses to 
the 8 CD8+ T cell epitopes at 3 time points, i.e., week 6 (E,F), 12 (G,H) and 24 (I,J) after vaccination. 
             
 Figure 2-4: Gating scheme for cytokine producing CD8+T cells 
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Figure 2-4: Gating scheme for cytokine producing CD8+T cells. Cells were stimulated with a control 
peptide or the MAA peptides present in the Ad vector encoded antigen. Cells were then stained for surface 
expression of CD44 and CD8 and intracellular cytokines such as IGN-γ, TNF-α and IL-2. Cells were 
analyzed and blots were generated. Cells were gates onto lymphoid, single, live CD8+ cells as described in 
Figure 2-1. They were then gated onto CD44low and CD44hiCD8+ cells (A). Both populations were gated on 
cells positive for TNF-α and/or IFN-γ (B-I) and TNF-α over IL-2 (not shown). To better illustrate the gates 
blots cells stimulated with the peptides carrying the subdominant epitopes (B,C) were concatenated.  
(B,C,F,G) show gates for cells stimulated with the control peptides, in B and F blots were concatenated, (C) 
and (G) show a single blot, (B) and (C) show blots for CD44low cells, (F) and (G) show blots for CD44hi cells.  
D and H show concatenated blots for CD44low (D) and CD44hi (H) cells stimulated with peptides carrying 
subdominant epitopes. (E) and (I) show blots for the same populations stimulated with the peptide carrying 
the immunodominant Trp-1455 epitope.  Boolean gates were set by FlowJo to determine counts and 
frequencies of cells producing the different combinations of cytokines. Counts were recorded and those 
obtained for each possible combination of cytokines with cells stimulated with the control peptide were 
subtracted from those obtained with peptides expressing an MAA-specific epitopes (for this results obtained 
with original blots rather than concatenated blots were used). Counts obtained for CD8+ T cells were then 
used to determine frequencies of cytokine producing cells over CD8+ cells. Frequencies for the 7 possible 
combinations of cytokines were summed to provide overall frequencies of responding cells. In Figure 2 the 
frequencies of CD44low and CD44hi cells producing cytokines over all CD8+ cells in response to the Trp-1455 
epitope are shown while Figure 2B shows the sum of frequencies to the other 6 peptides carrying 
immunosubdominant epitopes.  
 
In a pre-tumor challenge vaccination model, the increased efficacy of the gD adjuvanted 
vaccine is solely linked to magnitude of the MAA-specific CD8+ T cell responses 
    To determine if vaccination with the AdC68-gDMelapoly vector resulted in superior 
protection against tumor growth than vaccination with the AdC68-Melapoly vector, I immunized 
groups of mice (n=5-18) with 1010 vp of AdC68-gDMelapoly, 1011 vp of AdC68-Melapoly or 1011 
vp of AdC68-gD, the latter as a control for non-specific effects of the vector or gD. The dose for 
each vaccine was chosen to elicit relatively similar frequencies of MAA-specific CD8+T cells with 
overlaps between the groups. Fourteen days later mice were challenged with B16BrafV600E cells 
given s.c. Total cytokine+CD8+ T cell responses to the eight CD8+ T cell epitopes were measured 
before tumor challenge. As shown in Figure 2-5A, both vaccines induced significantly higher 
responses when compared to background stains of naïve T cells (mean frequencies 4.5% and 
9.3% for Melapoly and gD-Melapoly, 0.02% for control cells). The AdC68-gDMelapoly vector 
induced significantly higher CD8+ T cell responses compared to the AdC68-Melapoly vector (p < 
0.0001) and this was linked to enhanced survival rates upon tumor challenge (Figure 2-5C, p = 
0.0018 by Gehan-Breslow-Wilcoxon test). Specifically > 60% of AdC68gD-Melapoly vaccinated 
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mice as compared to < 20% of AdC68-Melapoly vaccinated mice remained tumor-free. When I 
compared subgroups with similar frequencies of MAA-specific CD8+ T cells by removing the low 
responders from the Melapoly group and the high responders from the gD-Melapoly group  
(Figure 2-5B, mean frequencies of the Melapoly subcohort: 5.7% and the gD-Melapoly 
subcohort: 6.5% p = 0.1), survival rates of the two vaccine groups were comparable (p = 0.08, 
Figure 2-5D). This suggests that in the pre-tumor challenge model vaccine efficacy is significantly 
influenced by the magnitude of MAA-specific CD8+ T cell responses.  
        Figure 2-5: Vaccine efficacy in mice vaccinated before tumor cell challenge 
        
9.3% for Melapoly and gD-Melapoly, 0.02% for control cells).
The AdC68-gDMelapoly vector induced significantly higher CD8+
T cell responses compared with the AdC68-Melapoly vector (p ,
0.0001), and this was linked to enhanced survival rates upon tumor
challenge (p = 0.0018 by Gehan–Breslow–Wilcoxon test; Fig. 3C).
Specifically, .60% of AdC68gD-Melapoly–vaccinated mice as
compared with ,20% of AdC68-Melapoly–vaccinated mice
remained tumor free. When we compared subgroups with similar
frequencies of MAA-specific CD8+ T cells by removing the low
responders from the Melapoly group and the high responders from
the gD-Melapoly group (mean frequencies of the Melapoly sub-
cohort: 5.7% and the gD-Melapoly subcohort: 6.5% p = 0.1;
Fig. 3B), survival rates of the two vaccine groups ceased to be
significantly different (p = 0.08; Fig. 3D). This suggests that in the
pretumor challenge model vaccine efficacy is significantly influ-
enced by the magnitude of MAA-specific CD8+ T cell responses.
In a posttumor challenge vaccination model, gD adjuvant
efficacy is not solely linked to the magnitude of MAA-specific
CD8+ T cell responses
We further compared the efficacy of the two vectors in a post-
challenge vaccination model. B16BrafV600E cells grow very rap-
idly in vivo; after tumor cell inoculation, most control mice require
euthanasia within 14–18 d. AdC68-induced T cell responses on the
other hand do not peak till 12–14 d after vaccination. Therefore, we
chose a fairly short interval of 3 d between tumor cell inoculation
and vaccination for our therapeutic vaccine studies. Accordingly,
groups of mice (n = 5–10) were challenged with B16BrafV600E
tumor cells on day 0 and vaccinated 3 d later with either 1011 vp of
the AdC68-Melapoly vector (n = 9) or 3 3 109vp and 1010 vp of
the AdC68-gDMelapoly vector (n = 8 and 10 for 3 3 109 and 1010
vp, repectively). A control group (n = 28) was vaccinated with 1011
vp of the AdC68-gD vector. CD8+ T cell responses were measured
2 wk later from blood by ICS for production of IFN-g, TNF-a,
granzyme B, and perforin. In addition, we assessed CD8+ T cell
responses by staining with the Trp-1455– and Trp-2180–specific
tetramers. MAA-specific CD8+ T cell responses tested by ICS were
significantly higher compared with background stains for both
vaccine groups, and higher in gDMelapoly than Melapoly-
vaccinated mice (means: Melapoly: 3.6%, gD-Melapoly: 5.2%,
controls: 0.27%, adjusted p values are shown in the figure legend;
Fig. 4Aa). The AdC68-gDMelapoly and Melapoly vector induced
significantly higher frequencies of Trp-1455 (means: Melapoly:
5.2%, gD-Melapoly: 6.3%, controls: 0.037%; Fig. 4Ba) and Trp-2180
tetramer+CD8+ T cells (means: Melapoly: 0.19% and gD-
Melapoly: 0.14% control cells: 0.042%; Fig. 4Ca) compared
with controls. Both vaccines significantly delayed tumor growth
and prolonged overall survival compared with control mice (p ,
0.0001; Fig. 4Da). Comparing the two vaccine groups showed that
AdC68-gDMelapoly–vaccinated mice survived significantly longer
than AdC68-Melapoly–vaccinated mice (p = 0.0039; Fig. 4Ad).
Because MAA-specific CD8+ T cell responses were higher in
the AdC68-gDMelapoly group than in the Melapoly group, we
selected eight mice from the AdC68-Melapoly vaccine group and
FIGURE 3. Vaccine efficacy in mice vaccinated before tumor cell challenge. Groups of C57BL/6 mice (n = 5-18) were vaccinated with 1011 vp AdC68-
gD, 1011 vp AdC68-Melapoly, or 1010 vp AdC68-gDMelapoly vectors. Fourteen days later, PBMC samples were tested for CD8+ T cell responses to all of
the MAA epitopes present in the vaccine. (A) The sum of tumor Ag-specific CD8+ T cell percentages for individual mice. *, Significant differences as
detailed in legend to Fig. 1. Melapoly versus gDMelapoly: p , 0.0001, Melapoly versus naive: p = 0.0014, gDMelapoly versus naive: p , 0.0001. (B) The
sum of tumor Ag-specific CD8+ T cell percentages in the two subcohorts that showed comparable CD8+ T cell responses. Subcohorts were selected by
excluding animals with frequencies of MAA-specific CD8+ T cells below the mean of the Melapoly group or above the mean of the gDMelapoly group.
Melapoly versus gDMelapoly, p = 0.1, Melapoly versus naive: p , 0.0001, gDMelapoly versus naive: p , 0.0001. (C) Survival rates of the entire group,
measured for 60 d. Melapoly versus naive: p , 0.0001, gD-Melapoly versus naive: p , 0.0001, Melapoly versus gDMelapoly: p = 0.0018. (D) Survival
rates of the of the Melapoly subcohort in comparison with the gDMelapoly and the control group. Melapoly versus controls: p , 0.0001, gD-Melapoly
versus controls: p = 0.0003, Melapoly versus gDMelapoly: p = 0.08. In (C) and (D), control animals are shown as X, AdC68-Melapoly-vaccinated mice are
shown as open squares, AdC68-gDMelapoly-vaccinated mice are shown as closed squares.
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FIGURE 2-5. Vaccine efficacy in mice vaccina ed before tumor cell challenge. Groups of 57BL/6 mice 
(n=5-18) were vaccinated with 1011vp AdC68-gD, 1011vp AdC68-Melapoly or 1010vp AdC68-gDMelapoly 
vectors. F urteen days later PB C sam les were t sted for CD8+ T cell responses to all of th  MAA 
epitopes pr sent in the vaccine. (A) The sum f tumor antigen-s ecific CD8+ T cell p rcentages for 
individual mice. (*) indicates significant differences as detailed in legend to Fig. 1. Melapoly vs. gDMelapoly: 
p < 0.0001, Melapoly vs. naïve: p = 0.0014, gDMelapoly vs. naïve: p < 0.0001. (B) The sum of tumor 
antigen-specific CD8+ T cell percentages in the two subcohorts that showed comparable CD8+ T cell 
responses. Subcohorts were selected by excluding animals with frequencies of MAA-specific CD8+ T cells 
below the mean of the Melapoly group or above the mean of the gDMelapoly group.  Melapoly vs. 
gDMelapoly, p = 0.1, Melapoly vs. naïve: p < 0.0001, gDMelapoly vs. naïve: p < 0.0001. (C) Survival rates of 
the entire group, measured for 60 days. Melapoly vs. naïve: p < 0.0001, gD-Melapoly vs. naïve: p < 0.0001, 
Melapo y vs. gDMelapoly: p = 0.0018 (D) Survival rates of the of the M lapoly subcohort in comparison to 
the gDMelapoly and the control roup. Melapoly vs. controls: p < 0.0001, gD-Melapoly vs. controls: p = 
0.0003, Melapoly vs. gDMelapoly: p = 0.08. In (C) and (D) control animals are shown as X, AdC68-
	
	
47	
Melapoly-vaccinated mice are shown as open squares, AdC68-gDMelapoly-vaccinated mice are shown as 
closed squares. 
 
In a post-tumor challenge vaccination model, the efficacy of the gD adjuvanted vaccine is 
not solely linked to the magnitude of MAA-specific CD8+ T cell responses 
    I further compared the efficacy of the two vectors in a post-challenge vaccination 
model. B16BrafV600E cells grow very rapidly in vivo; after tumor cell inoculation most control mice 
require euthanasia within 14-18 days. AdC68-induced T cell responses on the other hand do not 
peak till 12-14 days after vaccination. Therefore, I chose a fairly short interval of 3 days between 
tumor cell inoculation and vaccination for my therapeutic vaccine studies. Accordingly, groups of 
mice (n=5-10) were challenged with B16BrafV600E tumor cells on day 0 and vaccinated three days 
later with either 1011vp of the AdC68-Melapoly vector (n=9) or 3x109vp and 1010vp of the AdC68-
gDMelapoly vector (n=8 and 10 for 3x109vp and 1010vp, respectively). A control group (n=28) was 
vaccinated with 1011vp of the AdC68-gD vector. CD8+ T cell responses were measured two 
weeks later from blood by ICS for production of IFN-γ, TNF-α, granzyme B and perforin. In 
addition, I assessed CD8+ T cell responses by staining with the Trp-1455- and Trp-2180-specific 
tetramers. MAA-specific CD8+ T cell responses tested by ICS were significantly higher compared 
to background stains for both vaccine groups, and higher in gDMelapoly than Melapoly 
vaccinated mice (means: Melapoly: 3.6%, gD-Melapoly: 5.2%, controls :0.27%, adjusted p-values 
are shown in the figure legend, Figure 2-6Aa). The AdC68-gDMelapoly and Melapoly vectors 
induced significantly higher frequencies of Trp-1455 (means: Melapoly: 5.2%, gD-Melapoly: 6.3%, 
controls: 0.037%, Figure 2-6Ba) and Trp-2180 tetramer+CD8+ T cells (means: Melapoly: 0.19% 
and gD-Melapoly: 0.14% control cells: 0.042%, Figure 2-6Ca) compared to controls. Both 
vaccines significantly delayed tumor growth and prolonged overall survival compared to control 
mice (p<0.0001, Figure 2-6Da). Comparing the two vaccine groups showed that AdC68-
gDMelapoly vaccinated mice survived significantly longer than AdC68-Melapoly vaccinated mice 
(p = 0.0039, Figure 2-6Da).  
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    As MAA-specific CD8+ T cell responses were higher in the AdC68-gDMelapoly group 
than in the Melapoly group, I selected 8 mice from the AdC68-Melapoly vaccine group and 14 
mice from the AdC68-gDMelapoly vaccine group with comparable frequencies of total 
cytokine+CD8+ T cell responses (means: Melapoly: 3.9%, gDMelapoly: 4.0%, Figure 2-6Ab), Trp-
1455 tetramer+ CD8+ T cells (means: Melapoly: 3.0% and gDMelapoly: 3.1%, Figure 2-6Bb) and 
Trp-2180 tetramer+ CD8+ T cell responses (means: Melapoly: 0.19% and gD-Melapoly 0.14%, 
Figure 2-6Cb). Again in the subcohorts both vaccines significantly delayed tumor growth and 
prolonged survival compared to control mice (p<0.0001). Although mice had been selected based 
on comparable frequencies of MAA-specific CD8+ T cell responses, the AdC68-gDMelapoly 
vaccinated subcohort showed significantly prolonged survival rates compared to the AdC68-
Melapoly vaccinated subcohort (p=0.015, Figure 2-6Db).  
    To assess if vaccine-induced T cell responses differed in tissues, I analyzed MAA-
specific CD8+ T cell responses to all epitopes by ICS in blood, spleens and tumors at the time of 
necropsy, when the size of tumor exceeded a surface area of ~ 100 mm2. Interestingly, total 
cytokine+CD8+ T cell responses in the blood and tumors of AdC68-Melapoly vaccinated mice 
were significantly higher than those of AdC68-gDMelapoly vaccinated mice (mean frequencies: 
blood, spleens, tumors: Melapoly: 2.2%, 1.5%, 3.7%; gD-Melapoly: 1.2%, 1.4%, 2.1%; controls: 
0.049%, 0.12%, 0.027%; Figure 2-6Ac, p-values are shown in the figure legend). For Trp-1455-
specific CD8+ T cell responses, both vaccines induced significant responses in the different 
compartments compared to naïve cells. The AdC68-Melapoly group again showed significantly 
higher responses in tumors compared to mice immunized with AdC68-gDMelapoly (mean 
frequencies: blood, spleens, tumors: Melapoly: 2.7%, 2.0%, 7.8%; gD-Melapoly: 1.6%, 1.0%, 
2.7%; controls: 0.085%, 0.043%, 0.14%; Figure 2-6Bc; gating strategies Figure 2-7).  Trp-2180- 
specific responses were insignificant in blood but reached significance for both vaccine groups for 
cells from spleens and tumors compared to naive samples (mean frequencies: blood, spleens, 
tumors: Melapoly: 0.18%, 0.25%, 0.66%; gDMelapoly: 0.14%, 0.33%, 0.89%; controls: 0.016, 
0.02, 0.13%; Figure 2-6Cc). MAA-specific CD4+ T cell responses were analyzed in parallel; they 
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showed no differences before challenge but after challenge were higher in spleens of Melapoly-
vaccinated mice  (mean frequencies in spleens 1.5% and 0.59% for Melapoly and gD-Melapoly, 
respectively, p = 0.012, data not shown). Overall these results indicated that in the post-challenge 
vaccine model better protection achieved with the gD adjuvanted vaccine could not solely be 
explained by induction of higher frequencies of MAA-specific CD8+ T cells. 
Figure 2-6: Vaccine efficacy in mice vaccinated after tumor cell challenge 
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FIGURE 2-6. Vaccine efficacy in mice vaccinated after tumor cell challenge. Groups of C57BL/6 mice 
(n=9-30) were challenged with B16BrafV600E cells given s.c. 3 days before vaccination with 1011vp AdC68-
gD, 1011vp AdC68-Melapoly or 3 x109 vp and 1010 vp AdC68-gDMelapoly vector. Subcohorts were selected 
by excluding animals that had frequencies of MAA-specific CD8+T cells below the mean of the Melapoly 
group divided by the fold difference between the gD-Melapoly over Melapoly group (1.34) or above the 
mean of the gDMelapoly group multiplied by the fold difference. (a, b) PBMCs were tested 12 days after 
vaccination. (c) Cells from blood, spleens and tumors were tested at necropsy. (aA-aD) shows responses 
and survival rates of all mice, (bA-bD) and (cA-cC) show responses  and survival rates of the subcohorts. 
(*) indicates significant difference between two groups as described in legend to Fig. 2-2 with the following 
p-values: (Aa) both vaccine groups vs. controls: p < 0.0001;  Melapoly vs. gDMelapoly: p = 0.01. (Ab) both 
vaccine groups vs. to controls: p < 0.0001; Melapoly vs. gDMelapoly: p = 0.99. (Ac) Blood: Melapoly vs. 
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controls: p < 0.0001, gDMelapoly vs. controls: p = 0.0003, Melapoly vs. gDMelapoly: p = 0.011, Spleen: 
Melapoly vs. controls: p = 0.0003, gDMelapoly vs. controls: p < 0.0001, Tumors: all comparisons:  p < 
0.0001. (Ba) both vaccines vs. controls p < 0.0001, Melapoly vs. gDMelapoly p = 0.28. (Bb) both vaccine 
groups vs. controls: p < 0.0001, Melapoly vs. gDMelapoly: p = 0.07. (Bc) Blood: Melapoly vs. controls: p < 
0.0001, gDMelapoly vs. controls: p = 0.0029, Melapoly vs. gDMelapoly p =0.047, Spleen: Melapoly vs. 
controls: p < 0.0001, gDMelapoly vs. controls: p = 0.04, Tumors: all comparisons:  p < 0.0001. (Ca) both 
vaccines vs. controls: p < 0.0001. (Cb) Melapoly vs. controls: p < 0.0001, gDMelapoly vs. controls: 0.0002. 
(Cc)  Spleen: Melapoly vs. controls: p = 0.02, gDMelapoly vs. controls: p < 0.0001, Tumors: both vaccine 
groups vs. controls: p < 0.0001, Melapoly vs. gDMelapoly p = 0.0187. 
 
Figure 2-7: Gating Scheme for MAA-specific TILs and their production of cytokines and 
lytic enzymes          
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FIGURE 2-7. Gating Scheme for MAA-specific TILs and their production of cytokines and 
lytic enzymes. MAA-specific TILs were gated on lymphoid, live, single CD8+T cells. CD8+T cells were 
gated on CD44- and CD44+ cells (A, F). For tetramer stains CD44-CD8+(B,D) and CD44+CD8+(C,E) cells 
were gated on cells positive for the Trp-1(B,C) and Trp-2(D,E) tetramer. For ICS CD44-CD8+(G,I) and 
CD44+CD8+ cells were gated on TNF-α over IFN-γ (G,H) or perforin over granzyme (I,J). Frequencies were 
calculated after subtraction of background data obtained with cells cultured with a control peptide.  
 
MAA-specific CD8+ T cell phenotypes  
   Chronic exposure to antigen can lead to T cell exhaustion, which is characterized by 
progressive loss of T cell functions and eventual cell death (43,111). To determine if gD affected 
the differentiation pathways of T cells, I assessed the expression of several exhaustion markers, 
i.e., 2B4, LAG-3 and PD-1 on Trp-1455-and Trp-2180-specific CD8+ T cells in spleens and tumors at 
the time of necropsy, using the two subcohorts with comparable CD8+ T cell responses. 
Expression of exhaustion markers was also assessed on CD44-CD8+ (naïve) T cells and 
CD44+tet-CD8+ (memory) T cells. The latter population, negative for Trp-1455 and Trp-2180 
tetramer-specific CD8+ T cells, presumably contained CD8+ T cells to other MAAs in the vaccine, 
to antigens of the Ad vaccine carrier and to unrelated antigens encountered previously. Figure 2-
8A shows expression levels of the three exhaustion markers as mean fluorescence intensity 
(MFI) of the different dyes attached to the marker-specific antibodies. Significant differences were 
found between CD44-CD8+ and CD44+CD8+ T cells in spleens and tumors only for 2B4 (Figure 
2-8A). Differences between CD44-CD8+ or CD44+CD8+ T cells and vaccine-induced tetramer-
positive CD8+ T cells were seen for all markers with the exceptions of 2B4 on Trp-1455+CD8+ cells 
from spleens and 2B4 and PD-1 on Trp-2180+CD8+TILs. I also observed significant differences 
between the two vaccine subcohorts as well as between CD8+ T cells to the two epitopes. In 
particular, 2B4 showed higher expression on Trp-2180- than Trp-1455- specific CD8+ T cells 
induced by either vaccine in spleens (mean MFI Melapoly: Trp-1455 vs. Trp-2180: 158 vs. 269, 
gDMelapoly: Trp-1455 vs. Trp-2180: 166 vs. 284, adjusted p-values are shown in the legend to 
Figure 2-8A).  In both vaccine groups LAG-3 expression in spleens and in tumors was higher on 
Trp-1455- than Trp-2180-specific CD8+ T cells. In tumors, Trp-1455- specific CD8+ T cells showed 
significantly lower level of LAG-3 expression in AdC68-gDMelapoly vaccinated animals compared 
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to those from AdC68-Melapoly vaccinated mice (mean MFI: spleen: Melapoly: Trp-1455 vs. Trp-
2180: 436 vs. 224, gDMelapoly: Trp-1455 vs. Trp-2180: 401 vs. 313; tumors: Melapoly: Trp-1455 vs. 
Trp-2180: 875 vs. 504, gDMelapoly: Trp-1455 vs. Trp-2180: 728 vs. 609). In spleens, PD-1 was 
expressed at higher levels on Trp-2180- than Trp-1455-specific CD8+ T cells and this reached 
significance for those induced by AdC68-gDMelapoly. Within tumors again Trp-1455-specific CD8+ 
T cells that had been elicited by the AdC68-gDMelapoly vaccine showed lower PD-1 expression 
compared to those elicited by the AdC68-Melapoly vaccine. In both vaccine groups, Trp-1455-
specific CD8+ T cells expressed higher levels of PD-1 compared to those specific for Trp-2180 
(mean MFI: spleen: Melapoly: Trp-1455 vs. Trp-2180: 97 vs. 126, gDMelapoly: Trp-1455 vs. Trp-2180: 
89 vs. 151; tumors: Melapoly: Trp-1455 vs. Trp-2180: 1190 vs. 400, gDMelapoly: Trp-1455 vs. Trp-
2180: 721 vs. 297). 
    In addition, I determined the percentages of Trp-1455- and Trp-2180- specific CD8+TILs 
that were positive for either of the exhaustion markers and compared the results with those on 
naïve (CD44-) or memory tetramer- CD8+ T cells (Figure 2-8B, a-c, Figure 2-9). Only very low 
percentages of CD44-CD8+ T cells expressed any of the three exhaustion markers (< 2%). 
Percentages of marker+CD44+tet-CD8+ T cells were intermediate (2B4: 19%, 15%; LAG-3: 17%, 
12%; PD-1: 23%, 41% for Melapoly and gDMelapoly vaccinated mice). Expression of individual 
markers was significantly higher on CD44+CD8+ cells than on naïve cells. Percentages of Trp-
1455-or Trp-2180-specific CD8+ T cells positive for any of the three exhaustion markers were again 
significantly higher when compared to CD44-CD8+ or tetramer-CD44+CD8+ cells. Comparing the 
two vaccine subcohorts or Trp-1455- and Trp-2180-specific CD8+ T cells within each vaccine group 
showed no significant differences for percentages of 2B4+ cells (means: Melapoly: Trp-1455 vs. 
Trp-2180: 52% vs. 39%, gDMelapoly: Trp-1455 vs. Trp-2180: 44% vs. 33%). LAG-3+ cells were 
significantly more common within Trp-1455- specific CD8+ T cells in both vaccine groups (means: 
Melapoly: Trp-1455 vs. Trp-2180: 87% vs. 48%, gDMelapoly: Trp-1455 vs. Trp-2180: 81% vs. 58%) as 
were PD-1+CD8+ cells in Melapoly-vaccinated mice. Interestingly percentages of PD-1+ Trp-1455- 
specific CD8+ cells were significantly lower in the AdC68gD-Melapoly group than in mice 
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immunized with AdC68-Melapoly (means: Melapoly: Trp-1455 vs. Trp-2180: 84% vs. 67%, 
gDMelapoly: Trp-1455 vs. Trp-2180: 63% vs. 57%).  
   Exhaustion leads to sequential expression of several markers (43). Accordingly, I 
further analyzed tumor-derived T cells for co-expression of PD-1, LAG-3 and 2B4 (Figure 2-8B, 
d-f). Again I found that higher percentages of Trp-1455- and Trp-2180-specific CD8+ T cells co-
expressed two or three markers compared to CD44-CD8+ or tetramer-CD44+CD8+ cells. Trp-1455-
specific CD8+ T cells had in general higher frequencies of PD-1+LAG-3+ and PD-1+LAG-3+2B4+ 
cells compared to Trp-2180-specific CD8+ T cells. Trp-1455-specific CD8+ cells expressing two or 
three of the markers were present at significantly lower frequencies in gDMelapoly than Melapoly-
immunized mice (means: Melapoly vs. gDMelapoly: PD-1+2B4+: Trp-1455: 47% vs. 35%, Trp-2180: 
32% vs. 24%; PD-1+LAG-3+: Trp-1455: 69% vs. 53%, Trp-2180: 29% vs. 24%; PD-1+2B4+LAG-3+: 
Trp-1455: 45% vs. 34%, Trp-2180: 25% vs. 20%).  
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Figure 2-8: MAA-specific CD8+ T cell phenotype 
					
FIGURE 5. MAA-specific CD8+ T cell phenotypes. Phenotypes of CD8+ T cells isolated from spleens and tumors of the two subcohorts shown in Fig. 4
were tested for expression of 2B4, LAG-3, and PD-1. (A) MFI of 2B4 (a, d), LAG-3 (b, e), and PD-1 (c, f) fluorochrome-labeled Abs on CD442CD8+,
tetramer2CD44+CD8+ and tetramer+CD44+CD8+ T cells from spleens (a–c) and tumors (d, f). Open boxes show results for CD8+ T cells from AdC68-
Melapoly–vaccinated mice, gray boxes indicated CD8+ T cells from AdC68-gDMelapoly vaccinated mice. *, Significant differences as detailed in legend to
Fig. 1 between groups connected by lines (dashed lines for differences between control cells or between control cells and Ag-specific CD8+ T cells, solid lines
for differences between specific CD8+ T cells). The following p values were obtained for Trp-1455 and Trp-2180 comparisons: (Aa) Trp-1455 versus Trp-2180:
Melapoly: p , 0.0001, gDMelapoly: p , 0.0001; (Ad) none; (Ab) Trp-1455 versus Trp-2180: Melapoly: p , 0.0001, gDMelapoly: p = 0.0056; (Ae) Trp-1455
versus Trp-2180: Melapoly: p , 0.0001; (Ac) Trp-1455 versus Trp-2180: gDMelapoly: p , 0.0001; (Af) Trp-1455 versus Trp-2180: Melapoly: p , 0.0001,
gDMelapoly: p = 0.028, Melapoly versus gDMelapoly: Trp-1455: p = 0.0008. (B) Percentages of tumor-derived naive CD44
2CD8+, tetramer2CD44+CD8+, and
tetramer+CD44+CD8+ T cells that were positive for a given marker or combinations of exhaustion markers. Cells from AdC68-Melapoly–vaccinated mice are
shown as open boxes, and cells from AdC68-gDMelapoly vaccinated mice are shown as gray boxes. Whiskers show 5–95th percentile, lines show 50th
percentile, + within boxes indicates means. *, Significant differences between groups as described in legends to Fig. 1. (Ba) (Figure legend continues)
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Mean fluorescence intensity (MFI) of 2B4 (a, d), LAG-3 (b, e) and PD-1 (c, f) fluorochrome-labeled 
antibodies on CD44-CD8+, tetramer-CD44+CD8+ and tetramer+CD44+CD8+ T cells from spleens (a-c) and 
tumors (d-f). Open boxes show results for CD8+ T cells from AdC68-Melapoly vaccinated mice, grey boxes 
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indicated CD8+ T cells from AdC68-gDMelapoly vaccinated mice. (*) indicates significant differences as 
detailed in legend to Fig. 1 between groups connected by lines (dashed lines for differences between control 
cells or between control cells and antigen-specific CD8+ T cells , solid lines for differences between specific 
CD8+ T cells). The following p-values were obtained for Trp-1455 and Trp-2180 comparisons: (Aa): Trp-1455 vs. 
Trp-2180:  Melapoly: p < 0.0001, gDMelapoly: p < 0.0001; (Ad): none; (Ab) Trp-1455 vs. Trp-2180:  Melapoly: p 
< 0.0001, gDMelapoly: p = 0.0056; (Ae) Trp-1455 vs. Trp-2180:  Melapoly: p < 0.0001; (Ac) Trp-1455 vs. Trp-
2180: gDMelapoly: p < 0.0001; (Af) Trp-1455 vs. Trp-2180:  Melapoly: p < 0.0001, gDMelapoly: p = 0.028, 
Melapoly vs. gDMelapoly: Trp-1455: p = 0.0008. 5B Percentages of tumor-derived naïve CD44-CD8+, 
tetramer-CD44+CD8+, and tetramer+CD44+CD8+ T cells that were positive for a given marker or 
combinations of exhaustion markers. Cells from AdC68-Melapoly vaccinated mice are shown as open 
boxes, cells from AdC68-gDMelapoly vaccinated mice are shown as grey boxes. Whiskers show 5-95 
percentile, lines show 50 percentile, + within boxes indicates means.  (*) indicates significant differences 
between groups as described in legends to Fig. 1. (Ba) Trp-1455 vs. Trp-2180:  Melapoly: p = 0.031. (Bd) 
Melapoly vs. gDMelapoly: Trp-1455: p = 0.035; Trp-1455 vs. Trp-2180:  Melapoly: 0.019. (Bb): Trp-1455 vs. Trp-
2180:  Melapoly: p < 0.0001, gDMelapoly: p < 0.0001. (Be) Melapoly vs. gDMelapoly: Trp-1455: p = 0.0036; 
Trp-1455 to Trp-2180: Melapoly: p < 0.0001, gDMelapoly: p < 0.0001. (Bc) Melapoly vs. gDMelapoly: Trp-1455: 
p = 0.0006, Trp-1455 vs. Trp-2180: Melapoly p = 0.016. (Bf) Melapoly vs. gDMelapoly: Trp-1455: p = 0.039; 
Trp-1455 vs. Trp-2180:  Melapoly: p = 0.0004, gDMelapoly: p = 0.021. 
Figure 2-9: Gating scheme for expression of markers on CD8+T cells  
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FIGURE 2-9. Gating scheme for expression of markers on CD8+T cells. Cells were gated on lymphoid, 
single live CD8+ cells as shown in Figure 1. Cells were then gated onto CD44low and CD44hi cells (A). 
CD44hi cells were gated on cells positive for either of the two tetramers and on cells negative for either of the 
two tetramers (B).  CD44- (C,D,G,H,K), tetramer+CD44+ (E,F,I,J,L) and tetramer-CD44+ cells were then 
gated onto LAG-3 (C,E), 2B4 (D,F) and PD-1 (G,I). The gates were adjusted so that CD44-CD8+ cells had 
less than 2% of marker positive cells. Cells were then gated onto 2B4 over PD-1 to identify cells positive for 
both markers (H,J). Cells double positive for PD-1 and 2B4 were then gated onto LAG-3 (K,L) to identify 
cells positive for all three markers.   
    Markers that are indicative for exhaustion are also upregulated upon activation. To 
ensure that AdC68-gDMelapoly-induced TILs showed better preservation of function as would be 
expected of less exhausted CD8+ T cells, I compared the proportions of Trp-1 specific CD8+ T 
cells that produced only IFN-γ or IFN-γ together with TNF-α between the two vaccine groups. For 
these comparisons cells were isolated from tumors at days 30-35 after vaccination. AdC68-
gDMelapoly-induced Trp-1-specific CD8+ T cells had significantly higher proportions of Trp-1 
specific CD8+ TILs that produced both cytokines compared to AdC68-Melapoly-induced TILs 
(mean AdC68-gDMelapoly: 0.47, AdC68-Melapoly: 0.3, p = 0.04 by two-tailed t-test). To further 
ensure that Trp-1-specific TILs with increased expression of PD-1 or PD-1 and LAG-3 were 
indeed exhausted rather than recently activated, I tested PD-1+ and PD-1- TILs for production of 
IFN-γ and TNF-α upon stimulation with the Trp-1455 peptide. As shown in Figure 2-10A, slightly 
higher frequencies of Trp-1 specific CD8+ T cells from blood produced IFN-γ together with TNF-α 
than IFN-γ only. In tumors this proportion shifted and nearly 70% of Trp-1 specific TILs produced 
only IFN-γ suggesting loss of function (mean frequencies of Trp-1-specific CD8+ T cells: blood: 
IFN-γ+TNF-α- vs. IFN-γ+TNF-α+: 0.32% vs. 0.57%; tumor: 1.85% vs. 0.84%). Co-stains for PD-1 
showed significantly higher PD-1 expression on mono-functional Trp-1-specific CD8+ TILs as 
compared to those that produced both cytokines  (mean PD-1 MFI values: blood: IFN-γ+TNF-
α- vs. IFN-γ+TNF-α+: 174 vs. 143, tumor: 1236 vs. 774, Figure 2-10B). An analysis for expression 
of T-bet, which controls transcription of effector molecules and inhibits expression of PD-1, 
showed that T-bet levels were low on naïve circulating CD8+ T cells and markedly increased on 
blood-derived Trp-1-specific CD8+ T cells. Tumor-infiltrating Trp-1-specific CD8+ T cells showed a 
marked reduction in T-bet expression (Figure 2-10C), which corresponded to expression levels of 
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exhaustion/activation markers (mean T-bet MFI values: CD44-CD8+ T cells: 6.2; Trp-1 specific 
CD8+ T cells blood vs. TILs: 464.2 vs. 204.6); Trp-1-specific CD8+ TILs that expressed high levels 
of PD-1 or PD-1 and LAG-3 had reduced levels of T-bet as compared to those with low PD-1 or 
PD-1 and LAG-3 expression (Figure 2-10D-F) (mean T-bet MFI values: PD-1+ vs. PD-1-: 191.4 
vs. 286.2; PD-1+LAG-3+ vs. PD-1-LAG-3- : 181.3 vs. 256). Overall these results show that 
increased expression of PD-1 was associated with loss of polyfunctionality and downregulation of 
T-bet, confirming that MAA-specific CD8+ T cells induced by the vaccines were differentiation 
towards exhaustion within the TME.  
 Figure 2-10: MAA-specific T cell functions in relation to phenotypes  
FIGURE 2-10 MAA-specific T cell functions in relation to phenotypes. Mice with 3-day old B16BrafV600E 
tumors were vaccinated with 1010 vp of AdC68-gDMelapoly. Lymphocytes from blood and tumors were 
isolated 4 weeks later. (A) Frequencies of CD8+ T cells producing IFN-g only or IFN-g together with TNF-a 
were determined by ICS. By t-tests frequencies of Trp-1-specific IFN-g+TNF-a+CD8+ T cells were higher in 
blood than those of IFN-g+TNF-a-CD8+ T cells (p = 0.036) while in TILs frequencies of Trp-1-specific CD8+ T 
cells producing only IFN-g were significantly higher (p = 0.0066). (B) shows levels of PD-1 expression on 
Trp-1-specific CD8+ T cells that produced only IFN-g or IFN-g together with TNF-a. Expression levels were 
comparable in blood-derived cells but significantly higher on TILs that were only positive for IFN-g than on 
those that produced both cytokines (p = 0.024). (C) shows levels of T-bet expression on naïve CD44-CD8+ 
lymphocytes from blood and on Trp-1-specific CD8+ T cells from blood and tumors. Trp-1-specific CD8+ T 
cells expressed significantly higher levels of T-bet as compared to naïve CD8+ T cells (p < 0.0001). T-bet 
expression was higher on blood than on tumor-derived Trp-1-specific CD8+ T cells (p < 0.0001). (D) shows 
levels of T-bet expression on Trp-1-specific TILs separated into subgroups according to levels of PD-1 or 
PD-1 and LAG-3 expression. Levels of T-bet expression were significantly higher on PD-1- as compared to 
T cells blood versus TILs: 464.2 versus 204.6); Trp-1-specific
CD8+ TILs that expressed high levels of PD-1 or PD-1 and
LAG-3 had reduced levels of T-bet as compared with those with
low PD-1 or PD-1 and LAG-3 expression (Fig. 6D–F) (mean T-bet
MFI values: PD-1+ versus PD-1-: 191.4 versus 286.2; PD-1+LAG-
3+ versus PD-1-LAG-3-: 181.3 versus 256). Overall these results
show that increased expression of PD-1 was associated with loss
of polyfunctionality and downregulation of T-bet, confirming that
MAA-specific CD8+ T cells induced by the vaccines were dif-
ferentiation toward exhaustion within the TME.
Taken together, these results demonstrate complex patterns of
up-regulation of exhaustion markers during tumor progression that
were affected by the vaccines, the TcR specificity as well as the
anatomic sites from which T cell had been isolated. Within tumors,
MAA-specific CD8+ T cells induced by the AdC68-gDMelapoly
vector were less exhausted compared with those induced by the
AdC68-Melapoly vector, fewer cells expressed exhaustion mark-
ers, and they were able to delay tumor progression for longer
periods of time. In addition, tumor-infiltrating CD8+ T cells spe-
cific to the dominant Trp-1455 epitopes showed more evidence
of exhaustion compared with those specific to the subdominant
Trp-2180 epitope.
Discussion
T cell activation is finely tuned upon binding of the TcR to its
cognate Ag-MHC class I molecule complex through additional in-
teractions with costimulatory and coinhibitory receptors (28, 29).
Coinhibitory receptors include CTLA-4, PD-1, BTLA, and others.
BTLA, unlike PD-1 and CTLA-4, is expressed on both naive and
activated T cells (30) and thereby presumably regulates T cell ac-
tivation at several stages. PD-1 and CTLA-4 inhibit downstream
signals transmitted upon TcR ligation such as induction of the
Trp-1455 versus Trp-2180: Melapoly: p = 0.031. (Bd) Melapoly versus gDMelapoly: Trp-1455: p = 0.035; Trp-1455 versus Trp-2180: Melapoly: 0.019. (Bb):
Trp-1455 versus Trp-2180: Melapoly: p , 0.0001, gDMelapoly: p , 0.0001. (Be) Melapoly versus gDMelapoly: Trp-1455: p = 0.0036; Trp-1455 to Trp-2180:
Melapoly: p , 0.0001, gDMelapoly: p , 0.0001. (Bc) Melapoly versus gDMelapoly: Trp-1455: p = 0.0006, Trp-1455 versus Trp-2180: Melapoly p = 0.016.
(Bf) Melapoly versus gDMelapoly: Trp-1455: p = 0.039; Trp-1455 versus Trp-2180: Melapoly: p = 0.0004, gDMelapoly: p = 0.021.
FIGURE 6. MAA-specific T cell functions in relation to phenotypes. Mice with 3-d-old B16BrafV600E tumors were vaccinated with 10
10 vp AdC68-
gDMelapoly. Lymphocytes from blood and tumors were isolated 4 wk later. (A) Frequencies of CD8+ T cells producing IFN-g only or IFN-g together with
TNF-a were determined by ICS. By t tests frequencies of Trp-1–specific IFN-g+TNF-a+CD8+ T cells were higher in blood than those of IFN-g+TNF-a-
CD8+ T cells (p = 0.036), whereas in TILs, fr quencies f Trp-1-specifi CD8+ T cells producing only IFN-g were significantly higher (p = 0.0066). (B)
shows levels of PD-1 expression on Trp-1–specific CD8+ T cells that produced only IFN-g or IFN-g together with TNF-a. Expression levels were
comparable in blood-derived cells but significantly higher on TILs that were only positive for IFN-g than on those that produced both cytokines (p = 0.024).
(C) shows levels of T-bet expression on naive CD44-CD8+ lymphocytes from blood and on Trp-1–specific CD8+ T cells from blood and tumors. Trp-1–
specific CD8+ T cells expressed significantly higher levels of T-bet as compared with naive CD8+ T cells (p , 0.0001). T-bet expression was higher on
blood than on tumor-derived Trp-1–specific CD8+ T cells (p , 0.0001). (D) shows levels of T-bet expression on Trp-1–specific TILs separated into
subgroups according t levels of PD-1 or PD-1 and LAG-3 expression. Levels of T-bet expression were significantly higher on PD-12 as compared with
PD-1+ cells (p = 0.0001) and on PD-12LAG-32 cells than on PD-1+LAG-3+ cells (p = 0.0002). (E) Gating scheme onto PD-1+ and PD-12 cells following
initial gating on live lymphoid cells, CD8+ cells, CD44hi cells, and Trp-1 tetramer+ cells as shown in Supplemental Fig. 1. (F) Expression levels of T-bet on
PD-12 (dashed line) and PD-1+ Trp-1–specific CD8+ T cells.
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PD-1+ cells (p = 0.0001) and on PD-1-LAG-3- cells than on PD-1+LAG-3+ cells (p = 0.0002). (E) Gating 
scheme onto PD-1+ and PD-1- cells following initial gating on live lymphoid cells, CD8+ cells, CD44hi cells 
and Trp-1 tetramer+ cells as shown in Suppl. Fig. 1. (F) Expression levels of T-bet on PD-1- (dashed line) 
and PD-1+ Trp-1-specific CD8+ T cells. 
     Taken together these results demonstrate complex patterns of up-regulation of 
exhaustion markers during tumor progression that were affected by the vaccines, the TcR 
specificity as well as the anatomic sites from which T cell had been isolated. Within tumors MAA-
specific CD8+ T cells induced by the AdC68-gDMelapoly vector were less exhausted compared to 
those induced by the AdC68-Melapoly vector, fewer cells expressed exhaustion markers and they 
were able to delay tumor progression for longer periods of time. In addition, tumor-infiltrating 
CD8+ T cells specific to the dominant Trp-1455 epitopes showed more evidence of exhaustion 
compared to those specific to the subdominant Trp-2180 epitope. 
 
DISCUSSION 
	
    T cell activation is finely tuned upon binding of the TcR to its cognate antigen-MHC 
class I molecule complex through additional interactions with co-stimulatory and co-inhibitory 
receptors (264,265). Co-inhibitory receptors include CTLA-4, PD-1, BTLA and others. BTLA, 
unlike PD-1 and CTLA-4, is expressed on both naïve and activated T cells (266) and thereby 
presumably regulates T cell activation at several stages. PD-1 and CTLA-4 inhibit downstream 
signals transmitted upon TcR ligation such as induction of the protein kinase B pathway (PKB), 
albeit through distinct pathways (114,267). PKB in turn regulates cell survival as well as glucose 
metabolism and is therefore crucial for successful activation and expansion of T cells (268). The 
exact signaling pathway downstream of BTLA remains unknown. Similar to PD-1 and CTLA-4, 
the cytoplasmic domain of BTLA contains immune-receptor tyrosine based inhibitory motifs (269) 
that may dampen TcR signaling.  
    Although modulators of HVEM signaling have not yet been tested in humans, the 
TNFRSF14 locus, which encodes HVEM, has been linked to increased risks for ulcerative colitis 
(270), systemic lupus erythomatodus (271) and rheumatoid arthritis (272), stressing the 
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importance of this regulatory pathway. Similarly, genetic deletions of BTLA or HVEM cause 
exacerbated inflammatory reactions (273) and accelerated rejection of partially mismatched 
transplants in mice (274).  
     It has been shown that HVEM is expressed on tumor cells such as B cell lymphomas 
(275) or metastatic melanomas. BTLA on the other hand is highly expressed on melanoma-
specific CD8+ T cells and it has been argued that the impaired proliferative capacity of MAA-
specific T cell in melanoma patients is linked to immunoinhibitory signals from HVEM+ tumor cells 
(276). In another study NY-ESA-1-specific CD8+ T cells from end-stage melanoma patients were 
shown to express elevated levels of PD-1 and BTLA (277). T cells were defective in their ability to 
proliferate or secret factors in response to antigenic stimulation, which could in part be restored 
by blocking PD-1 and/or BTLA signaling. This suggests that inhibitors of BTLA should be 
explored as additives to active immunotherapy of melanoma.  
    As we showed previously, blockade of the BTLA-HVEM pathway through HSV-1 gD 
during antigen-driven T cell stimulation numerically augments CD8+ T cell responses (244,263). 
This was confirmed in the current study using vaccines expressing multiple epitopes derived from 
MAAs. In a prophylactic melanoma model, the superior protection achieved upon gD-mediated 
blockade of the HVEM pathways at the time of T cell induction was correlated with the magnitude 
of MAA-specific CD8+ T cell responses. Using different doses of the two vaccines, i.e., AdC68-
Melapoly and AdC68-gDMelapoly, mice that developed approximately equal frequencies of MAA-
specific T cells showed comparable levels of protection against tumor challenge. In contrast, in 
mice that were inoculated first with melanoma cells and then vaccinated with either of the two 
vectors, the magnitude of the vaccine-induced MAA-specific CD8+ T cell responses was not the 
sole factor that determined vaccine efficacy; in mice with approximately comparable frequencies 
of MAA-specific CD8+ T cells following vaccination with the AdC68-Melapoly or AdC68-
gDMelapoly vectors, those that received the latter survived significantly longer. Cytokine profiles 
of antigen-specific CD8+ T cells were largely comparable between the two vaccine groups before 
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and after challenge with responses being dominated by CD8+ T cells producing IFN-γ alone or in 
combination with TNF-α(not shown) as is typical for T cells induced by Ad vectors.  
    Paradoxically, at the time of necropsy AdC68-Melapoly vaccinated animals had 
significantly higher frequencies of MAA-specific CD8+ T cells in some tissues compared to those 
vaccinated with AdC68-gDMelapoly. This again confirms that protection did not solely correlate 
with frequencies of vaccine-induced T cells. Further analysis of MAA-specific CD8+ T cells for 
expression of activation/exhaustion markers showed that within tumors lower frequencies of 
AdC68-gDMelapoly-induced CD8+ T cells expressed LAG-3, PD-1, PD-1 together with LAG-3 or 
2B4 or all three markers as compared to AdC68-Melapoly induced CD8+ T cells. These markers 
are not only indicative for exhaustion but they are also increased upon recent CD8+ T cells 
activation. Antigens derived from the tumor may have provided further activation signals to the 
MAA-specific CD8+ T cells, which then contributed to their elevated levels on tumor-infiltrating 
MAA-specific CD8+ T cells. Nevertheless, as these activation signals should have been provided 
to T cells in both vaccine cohorts, I assume that the differences in expression levels on tumor-
infiltrating MAA-specific CD8+ T cells in Melapoly and gDMelapoly-vaccinated mice reflected 
differences in their stage of exhaustion. This was further confirmed by loss of polyfunctionality 
and T-bet expression on cells with increased expression of immunoinhibitory markers. In turn, my 
finding suggests that the relative resistance to tumor-driven exhaustion of MAA-specific CD8+ T 
cells generated in presence of gD resulted in prolonged control of tumor progression.  
   T cell exhaustion, a consequence of continued antigen-driven-stimulation of T cells, 
was initially described in chronic viral diseases such as those caused by lymphocytic 
choriomeningitis virus infection of mice (111) or human immunodeficiency virus (278) or hepatitis 
C virus infection (279) of humans. It was subsequently observed in cancer patients. 
Differentiation towards exhaustion is initially characterized by increased expression of PD-1 on 
the T cell surface, which over time is joined by other co-inhibitors (103). Expression of PD-1 is 
regulated by TcR ligation (280) and at the transcriptional level by NFAT1c (281). T cells with high 
affinity TcRs appear to be more sensitive to antigen-driven exhaustion compared to those with 
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lower affinity TcRs (282). This is supported by my finding that within tumors CD8+ T cells specific 
to the subdominant Trp-2180 epitope appeared less exhausted; vaccine-induced Trp-2180-specific 
CD8+T cells expressed lower levels of PD-1 or LAG-3 as compared to CD8+ T cells specific to the 
more dominant Trp-1455 epitope. The same pattern was seen for MAA-specific CD8+ T cells that 
were double or triple positive for PD-1, 2B4 and/or LAG-3. Notwithstanding, it should be pointed 
out that the finding that higher TcR affinity promotes exhaustion remains debatable, although it is 
compatible with the highly reproducible finding that exhaustion is primarily driven by continued 
TcR ligation (283). Other pathways that prevent antigen-driven exhaustion of CD8+ T cells 
induced by the gD-adjuvanted vaccine may have contributed the results, but cannot be explored 
without additional knowledge of the BTLA/CD160 signaling pathways.  
     Active cancer immunotherapy with traditional vaccines that boost tumor-specific T cell 
responses has performed poorly in patients with advanced cancer. Additional strategies that 
block immunoinhibitory pathways may improve the efficacy of cancer vaccines. Here I show that 
adjuvanting a tumor vaccine with HSV-1 gD could induce tumor antigen-specific CD8+ T cells with 
increased resistance to exhaustion. This approach, unlike other reagents that block 
immunological checkpoints such as antibodies to PD-1 or CTLA-4, selectively affects tumor 
antigen-specific T cells and presumably will not globally perturb the exquisitely fine-tuned balance 
of the immune system.  
 
MATERIALS AND METHODS 
	
Mice 
Female C57Bl/6 mice (6-8 weeks) were purchased from the National Cancer Institute (NCI) and 
housed at the Wistar Institute Animal Facility. All procedures were performed under the guideline 
of protocols approved by the IACUC of the Wistar Institute.  
 
Cell lines 
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The B16BrafV600E cell line was derived from B16.F10 cells transduced with lentiviral vector pLU-
EF1a-mCherry expressing mouse BrafV600E (provided by Dr. M Herlyn lab, Wistar Institute, 
Philadelphia, PA). The mutant cell line showed the same in vivo growth characteristics as 
unmodified B16.F10 cells. E1-transfected HEK 293 cells were used to propagate Ad vectors. 
Cells were cultured with DMEM supplemented with 10% FBS. 
Construction of recombinant Ad vectors 
I designed the Melapoly transgene to express a number of MAA-specific CD4+ T cell and CD8+ T 
cell epitopes. An endoplasmic reticulum (ER) targeting signal sequence was included at the N-
terminal end of the sequence(284). Three human (h)Trp-2-specific CD4+ T cell epitopes(285) as 
well as the universal T helper cell epitope PADRE(286) were incorporated into the Melapoly 
construct. CD8+ T cell epitopes were derived from human and mouse Trp-2, human gp100, 
mouse Trp-1 and BrafV600E. Epitopes from Trp-1 and Braf antigens were modified to enhance their 
binding to MHC class I molecules(287). A Flag-tag was added to the C-terminal end. I designed 
the spacer sequences according to several analysis programs, including PAPROC I 
(http://www.paproc.de), Netchop 3.1 (http://www.cbs.dtu.dk/services/NetChop/), and IEBD 
Analysis Resource (http://tools.immuneepitope.org/main/). The spacers were inserted between 
each CD4+ and CD8+ T cell epitope to reduce interference of epitope processing(288,289). The 
Melapoly gene was codon optimized and inserted into the pUC57 vector (Genescript, Piscataway, 
NJ). The Melapoly transgene was sequenced and cloned it into the pShuttle vector by EagI 
digestion. To construct the AdC68-gDMelapoly vector, the Melapoly transgene was fused into the 
N terminus of HSV-1 gD. The pShuttle gDMelapoly vector was generated by PCR using pShuttle 
Melapoly as the template, gDMelaFwAgeI CGACCGGTTAGCTAAGTTTGTGGCCGCTTG and 
gDMelaRvAvrII CGCCTAGGTGCTGCTGCTGCAATGCTC as primers. The PCR product was 
cleaved by AgeI and AvrII and cloned into the pShuttle gD-Flag vector. The inserts containing 
regulatory sequences of the pShuttle vector were subcloned into the E1-deleted AdC68 viral 
molecular clone using I-CeuI and PI-SceI sites. Recombinant AdC68 vectors were rescued, 
propagated on HEK 293 cells, purified by CsCl-gradient centrifugation and titrated as 
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described(290). The concentration of each virus batch was determined by measuring virus 
particles (vp) by spectrophotometry at 260nm.  
 
Real-Time PCR  
I infected HEK 293 cells with 1010vp and 1011vp doses of AdC68-Melapoly and AdC68-
gDMelapoly vectors. Cells were harvested 24 hours later and total RNA was isolated from each 
sample using RNeasy Mini Kit (Qiagen, Venlo, Netherlands). cDNA samples were obtained by 
reverse transcription using 2ug RNA/sample with high capacity cDNA reverse transcription kit 
(Applied Biosystems, Foster City, CA). 20ng cDNA/sample was used for real-time PCR using 
Fast SYBR green mastermix (Applied Biosystems, Foster City, CA). To obtain standards for real-
time PCR, I performed regular PCR for Melapoly and GAPDH (housekeeping gene as internal 
control) using the cDNA samples. I ran the PCR products on 1% agarose gel, purified the PCR 
products of the expected sizes (MiniElute gel extraction kit, Qiagen, Netherlands)  and measured 
the DNA concentration using spectrometry. I diluted the purified Melapoly and GAPDH DNAs 
from 5ng to 0.156ng for real-time PCR standards. For real-time PCR, cDNA samples were 
replicated for both Melapoly and GAPDH using the 7500 Fast real-time PCR machine (Applied 
Biosystems, Foster City, CA). The primer sequences are as follows: regular PCR MelapolyFw 
ACAGGAAACTTCGCCGCTGC, MelapolyRv TGCCATATATCCGAGGTTGTCTG, real-time PCR 
MelapolyRv1 TGATCGGCTGCAGCCACGTC; regular PCR GAPDHFw 
GGTGAAGGTCGGTGTGAACGGATTT, GAPDHRv AATGCCAAAGTTGTCATGGATGACC and 
real-time PCR GAPDHFw1 TGCCCCCATGTTTGTGATGG. The final concentrations of Melapoly 
cDNA from both vector-infected samples were analyzed and compared after normalization to 
GAPDH.  
 
Immunization and challenge of mice 
Groups of C57BL/6 mice were vaccinated i.m. with the AdC68 vectors diluted in PBS into the 
tribialis anterior muscle of each hind limb, with doses ranging from 3 x 109 to 1011 vp per mouse. 
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In tumor challenge experiments, B16BrafV600E cells suspended in serum-free medium were 
inoculated s.c. into the right flank of mice. For pre-and post-tumor challenge experiments, 5x104 
cells were injected and mice were vaccinated 14 days before or 3 days after tumor cell challenge. 
I monitored tumor growth by measuring the perpendicular diameters of tumors at least three 
times a week. Mice were euthanized once tumors exceeded a surface area of 100 mm2. Mice 
were monitored for a period of 60 days post tumor challenge.  
 
Isolation of lymphocytes 
PBMCs and splenocytes were harvested as described before(244). To obtain tumor-infiltrating 
lymphocytes (TILs), tumors were cut into small fragments and treated with 2mg/ml collagenase P 
and 1mg/ml DNase I (Life Technologies, Carlsbad, CA) diluted in Hank’s balanced salt solution 
(HBSS,1X) (Thermo Fisher Scientific, Pittsburgh, PA) with agitation for 1 hour. Tumor fragments 
were homogenized, filtrated and lymphocytes were purified by Percoll-gradient centrifugation.  
 
Tetramer and intracellular cytokine staining 
To detect tetramer-specific CD8+T cells, I stained cells with a PE-labeled tyrosinase-related 
protein 1 (Trp-1)-specific MHC class I (H-2Db) tetramer carrying the TAPDNLGYM peptide and an 
Alexa647-labeled tyrosinase-related protein 2 MHC class I (H-2Kb) tetramer carrying the 
SVYDFFVWL peptide (obtained from the NIAID Tetramer Facility, Atlanta, GA). The following 
antibodies were also used for staining: anti-CD8-PerCPCy5.5, PacBlue or Alexa700, CD4-
PercpCy5.5, CD44-PacBlue or Alexa700, LAG-3 PercpCy5.5, PD-1 PE-Cy7 (all from Biolegend, 
San Diego, CA), 2B4 FITC (eBioscience, San Diego, CA) and Amcyan fluorescent reactive dye 
(Life Technologies). For intracellular cytokine staining (ICS), CD8+ and CD4+ T cell responses to 
individual epitopes were measured using ~106 lymphocytes per samples. Cells were cultured in 
2% FBS DMEM medium with individual MHC class I or class II restricted peptides at a 
concentration of 5ug/ml (for peptides representing CD8+ T cell epitopes): mTrp-1455-463 
TAPDNLGYA, mTrp-1481-489 IAVVAALLL, mTrp-2522-529 YAEDYEEL, hTp-2180-188 SVYDFFVWL, 
	
	
65	
hTrp-2343-357 STFSFRNAL, mTrp-2363-371 SQVMNLHNL, hgp10025-33 KVPRNQDWL and mBRaf
 
594-
602 FGLANEKSI; or 10ug/ml (for peptides representing CD4
+ T cell epitopes): PADRE: 
AKFVAAWTLKAAA, hTrp-288-102: RKFFHRTCKCTGNFA, hTrp-2237-256: 
NESFALPYWNFATGRNECDV and mTrp-2363-376: SQVMNLHNLAHSPL (Genescript, Piscataway, 
NJ). To determine overall MAA-specific T cell responses, a peptide pool including all CD8+ and 
CD4+ T cell epitopes expressed by the Melapoly or gDMelapoly vectors was used for lymphocytes 
stimulation. A rabies virus glycoprotein peptide was used as a negative control. ICS was 
conducted as described before(261). Produced cytokines, enzymes were stained with the 
following antibodies: anti-IFN-γ-APC, IL-2-Alexa700 or FITC, TNF-α-PE-Cy7 (BioLegend, San 
Diego CA). Transcription factor T-bet was stained using Foxp3/Transcription factor staining buffer 
set (ebioscience) using anti-T-bet-PE-Cy7 antibody (eBioscience, San Diego CA). Cells tested by 
ICS were co-stained for exhaustion marker PD-1using anti-PD-1-Brilliant Violet 605 antibody 
(BioLegend, San Diego CA). Cells were analyzed by an LSRII (BD Biosciences, Franklin Lakes, 
NJ). Data were analyzed with FlowJo (TreeStar, Ashland, OR). Experiments using ICS or 
tetramer stains were controlled assessing responses of CD44-CD8+ cells within the same animals 
after preliminary experiments confirmed that results were comparable to those obtained with 
CD44+CD8+ cells of naïve mice or mice vaccinated with the AdC68-gD control vector.  
 
Statistical analysis  
I compared the differences of immune responses between more than two groups using one-way 
ANOVA followed by Holm-Sidak’s multiple comparisons. Immune responses affected by two 
factors (vaccine and tissue type or vaccine and cell type) were analyzed by two-way ANOVA with 
Holm-Sidak’s multiple comparisons. I performed Holm-Bonferroni correction for multiple 
comparisons within the same dataset. Survival rates between different treatment groups were 
compared using Gehan-Breslow-Wilcoxon test. Significance was set at p-values of or below 0.05. 
All statistical analyses were performed using Graphpad Prism6. Throughout the manuscript p-
values adjusted for type 1 errors are shown. 
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Chapter 3 
 
 
Depletion of FAP+ cells reduces immunosuppressive 
cells and improves metabolism and functions of CD8+T 
cells within tumors 
	
	
	
	
	
	
 
ABSTRACT 
	
The tumor stroma, which is essential to support growth and metastasis of malignant cells, 
provides targets for active immunotherapy of cancer. Previous studies have shown that depleting 
fibroblast activation protein (FAP)-expressing stromal cells reduces tumor progression and 
concomitantly increases tumor antigen (TA)-specific T cell responses. However the underlying 
pathways remain ill defined. Here I identify that immunosuppressive cells (ISCs) from tumor-
bearing mice impose metabolic stress on CD8+T cells, which is associated with increased 
expression of the co-inhibitor PD-1. In two mouse melanoma models, depleting FAP+ stroma cells 
from the tumor microenvironment (TME) upon vaccination with an adenoviral-vector reduces 
frequencies and functions of ISCs. This is associated with changes in the cytokine/chemokine 
milieu in the TME and decreased activity of STAT6 signaling within ISCs. Decreases in ISCs 
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upon FAP+ stromal cell depletion is associated with reduced metabolic stress of vaccine-induced 
tumor infiltrating CD8+T cells and their delayed progression towards functional exhaustion, 
resulting in prolonged survival of tumor-bearing mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter were adapted from: 
Zhang Y, Ertl HC. Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and 
functions of CD8+T cells within tumors. Oncotarget 2016; doi:10.18632/oncotarget.7818. 
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INTRODUCTION 
	
    Solid tumors are composed of neoplastic cells and tumor stroma. The stroma, which 
includes connective tissue, cancer-associated fibroblasts (CAFs), blood vessels and infiltrating 
inflammatory cells, is essential for progression of solid tumors (291-294). Tumor stroma also 
protects malignant tumor cells from an onslaught by the immune system by subverting protective 
immune responses, while supporting those that are immunosuppressive (295-297). Targeting 
tumor stroma is thus being explored for treatment of cancer patients (298-300).  
    The supporting stroma of melanoma contains an abundance of CAFs, which are 
functionally distinct from fibroblasts in normal tissues (301-303). One key distinguishing feature is 
their selective expression of FAP, which is not present at high levels on cells of a healthy adult 
organism (304-306). FAP+ stromal fibroblasts are essential to maintain the TME and promote 
cancer progression. They inhibit TA-specific immune responses by producing cytokines and 
chemokines, which attract immunosuppressive cells (ISCs) including regulatory T cells (Tregs), 
myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) 
(128,129). Factors secreted by FAP+ stromal cells may also interfere with T cell-tumor cell 
interactions and hinder tumor cell lysis (130). Genetic depletion of FAP, vaccines targeting FAP 
or T cells with a FAP-specific chimeric antigen receptor (CAR) inhibit tumor growth in part by 
enhancing tumor-specific immune responses (124,131-133); however the underlying mechanisms 
remain poorly understood.  
     T cell responses within tumors are impaired by numerous mechanisms such as 
increases of co-inhibitors upon chronic antigen stimulation and accumulation of tumor-infiltrating 
ISCs. Recently it has been reported that lack of glucose within the TME poses metabolic stress 
on tumor-infiltrating T lymphocytes (TILs), which contributes to their functional exhaustion and 
impairs their antitumor performances (192,197).  I hypothesized that depletion of FAP+ stromal 
cells may reduce the metabolic stress of TA-specific TILs and thereby improve their effector 
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functions and the overall efficacy of active immunotherapy. To test this hypothesis, I used a 
replication-defective adenovirus (Ad)-based vaccine expressing FAP given together with an Ad 
vaccine expressing multiple epitopes from melanoma-associated antigens (MAAs) in two mouse 
melanoma models. My data show that vaccination against FAP significantly improves the 
therapeutic efficacy of the traditional cancer vaccine by destroying FAP+ stroma cells. In addition 
it reduces numbers and functions of tumor-infiltrating ISCs by changing the cytokine/chemokine 
milieu within the TME and inhibiting the activity of the STAT6 signaling pathway within ISCs. I 
show in vitro that ISCs enhance the mitochondrial metabolic stress of activated CD8+T cells and 
increases expression of the co-inhibitor PD-1. In the same token, the decreased levels of ISCs 
within the TME upon FAP vaccination is associated with reduced metabolic stress of vaccine-
induced MAA-specific CD8+T cells, improved frequencies and effector functions of these cells and 
their delayed progression towards exhaustion. 
     My data support further exploring the tumor-stroma-targeting vaccines for active 
immunotherapy of cancer. 
 
RESULTS 
	
The AdC68-mFAP vaccine elicits robust antibody and T cell responses in different mouse 
melanoma models 
    To achieve immune-mediated destruction of the tumor stroma, I developed a vaccine 
based on a replication-defective Ad vector of chimpanzee serotype 68 (AdC68), which expresses 
full-length murine FAP from a CMV promoter-driven transgene incorporated into the vector’s 
deleted E1 domain. The vaccine expressed FAP in transduced HEK 293 cells in a dose-
dependent fashion (Figure 3-1A). The vaccine, termed AdC68-mFAP, elicited robust FAP-
specific antibody responses in mice as tested by a FAP- specific ELISA with sera from individual 
vaccinated mice (Figure 3-1B). I further tested AdC68-mFAP for induction of FAP-specific 
CD8+T cells by measuring vaccine-induced responses to 16 potential CD8+T cell epitopes of 
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mouse FAP (Figure 3-1C). The epitopes were selected based on their predicted high affinity to 
MHC class I antigens H-2Db and H-2Kb. The vaccine was tested in wild-type C57BL/6 mice and 
transgenic Tyr::CreER, BrafCA/+
 
Pten lox+/lox 
 
mice. The transgenic mice were genetically engineered 
to develop melanoma upon Cre-mediated disruption of Pten expression (307). This model, which 
recapitulates the genetic mutations of human melanoma, is a highly clinically relevant model for 
pre-clinical evaluation of therapies for melanoma. In both mouse strains AdC68-mFAP induced 
CD8+T cells that produced mainly interferon (IFN)-γ or tumor necrosis factor (TNF)-α in response 
to in vitro stimulation with FAP-derived peptides representing each of the 16 epitopes expressed 
by the vaccine (Figure 3-1D-E). Frequencies of FAP-specific CD8+T cell responses were 
significantly higher in transgenic mice. FAP-specific CD8+T cells elicited in C57BL/6 mice mainly 
recognized epitopes 1 and 5-9, while those in BrafCA/+
 
Pten lox+/lox 
 
mice mainly responded to 
epitopes 5, 9, 10, 12 and 15. To confirm that the FAP-specific CD8+T cells were able to kill their 
target cells, I performed in vivo cytotoxicity assay in C57BL/6 mice immunized with AdC68-mFAP 
or a control Ad vector. Syngeneic splenocytes were pulsed either with FAP peptides (i.e., 
peptides 1, 5, 7, 8 and 9) or a control peptide. They were then labeled with high or low 
concentrations of CFSE, respectively. The two cell populations were mixed in a 1:1 ratio and 
transferred to recipient mice that had been immunized 2 weeks earlier with either AdC68-mFAP 
or a control Ad vector. Compared to control mice, the transferred cells showed significant loss of 
the CFSE hi FAP peptide-pulsed cell population in relation to the CFSElow control population in 
AdC68-mFAP vaccinated mice (34.5% of CFSE hi cells were lysed in the AdC68-mFAP vaccine 
group, FAP group vs. control group p=0.0011), suggesting that FAP-specific CD8+T cells elicited 
by AdC68-mFAP vaccine mediated specific target cell lysis (Figure 3-1F). Together these data 
show that the AdC68-mFAP vaccine is immunogenic and induces robust FAP-specific B and T 
cell responses in different mouse strains. 
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Figure 3-1: The AdC68-mFAP vaccine induces FAP-specific antibody and CD8+T cell 
responses 
               
 
Figure 3-1: The AdC68-mFAP vaccine induces FAP-specific antibody and CD8+T cell responses. (A) 
HEK 293 cells were infected with different doses of AdC68-mFAP vector and protein was harvested 48 
hours later. Full-length murine FAP was visualized by Western blot using β-actin as an internal control. (B) 
FAP-specific antibody responses elicited by the AdC68-mFAP vaccine at different time points after 
vaccination. Results show mean values of FAP antibody titers in serum with standard error of mean (SEM) 
determined by indirect ELISA. (C) Schematic cartoon shows different components of FAP and the 16 CD8+T 
cell epitopes within FAP that are predicted to bind H-2Kb or H-2Dbwith high affinity. (D) Left: Magnitude and 
polyfunctions of CD8+T cells directed to individual FAP epitopes in transgenic mice. Right: Representative 
flow plots illustrate vaccine-induced CD8+T cell response to FAP peptide 5. The production of IFN-γ, TNF-α, 
granzyme B and perforin were measured. (E) Magnitude and polyfunctions of CD8+T cell responses to 
individual FAP epitopes in C57BL/6 mice. (D-E) Color scheme illustrates different combinations of factors 
that were produced. (F) Representative histograms show in vivo cell lysis by AdC68-mFAP vaccine-induced 
CD8+T cells of CFSEhicells pulsed with FAP peptides. Blue histograms: CFSE+ splenocytes from mice 
vaccinated with control vector 2 weeks earlier. Red histogram: CFSE+ splenocytes from mice vaccinated 
with AdC68-mFAP vector 2 weeks earlier.  
AdC68-mFAP delays tumor growth and improves survival of melanoma-bearing mice 
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    To assess if the FAP vaccine was likely to influence tumor progression, I analyzed 
FAP+ tumor stroma cells from BrafCA/+Ptenlox+/lox+mice that upon treatment with 4-
hydroxyltamoxifen (4-HT) developed tumors. C57Bl/6 mice challenged with a B16F10 cell line 
modified to express BrafV600E (B16BrafV600E, referred to as B16) were tested as well. The BrafV600E 
epitope, which is highly prevalent in human melanoma, was included to better assess the 
potential of the vaccine in treating melanoma patients. Expression of FAP within the stroma of ~ 4 
week- old BrafCA/+Ptenlox+/lox+ and B16 tumors was confirmed at the mRNA (not shown) and 
protein level (Figure 3-2A, 2C). A high percentage (~40-50%) of CD3-CD14-CD4low cells from 
tumors of the transgenic mice stained positive for FAP. In contrast, the proportion of FAP+ cells 
was lower in B16 tumors. The expression of mutated Braf within the B16 tumor cells may have 
affected levels of FAP+ cells, as a different B16.F10 tumor with wild-type Braf but modified to 
express GFP had markedly higher percentages of FAP+ cells (~ 25%, data not shown). Most of 
the FAP+ cells within either tumor only expressed low to intermediate levels of CD45. Compared 
to FAP- cells, FAP+ cells from either tumors expressed significantly higher levels of mesenchymal 
stromal cell markers CD90 and Sca-1, confirming the stromal cell lineage of FAP+ cells [14] 
(Figure 3-2B, 2D).  
Figure 3-2: Vaccination with the AdC68-mFAP vector improves survival of tumor-bearing 
mice 
 
Figure 3-2: Vaccination with the AdC68-mFAP vector improves survival of tumor-bearing mice. (A, C) 
Representative flow plot shows the presence of CD45-FAP+ cells within tumors from BrafCA/+Ptenlox/lox 
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transgenic mice (A) or within B16 tumors (C). (B, D) Histograms indicate the expression of mesenchymal 
stroma cell markers CD90 and Sca-1 on CD45-FAP+ (dark grey) and CD45-FAP- cells (white) in tumors from 
transgenic mice (B) or in B16 tumors (D). 
   To measure the effect of AdC68-mFAP vaccination on tumor progression, I first used 
BrafCA/+Ptenlox+/lox+ mice, in which tumors had been initiated 3 weeks earlier (Figure 3-2E). I 
vaccinated mice bearing similar sized tumors with either a control AdC68 vector or AdC68-mFAP. 
Additional groups received AdC68-mFAP together with a tumor-cell targeting melanoma vaccine 
termed AdC68-gDMelapoly. AdC68-gDMelapoly vaccine expresses a series of melanoma-
associated antigen (MAA) epitopes within herpes simplex virus glycoprotein D (gD) and can elicit 
robust CD8+T cell responses to multiple MAAs as described before (308). Other mice received 
AdC68-gDMelapoly mixed with a control AdC68 vector, the latter to ensure that mice received 
equal doses of vaccine. AdC68-mFAP or AdC68- gDMelapoly vector given alone each achieved 
significant delay in tumor progression compared to the control vaccine. Tumor growth was 
comparable in the two groups that received single vectors (p=0.31) (Figure 3-2F), but was further 
retarded when the vaccines were combined (gDMelapoly+Co vs. gDMelapoly+FAP: p=0.0096).  
      I further assessed vaccine efficacy in the transplantable B16 tumor model. C57Bl/6 
mice were vaccinated with the different vectors three days after tumor challenge (Figure 3-2G). I 
chose an early time point after tumor challenge to assess the vaccines, as my previous studies 
showed that the AdC68-gDMelapoly vaccine, which completely protects mice that are vaccinated 
before tumor challenge can only rarely lead to cures if given three days after tumor challenge 
(308). Compared to the control group, mice immunized only with AdC68-mFAP showed delayed 
tumor progression and significantly prolonged survival (p=0.0089, Figure 3-2H). Vaccine efficacy 
was further improved when mice were immunized with a mixture of AdC68-mFAP and AdC68-
gDMelapoly; while ~16% of AdC68-gDMelapoly-vaccinated mice were completed protected from 
tumor challenge, immunization with the vaccine mixture early after tumor challenge more than 
doubled the numbers of mice (~35%) that remained tumor-free for at least 90 days after tumor 
induction. In mice that developed tumors, those that received the AdC68-mFAP or AdC68-
gDMelapoly vaccine alone showed significantly reduced tumor weight on day 25 after tumor 
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challenge compared to control mice. Combining AdC68-gDMelapoly with AdC68-mFAP further 
decreased tumor weight (Figure 3-2I).  
 
Figure 3-2. (E) Schematic representation of experimental set up to test vaccine efficacy in transgenic mice. 
Tumors were induced in transgenic mice by 4-HT treatment for 3 consecutive days. Mice were vaccinated 
with different vectors 3 weeks after tumor induction. (F) Graph shows Kaplan-Meier survival curves of mice 
that received the different vaccine regimens (n=10-14/group). Open square: control group (AdC68-gD 
vector); Diamond: control+AdC68-mFAP vaccine group; Black triangle: AdC68-gDMelapoly+ AdC68-gD 
vaccine group; Circle: AdC68-gDMelapoly+ AdC68-mFAP vaccine group. AdC68-gD vs. FAP+ AdC68-gD: 
p=0.0003; AdC68-gD vs. gDMelapoly + control: p=0.0001; gDMelapoly + AdC68-gD vs. gDMelapoly + FAP: 
p=0.0096. (G) Schematic representation of experimental set up to test vaccine efficacy in mice bearing 
transplantable B16 tumors. C57BL/6 mice were challenged with B16 tumor cells and vaccinated three days 
later with different vectors. (H) Graph shows Kaplan-Meier survival curves of mice that received the different 
vaccine regimens (n=15-35/group). Symbols representing each vaccine group are the same as those used 
in 2F. Control vs. FAP + control: p=0.0089; gDMelapoly+ AdC68-gD vs. gDMelapoly + FAP: p=0.03.  (I) 
Tumor weight comparisons among different vaccine groups on day 25 after B16 tumor challenge. Data are 
presented as mean with SEM. AdC68-gD vs. FAP + AdC68-gD: p=0.014; AdC68-gD vs. gDMelapoly + 
AdC68-gD: p=0.0001; AdC68-gD vs. gDMelapoly + FAP: p<0.0001; gDMelapoly + AdC68-gD vs. 
gDMelapoly + FAP: p=0.03.  
 
     Both sets of data confirm that targeting FAP+ tumor stroma cells results in significantly 
prolonged survival of melanoma-bearing mice. Combining a conventional tumor cell-targeting 
vaccine with a vaccine directed against the tumor stroma offers further therapeutic benefits in 
mouse melanoma models.  
AdC68-mFAP-induced CD8+T cell responses reduce FAP+ stromal cells within the TME.  
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     To determine the mechanism by which the AdC68-mFAP vaccine delayed tumor 
progression, I first analyzed whether AdC68-mFAP vaccine-induced immune responses could 
destroy FAP+ stroma cells. Tyr::CreER, BrafCA/+Ptenlox+/lox+ transgenic mice bearing 3 week-old 
tumors and C57Bl/6 mice with 3 day-old B16BrafV600E tumors were vaccinated with the control 
vector only, AdC68-mFAP with the control vector or AdC68-gDMelapoly mixed with either the 
control vector or the AdC68-mFAP vector. Numbers and percentages of CD45-FAP+ stroma cells 
within tumors were measured 3 month later from transgenic mice and ~ 4 weeks later from B16 
tumor-bearing mice. AdC68-mFAP given alone or with AdC68-gDMelapoly significantly reduced 
FAP+ stroma cells within tumors in both models, reflected by decreases in percentages (Figure 3-
3A) and numbers (Figure 3-3B, 3C). Within transgenic tumors the FAP vaccine caused a 
significant reduction in FAP+ cells and this was slightly more pronounced if the AdC68-
gDMelapoly vaccine was given simultaneously (Figure 3-3B). Mice immunized only with AdC68-
gDMelapoly also had lower levels of FAP+ cells. I assume that this may reflect that FAP+ cells 
become more frequent during tumor growth so that a vaccine that delays tumor progression also 
reduces accumulation of FAP+ cells. Results differed for B16 tumors. In this model the FAP 
vaccine reduced FAP+ cells as in the transgenic tumors. In contrast, the AdC68-gDMelapoly 
vaccine given together with a control vector did not affect levels of the tumors’ FAP+ stroma cells 
(Figure 3-3C). Nevertheless, when AdC68-gDMelapoly and AdC68-mFAP vectors were 
combined FAP depletion was more pronounced than upon vaccination with AdC68-mFAP only.  
    Reduction of FAP+ cells upon vaccination with AdC68-mFAP suggests their depletion 
by vaccine-induced T cells. This was confirmed indirectly by testing whether T cells are required 
for AdC68-mFAP-mediated delay in tumor progression. I depleted CD4+ or CD8+ or both T cell 
subsets from mice challenged with B16 tumors and then vaccinated them 3 days later with 
AdC68-mFAP. Depletion of CD8+T cells completely abrogated the effect of the AdC68-mFAP 
vaccine on tumor progression. Depletion of CD4+T cells had no effect (Figure 3-3D).  
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Figure 3-3: Immunization with AdC68-mFAP reduces numbers of FAP+ cells within both 
transgenic BrafCA/+Ptenlox/lox and transplantable B16 tumors in a CD8+T cell dependent 
manner 
 
 
Figure 3-3: Immunization with AdC68-mFAP reduces numbers of FAP+ cells within both transgenic 
BrafCA/+Ptenlox+/lox+ and transplantable B16 tumors in a CD8+T cell dependent manner. (A) 
Representative flow plots show percentages of CD45-FAP+ cells from 3 month-old tumors of transgenic mice 
that received AdC68-gD (control), AdC68-mFAP + AdC68-gD, AdC68-gDMelapoly + AdC68- gD or AdC68-
gDMelapoly + AdC68-mFAP 3 weeks after initial tumor-induction with 4-HT. (B) Relative numbers of CD45-
FAP+ cells per million CD45-CD3-CD14-CD19- cells from 3 month-old tumors isolated from transgenic mice 
that received the control vector (AdC68-gD, black bar), the AdC68-mFAP + AdC68-gD (open bar), the 
AdC68-gDMelapoly+ AdC68-gD (dark grey bar), or the AdC68- gDMelapoly + AdC68-FAP (light grey bar) 
(n=4-5/group). Data were normalized to results from control group. AdC68-gD vs. FAP+ control: p=0.015; 
AdC68-gD vs. gDMelapoly + FAP: p=0.0006; AdC68-gD vs. gDMelapoly + AdC68-gD: p=0.049; gDMelapoly 
+ AdC68- gD vs. gDMelapoly + FAP: p=0.0083. (C) Relative numbers of CD45-FAP+ cells per million CD45-
CD3-CD14-CD19- cells from 1-month B16 tumors isolated from C57BL/6 mice that received different 
combinations of vectors 3 days after tumor challenge (n=5-10/group). Data were normalized to results from 
the control group. AdC68-gD vs. FAP + AdC68-gD: p<0.0001; AdC68-gD vs. gDMelapoly + FAP: 
p<0.00001; AdC68-gD vs. gDMelapol + AdC68-gD: p=0.9625; gDMelapoly + AdC68-gD vs. gDMelapoly + 
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FAP: p=0.0001. FAP + AdC68- gD vs. gDMelapoly + FAP: p=0.0001. (D) Kaplan-Meier survival curves of 
mice challenged with tumor cells and vaccinated with control or AdC68-mFAP vector. Mice were depleted of 
CD8+, CD4+ T cells or both (n=8-12/group). Statistical significant differences in terms of survival length and 
corresponding p-values are marked on the graph.  
ISCs that intensify metabolic stress if in vitro activated CD8+T cells are reduced upon FAP+ 
stroma cell depletion  
    Cytokines and chemokines produced within tumors are known to recruit ISCs, such as 
MDSCs and FoxP3+CD4+ regulatory T cells (Treg) (309). I hypothesized these ISCs may 
enhance the metabolic stress of MAA-specific TILs within TME and contributes to their functional 
exhaustion. I measured two subsets of MDSCs, i.e., monocytic (MO) MDSCs, which are 
phenotypically Gr-1int CD11b+, and granulocytic (polymorphonuclear, PMN) MDSCs, which are 
Gr-1hi CD11b+ and TAMs (Figure 3-4A). Most of TAMs within TME were skewed towards a M2 
phenotype with high expression of mannose receptor CD206 (310). I confirmed in vitro that the 
ISCs affected T cell proliferation by activating splenic naïve CD8+ T cells in vitro with antibodies to 
CD3 and CD28. Proliferation tested for at 5 days after activation significantly decreased upon co-
culture with PMN-MDSCs and TAMs. Some inhibition was seen upon co-culture with Gr-
1hiCD11b+ MDSCs although this failed to reach significance (Figure 3-4B).  
Figure 3-4: ISCs that enhance the metabolic stress and PD-1 expression of activated 
CD8+T cells were reduced by FAP+ tumor stromal cell depletion 
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Figure 3-4. ISCs that enhance the metabolic stress and PD-1 expression of activated CD8+T cells 
were reduced by FAP+ tumor stromal cell depletion. (A) Gating strategy for Gr-1hi and Gr-1int MDSCs 
and CD206+F4/80+ M2 type TAMs. (B) Gr-1intCD11b+ MDSCs and TAMs inhibit proliferation of CD8+T cells 
in vitro. Enriched CD8+T cells were labeled with celltrace violet and stimulated with anti-CD3 and anti-CD28 
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for 4 days, Gr-1intCD11b+ MDSCs were added to T cells at a ratio of 1:5 from day 0. Activated CD8+T cells 
without ISCs were used as positive control while CD8+T cells cultured without antibody stimulation were 
used as a negative control. Left: Proliferation index of CD8+T cells with or without stimulation or cocultured 
with MDSCs or TAM (n=4/group). Positive control vs. Gr-1intCD11b+co-culture: p=0.0023; positive control vs. 
TAM co-culture: p=0.023; positive control vs. negative control: p=0.009. Right: Histograms show cell 
proliferation of representative samples. Numbers on the left of the histograms show percentages of cells 
with reduced celltrace violet levels.  
    To determine whether ISCs affect T cell metabolism, I stimulated CD8+T cells from 
spleens of naïve mice in vitro in presence of different populations of ISCs isolated from B16 
tumor-bearing mice. Levels of mitochondrial reactive oxygen species (MROS) within activated 
CD8+T cells were measured on day 5 of culture. T cells upon activation increasingly use 
glycolysis for production of energy while resting T cells primarily use the more efficient 
tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) (311). MROS, which is 
mainly produced by OXPHOS, is highly toxic and can induce cell damage and death through 
activating intracellular signaling pathways (184). In healthy cells MROS is rapidly converted to 
water and oxygen. Its accumulation within cells is a hallmark of metabolic stress indicative of 
mitochondrial dysfunctions. Activated CD8+T cells co-cultured with MDSCs and TAMs showed 
significantly higher MROS levels compared to those stimulated without ISCs (Figure 3-4C), 
suggesting that ISCs impose metabolic stress on activated CD8+T cells. I next assessed whether 
increased metabolic stress contributes to inhibitory signaling in activated CD8+T cells by 
measuring expression of the co-inhibitor PD-1. PD-1 initially increases on activated CD8+T cells 
upon T cell receptor and CD28 ligation (114). Its constitutive high expression is viewed as a 
hallmark of exhaustion that limits the effectiveness of CD8+TILs (43). PD-1 dampens T cell 
responses in part by inhibiting the Akt/mTOR pathway and thereby energy production through 
glycolysis (267). In my CD8+T cells-ISCs co-culture 
system, addition of ISCs significantly increased PD-1 
expression on CD8+T cells (Figure 3-4D).  
Figure 3-4. (C) Enriched CD8+T cells from spleens of naive 
mice were stimulated in vitro with or without different subsets 
of ICSs from tumor-bearing mice. MROS levels in CD8+T 
cells stimulated for 5 days under different culture conditions 
are shown as mean MFI values with SEM. Positive Co. vs. 
Gr-1hi: p=0.0018; vs. Gr-1int: p=0.0003; vs. TAM: p=0.0047. 
(D) PD-1 expression on CD8+T cell on day 5 after co-culture 
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with different ISC subsets are shown as MFI with SEM. Positive Co. vs. Gr-1hi: p=0.0022; vs. Gr-1int: 
p=0.028; vs. TAM: p=0.029.  
 
     I next analyzed whether depleting FAP+ stroma cells can reduce ISCs within the TME. 
Transgenic mice bearing 3 months old tumors of similar sizes were analyzed first. Tumors from 
mice that received AdC68-mFAP alone compared to those from the control group showed 
significantly reduced percentages of both MDSC subsets; this was not achieved with mice that 
received AdC68-gDMelapoly with a control vector (Figure 3-4E). Combining AdC68-mFAP with 
AdC68-gDMelapoly caused a reduction in the more suppressive Gr-1intCD11b+MDSC subset 
while percentages of Gr-1hi CD11b+MDCSs reverted back to levels seen in control mice.  
Numbers of Tregs declined upon immunization with either vaccine regimen (Figure 3-4F), 
indicating that this was unrelated to FAP but more likely reflected the effect of enhanced immune 
response within the tumor upon vaccination with Ad vectors.    
 
Figure 3-4. (E–F) 
Transgenic mice bearing 
3-week tumors were 
vaccinated with control 
vector (AdC68-gD, black 
bar), FAP+AdC68-gD 
(empty bar), 
gDMelapoly+AdC68-gD 
(dark grey bar) or 
gDMelapoly+FAP (light 
grey bar) (n=5/group). 
Data show normalized 
cell counts of Gr-1hi and Gr-1intMDSCs over CD4-CD8- live cells (E) or normalized CD4+Foxp3+ cells (F) over 
live cells in 3 month-old tumors of mice from the different vaccine groups.  
     In B16 tumors I excluded the group of mice immunized with AdC68-mFAP only, as in 
this model reduction of FAP+ cells was significantly more pronounced by a vaccine regimen that 
combines AdC68-mFAP with the AdC68-gDMelapoly vector (Figure 3-3C). AdC68-gDMelapoly 
vaccinated-mice had slightly enhanced levels of Gr-1hiCD11b+ MDSCs; addition of the FAP 
vaccine reduced this population  (Figure 3-4G). Relative percentages of Gr-1intCD11b+ MDSCs 
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were reduced upon vaccination with AdC68-gDMelapoly. This reduction became more 
pronounced in tumors of mice that also received the FAP vaccine, suggesting that depleting FAP+ 
stromal cells contributed to the lower MDSC levels.  The vaccines did not reduce Tregs (Figure 
3-4H). In both tumor models frequencies of TAMs were not affected by the FAP vaccine. The 
vaccines thus had distinct effects on ISC numbers in the two tumor models.  
Figure 3-4. (G–H) Mice 
bearing 3 day-old B16 tumors 
were vaccinated with control 
vector (AdC68-gD, black bar), 
gDMelapoly+AdC68-gD (dark 
grey bar) or gDMelapoly+FAP 
(light grey bar) (n=14-
15/group). Data show 
normalized cell counts of Gr-
1hiand Gr-1int MDSCs over 
CD4-CD8- live cells (G) or 
normalized CD4+Foxp3+ cells 
(H) over live cells in 1 month-
old tumors of mice from the 
different vaccine groups. *: 
p<=0.05; **: p<0.01; ***: 
p<0.001; ****: p<0.0001.  
     Overall these data indicate that in either melanoma model targeting FAP+ tumor 
stroma cells reduces the content of MDSCs within tumors, which may create a more supportive 
niche for antigen-specific TILs by reducing their metabolic stress.   
 
Reduced suppressive functions of ISCs upon FAP+ stromal cell depletion is linked to 
changes in JAK-STAT pathway activation 
    MDSCs and TAMs suppress CD8+T cell functions through different mechanisms (309).  
It is well established that they produce high levels of inducible nitric oxide synthase (iNOS) and 
arginase 1(Arg1), which catabolize and deplete L-arginine, an important amino acid that is 
required to support T cell proliferation. In addition, iNOS generates nitric oxide (NO), which further 
inhibits function of T cells. MDSCs produce reactive oxygen species (ROS), which upon reaction 
with NO form superoxide anion, a metabolite that through nitration of T cell receptors induces T 
cell unresponsiveness (312). CAFs secrete chemokine (C-C motif) ligand 2 (CCL2), which 
recruits MDSCs. Other factors such as granulocytes macrophage colony-stimulating factor (GM-
	
	
81	
CSF), interleukin (IL)-4, IL-10, IL-13, transforming growth factor (TGF)-β promote differentiation 
and immunosuppressive functions of MDSCs (309,313). I therefore assessed if depleting FAP+ 
CAFs upon vaccination with AdC68-mFAP can change the functional profiles of ISCs. For these 
experiment I used the B16 model and combined the AdC68-gDMelapoly and AdC68-mFAP 
vaccines as this regimen as shown in Figure 3-3C achieved the highest reduction in FAP+ cells.  
Mice bearing 3-day old B16 tumors were vaccinated with AdC68-gDMelapoly together with 
control or AdC68-mFAP vectors. MO-MDSCs, PMN-MDSCs and TAMs were isolated from 
similar-sized tumors of the two groups of mice ~4 weeks after vaccination and levels of iNOS, 
Arg1 and ROS were measured by antibodies staining and flow analysis.  Both iNOS and Arg1 
expression was significantly decreased within ISCs from tumors of mice that received both MAA- 
and FAP-targeting vaccines compared to those received only AdC68-gDMelapoly (Figure 3-5A). 
ROS levels were comparable between the two vaccine groups for all ICS populations. 
Collectively, these data suggest that depletion of FAP+ cells reduces the immunosuppressive 
capacities of ISCs by decreasing their ability to produce iNOS and Arg1.  
Figure 3-5: Depleting FAP+ stromal cells reduces suppressive functions of ISCs in tumors 
and decreases their STAT6 activity.  
    
Figure 3-5. Depleting FAP+ stromal cells reduces suppressive functions of ISCs in tumors and 
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decreases their STAT6 activity. (A) Production of iNOS, Arg1 and ROS by MDSCs and TAMs from 
similar-sized 1 month-old B16 tumors were compared between mice that received AdC68-
gDMelapoly+AdC68-gD (light grey bar) or AdC68-gDMelapoly+ AdC68-mFAP (dark grey bar) (n=15/ group). 
Data are presented as percentages of cells positive for iNOS, Arg1 or ROS expression. Lower panel: 
representative histograms of iNOS, Arg1 and ROS expression in Gr-1+PMN-MDSCs in the two different 
vaccine groups. Numbers next to histograms indicate MFI values for the factors in the selected samples.     
   Previous studies showed that factors produced by tumor and tumor stromal cells 
activate Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathways in 
ISCs, which contributes to their expansion and activation (309,313). STAT3 is induced by a 
number of factors including IL-5, IL-6 and IL-10. It is the main transcriptional factor regulating 
MDSC expansion. STAT1 activated by IFN-γ and STAT6 activated by IL-4 or IL-13 upregulate the 
expression of iNOS and Arg1 in MDSCs (313). As vaccination with AdC68-mFAP given together 
with AdC68-gDMelapoly reduced iNOS and Arg1 expression in MDSCs and TAMs of tumor-
bearing mice, I analyzed whether the functional reductions of ISCs were linked to changes in 
STAT activation. I compared phosphorylated (p)STAT1, STAT3 and STAT6 levels in the three 
ISCs populations from B16 tumors of mice vaccinated with AdC68-gDMelapoly with either control 
or  AdC68-mFAP vector. Mice received tumors cells and were vaccinated 3 days later; similar-
sized tumors from each group were analyzed 4 weeks after vaccination. Addition of the FAP 
vaccine to AdC68-gDMelapoly had no effect on pSTAT1 or pSTAT3 levels, but significantly 
decreased pSTAT6 levels in all three ISC subsets (Figure 3-5B). These data indicate that 
vaccine-mediated depletion of FAP+ cells reduces the suppressive functions of ISCs, which is 
associated with their decreased activation of the STAT6 pathway.  
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Figure 3-5. (B) The phosphorylation of transcription factors STAT1, STAT3 and STAT6 were measured in 
MDSCs and TAMs using the same tumor samples as described in 5A (n=8-10/group). Data are shown as 
mean MFI values with SEM. Lower panel: histograms show representative pSTAT1/pSTAT3/pSTAT6 
expression in Gr-1intCD11b+MDSC samples from the two vaccine groups. MFI values of pSTAT expression 
in the selected samples are shown next to the histograms. Statistics shown as * were same as described in 
Figure 3-4.  
Targeting FAP+ cells changes cytokine/chemokine production within tumors 
    Reduced activity of STAT6 in tumor-infiltrating ISCs of mice that received AdC68-
mFAP together with AdC68-gDMelapoly most likely reflects vaccine-induced changes in 
cytokines or chemokines within the TME, which in turn recruit and activate ISCs.  
    I initially assessed whole tumors from mice that had been challenged 4-5 weeks before 
with B16 cells and received either AdC68-gDMelapoly with the control or the AdC68-mFAP vector 
three days later for a number of transcripts of cytokines and chemokine that may affect STAT 
signaling, ISCs recruitments or functions, or the balance of immune responses within the TME 
(312). Upon including AdC68-mFAP into the vaccine regimen transcripts for CCL5, CCL22, IL-4, 
IL-10 and TGF-β significantly decreased (Figure 3-6A). Th2 related chemokines CCL5 and 
CCL22 preferentially recruit T cells that lack the capacity to eliminate tumor cells by direct lysis, 
i.e., regulatory T cells and Th2 cells; the latter bias immune responses away from Th1 (314). 
Several cell subsets within tumors secrete IL-10 and TGF-β, which can contribute to immune 
suppression within the TME either through direct inhibition of cytolytic T cells or indirectly through 
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the recruitment and activation of ISCs. TGF-β can further activate fibroblasts, which in turn 
promotes their immunosuppressive activities (127,309). IL-4 activates the STAT6 pathway in 
ISCs, which directly supports their suppressive functions. The reduction of these factors following 
AdC68-mFAP vaccination indicates a less immunosuppressive TME that reduces ISC recruitment 
and functions and supports CD8+T cell effector functions.  Other factors, including C-X-C motif 
chemokine (CXCL) 10 and CXCL12, CCL2, IL-16 and IL-13, GM-CSF and stem cell factor (SCF) 
remained relatively stable upon addition of the AdC68-mFAP vaccine to AdC68-gDMelapoly. 
Figure 3-6: Depleting FAP+ stromal cells changes the TME’s cytokine and chemokine 
profile 
Figure 3-6: Depleting FAP+ stromal cells 
changes the TME’s cytokine and chemokine 
profile. Mice (n=7-8/group) were challenged 
with B16 tumors and vaccinated with AdC68-
gDMelapoly mixed with control or AdC68-
gDMelapoly mixed with AdC68- mFAP 3 days 
later. Tumors grown to about 1-1.5 cm in 
diameter were collected at necropsy (~4-5 
weeks after tumor challenge). (A)  
 Relative mRNA expression levels of selected 
cytokines and chemokines in tumors from the 
AdC68-gDMelapoly+AdC68-mFAP group were 
compared to those from the AdC68-
gDMelapoly+AdC69-gD control group. Data 
are shown as mean fold changes with SEM 
(TGF-β: p<0.0001; CCL5: p=0.0014; CCL22: 
p=0.0023; IL-4: p=0.030; IL-10: p<0.0001). 
 
   To assess the origin of different factors, I sorted cells into tumors cells, FAP+ stroma 
cells, MDSCs, TAMs, and infiltrating leukocytes (T cells [CD3+], B cells [CD19+], macrophages 
and neutrophils [CD14+]) following the gating strategy shown in Figure 3-6B. Most factors 
originated from an array of different cell types (Figure 3-6C). FAP reduction decreased 
transcripts for IL-10, TGF-β, CCL5 and CCL22 from CD14+ cells (Figure 3-6D), of which 20-40% 
were F4/80+ TAMs; CCL5 transcripts were also reduced in tumor cells. Reductions in IL-4 and IL-
10 transcripts were seen in numerous cell type including FAP+ stromal cells and inflammatory 
cells. The decreased transcripts of these cytokines/chemokines in different cell compartments 
within the TME suggests that reduction of FAP+ stroma cells has global effects that directly or 
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indirectly affect other cell subsets. FAP-reduction did not affect cytokine or chemokine production 
by MDSCs and TAMs, indicating that their decreased pSTAT6 activation was caused by 
exogenous changes in cytokine levels. Collectively my data suggest that AdC68-mFAP vaccine 
changes the cytokine/chemokine milieu within the TME by reducing production of inflammatory 
factors. This may through down-regulation of STAT6 signaling pathways decreases the 
recruitment and immunosuppressive functions of ISCs. 
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Figure 3-6. (B) Gating strategy used to sort different cell populations including FAP+ stromal cells, tumor 
cells, MDSCs, TAMs, CD3+T cells, CD14+cells and CD19+B cells from B16 tumors. (C) Abundance of 
selected cytokines and chemokines that show significantly reduced expression upon FAP+ stromal cell 
depletion in different cell populations of the TME. Tumor samples were from mice that received AdC68-
gDMelapoly+control vector. Data of mRNA levels are shown as mean values of arbitrary expression units 
(1/(target gene Ct - GAPDH Ct)) with SEM. (D) Relative mRNA levels of the indicated cytokines and 
chemokines in different cell populations from tumors of mice that received AdC68-gDMelapoly+AdC68-
mFAP over those of mice that received AdC68-gDMelapoly+control vector (n=6/group). (IL-4: FAP+ stroma: 
p<0.0001, TAM: p<0.0001, CD3: p=0.000065, CD14: p=0.033, CD19: p<0.0001; IL-10: FAP+ stroma: 
p<0.0001, CD3: p=0.016, CD14: p<0.0001, CD19: p<0.0001; TGF-β: CD14: p<0.0001; CCL5: tumor cells: 
p<0.0001, CD14: p<0.0001; CCL22: MDSC: p<0.0001, CD14: p<0.0001).  
Reducing FAP+ stromal cells reduces metabolic stress, decreases co-inhibitor expression 
and improves functions of vaccine-induced CD8+T cells 
   It has been shown previously that FAP+ stromal cells suppress tumor-specific immune 
responses (133) and FAP+ cell depletion enhances tumor infiltration by T lymphocytes (131,315). 
I hypothesized that depleting FAP+ cells, which reduced the frequencies and functions of ISCs 
within the TME, may lessen metabolic stress and delay exhaustion of MAA-specific CD8+TILs as 
suggested by my in vitro co-culture assay. Indeed, increased metabolic stress indicated by high 
MROS levels is associated with enhanced expression of the co-inhibitor PD-1 on MAA-specific 
CD8+TILs from either transgenic or C57BL/6 mice (Figure 3-7A). In either transgenic or C57BL/6 
mice with similar sized tumors, reducing FAP+ stromal cells significantly decreased percentages 
of MROShi Trp-1-specific CD8+TILs, especially those with lower mitochondrial membrane 
potential (MMP) (Figure 3-7B). Furthermore, co-inhibitor PD-1 levels were also significantly lower 
on MAA-specific CD8+TILs upon FAP+ cell depletion in both tumor models, suggesting that these 
cells were partially protected from exhaustion (Figure 3-7C).  
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Figure 3-7: Depleting FAP+ stromal cells with AdC68-mFAP vaccine reduces metabolic 
stress and improves effector functions of AdC68-gDMelapoly-induced CD8+T cells.  
 
Figure 3-7: Depleting FAP+ stromal cells through AdC68-mFAP vaccine reduces metabolic stress 
and improves effector functions of AdC68-gDMelapoly-induced CD8+T cells. (A) Percentages of PD-
1hi cells within MROShi or MROSlo Trp-1-specific CD8+TILs populations from tumors of mice that received 
either the control or the FAP vaccine. Both TILs from transgenic mouse tumors (left, n=5 mice/group) or 
C57/Bl6 tumors (right, n=5 mice/group) were analyzed. (B) Percentages of Trp-1-specific CD8+T cells with 
high levels of MROS from similar sized transgenic tumors (collected 3 month after tumor challenge, n=4-
5/group) or B16 tumors (collected 1 month after tumor challenge, n=9-14/group) of mice that received either 
AdC68-gDMelapoly+control (light grey) or AdC68- gDMelapoly+AdC68-mFAP (dark grey). TILs B16: 
p=0.018; TILs transgenic (tg): p=0.04. Flow plots show representative MMP and MROS expression in Trp-
1+CD8+T cells from transgenic tumors of mice that received either AdC68-gDMelapoly+AdC68-gD or 
AdC68- gDMelapoly+AdC68-FAP. (C) PD-1 expression on Trp-1-specific CD8+TILs from transgenic or B16 
tumor-bearing mice that received either AdC68-gDMelapoly+AdC68-gDMelapoly (light grey) or AdC68-
gDMelapoly+AdC68-mFAP (dark grey). Data are presented as percentages of Trp-1-specific CD8+T cells 
that show high expression of PD-1. TILs B16: p=0.0029; TILs transgenic (tg): p=0.045. Histograms: PD-1 
expression on representative Trp-1-specific CD8+TILs samples from the transgenic tumors of mice that 
received either combination of vaccines.  
   To further determine whether destroying FAP+ cells by AdC68-mFAP vaccination 
affects the functions of MAA-specific CD8+TILs, mice bearing 3 day-old B16 tumors were 
vaccinated with AdC68-gDMelapoly together with either the control or the AC68-mFAP vector. 
CD8+T cell responses to Trp-1455-463, the immunodominant epitope expressed by the AdC68-
gDMelapoly vector, were monitored by tetramer staining of peripheral blood mononuclear cells 
(PBMCs) from the two vaccine groups over the course of 50 days.  Depleting FAP+ tumor stromal 
cells significantly increased the overall Trp-1-specific CD8+T cell response in blood (p=0.038, 
area under the curve); differences were more pronounced at later time points, i.e. on days 35 and 
50 after vaccination (Figure 3-7D).  Mice were euthanized once tumors exceeded 1-1.5 cm in 
diameter and splenocytes and TILs were isolated. The mice that received the FAP vaccine 
exhibited significantly higher Trp-1-specific CD8+T cell responses in tumors (Figure 3-7E). The 
experiment was repeated with tumor-bearing Tyr::CreER, BrafCA/+Ptenlox+/lox+ transgenic mice and 
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results were comparable (Figure 3-7F). To assess whether the enhanced Trp-1-specific CD8+T 
cell frequencies were accompanied by an improvement of MAA-specific CD8+T cell effector 
functions, I tested PBMCs from B16 tumor-challenged mice for production of cytokines upon their 
in vitro stimulation with the MAA peptide pool, which included peptides representing the eight 
CD8+T cell epitopes expressed by the AdC68-gDMelapoly vaccine. Cells were then analyzed by 
intracellular cytokine staining (ICS) for production of IFN-γ and TNF-α. Overall frequencies of 
cytokine+CD8+T cells, i.e., the sum of percentages of T cells producing the two cytokines alone or 
in combination, were markedly higher in blood of mice that received the FAP vaccine together 
with the gDMelapoly vaccine (p=0.031, area under the curve) (Figure 3-7G).  This effect was 
mainly observed at the later time point, i.e. on day 35 after vaccination. On day 10 after 
vaccination MAA-specific CD8+T cells from blood of the two vaccine groups showed comparable 
patterns for single or double functions; by day 35 T cells from mice that received the FAP vaccine 
were significantly more polyfunctional compared to those from the control group (Fig 7H). At the 
time of euthanasia mice that received both vaccines had higher percentages of factor-producing 
MAA-specific CD8+ TILs compared to those received AdC68-gDMelapoly with control vector 
(Figure 3-7I) and CD8+TILs were more polyfunctional (Figure 3-7J), i.e., a significantly higher 
percentage of MAA-specific CD8+TILs cells produced both IFN-γ and TNF-α. 
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Figure 3-7. (D) Percentages of Trp-1 tetramer+CD8+T cells in blood of mice (n=15/group) challenged with 
B16 tumor cells and vaccinated with either AdC68-gDMelapoly+AdC68-gD (empty square) or AdC68-
gDMelapoly+AdC68-mFAP (black square). Responses were monitored for 50 days after vaccination. 
Responses compared by area under the curve (AUC): p=0.038; responses compared at individual time 
points on days 35: p=0.038; 42: p=0.047. (E) Trp-1-specific CD8+T frequencies in spleens and tumors of 
B16-tumor bearing mice (n=9-14/group) that received AdC68-gDMelapoly+AdC68-gD (light grey bar) or 
AdC68-gDMelapoly+AdC68-mFAP (dark grey bar) were compared ~1 month after tumor challenge. Spleen: 
p=0.66, TILs: p=0.03. (F) Trp-1-specific CD8+T frequencies in spleens and tumors of transgenic tumor-
bearing mice (n=5/group) received AdC68-gDMelapoly+AdC68-gD (light grey bar) or AdC68-
gDMelapoly+AdC68- mFAP (dark grey bar) were compared ~3 months after tumor induction. Spleen: 
p=0.70, TILs: p=0.0054. (G) Mice (n=15/group) were challenged with B16 tumor cells and vaccinated with 
vectors three days later. Percentages of factor-producing CD8+T cells upon stimulation with the MAA-
specific peptide pool was monitored in blood for 50 days after vaccination. Cells producing IFN-γ and/or 
TNF-α were measured and data are presented as the mean value of the sum of the responses with SEM. 
AUC: p=0.031; responses compared on day 35: p=0.032. (H) MAA-specific CD8+T cell polyfunctionality in 
PBMCs of B16 tumor challenged mice from two vaccine groups were compared on days 10 and 35 after 
vaccination. Pie slice colors black: IFN-γ+TNF-α+, grey: IFN-γ+TNF- α+, white: IFN-γ+TNF- α+. (I) Percentages 
of MAA-specific CD8+T cells from spleens and tumors of B16 tumor-bearing mice in each vaccine group that 
produced one or two cytokines at the time of necropsy (n=5/group). Light grey bar: AdC68-
gDMelapoly+AdC68-gD, dark grey bar: AdC68-gDMelapoly+AdC68-mFAP. TILs p=0.006. (J) Polyfunctions 
of MAA-specific CD8+T cells in spleen and tumors of B16 tumor-bearing mice in each vaccine group at the 
time of necropsy (n=5/group), data are presented as percentage of MAA-specific CD8+T cells that produce 
two cytokines. TILs p=0.0053. Flow blots show cytokines production in representative TIL samples from the 
different vaccine groups. Numbers on the corner indicate the percentages of CD8+T cells producing either 
IFN-γ or TNF-α.  
   Overall my data suggest that depleting FAP+ tumor stromal cells can decrease the 
metabolic stress of MAA-specific CD8+ TILs, which delay their differentiation towards functional 
exhaustion within the TME and result in significantly improved antitumor efficacy.  
 
DISCUSSION 
	
    Manipulating cells of the tumor stroma can achieve tumor regression. Decreases of 
MDSCs by factors that drive their differentiation towards mature antigen-presenting cells or 
macrophages has been shown to block their expansion or immune-inhibitory functions and 
prolong survival of tumor-bearing mice (316). Reduced tumor progression is also achieved by 
targeting FAP, an antigen that is selectively expressed on fibroblasts present in tumors or at sites 
of chronic inflammation or wound healing (131-133,317). Mice with a genetic deletion of the FAP 
gene show prolonged survival after tumor challenge (122). Accordingly, targeting FAP by active 
immunotherapy or T cells engineered to express a FAP-specific CAR decreases tumor growth 
and this is linked to reduced angiogenesis, changes in extracellular matrix proteins and 
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augmented anti-tumor immunity (317). Data presented here point to an additional mechanism in 
which an Ad vector designed to induce FAP+ cell-depleting CD8+T cells combined with a 
traditional cancer vaccine changes the immune balances within the TME by reducing levels of 
immunosuppression while enhancing functions of MAA-specific CD8+T cells through reducing 
their metabolic stress.  
   My combination vaccine achieved complete remission of a transplantable highly 
aggressive B16 tumor in ~35% of mice while median survival of those that develop tumors was 
extended ~ 3 fold. This strategy also significantly prolonged survival of transgenic melanoma 
mice, although in this model the vaccine was given to mice, which already had substantial tumor 
burdens.  It has been reported that eliminating FAP+ cells with CAR-T cells causes significant 
bone marrow toxicity and cachexia in some mice (304,318), thus dampening enthusiasm for the 
use of FAP-targeting immunotherapy. I failed to witness significant adverse events in mice that 
received the FAP vaccine. These opposing results may reflect fundamental differences between 
vaccine-induced CD8+T cells, which recognize MHC class I-associated peptides, and CAR-T cells, 
which are triggered by cell surface expressed protein. Accordingly CAR-T cells have resulted in 
serious adverse events in human recipients due to off target activity against cells that express 
barely detectable amounts of the T cells’ antigen (319). Several other studies that tested FAP-
specific CAR-T cells failed to observe significant toxicity in mice, which may reflect differences in 
the avidity and signaling capacity of different CARs (132,133,317,320). 
   Combining the FAP vaccine with a TA-expressing vaccine resulted in increased T cell 
recruitment to tumors (320) and improved TA-specific CD8+T cell responses as has been 
reported previously (131,315). In my study numbers of MAA-specific CD8+T cells increased within 
tumors upon depletion of FAP+ cells. This was mainly due to less pronounced contraction of 
vaccine-induced CD8+T cells. Better preservation of vaccine-induced MAA-specific CD8+T cell 
response may also have been caused by the marked reduction of tumor-infiltrating ISCs after 
FAP+ stromal cell depletion.  
   MDSCs are a heterogeneous population of immature myeloid cells. In most cancers 
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PMN-MDSCs, which are highly immune-suppressive, represent the majority of the total MDSC 
population. Targeted depletion of MDCSs increases survival of tumor-bearing mice (316,321). 
FAP+ fibroblasts through secretion of factors recruit and activate ISCs (314) and previous reports 
showed that an anti-fibrotic agent, which inhibits CAF functions, reduces ISC recruitment and 
functions (322,323). In my study, depletion of FAP+ cells upon vaccination reduced both MO- and 
PMN-MDSCs within the TME. This could reflect their reduced recruitment from the periphery, 
blockade of their expansion within tumors or increased differentiation into non immune-
suppressive, more mature myeloid cells. Reduced expression of immune-inhibitors, such as iNOS 
and Arg1 by ISCs in FAP vaccine-treated mice argues for the latter mechanism.   
   STAT signaling plays a key role in fate decisions of ISCs. Specifically STAT3 controls 
their expansion, while STAT1 and STAT6 regulate activation of MDSCs and production of 
immune-inhibitory factors. The FAP vaccine reduced STAT6 signaling, which is the likely cause 
for the observed reduction of Arg1 and iNOS production by ISCs in FAP-vaccinated mice. STAT 
signaling in turn is driven by the surrounding cytokine and chemokine milieu that is maintained by 
different cells of the TME. In mice that received the FAP vaccine the profile of 
cytokine/chemokine transcripts present within tumors shifted with pronounced reductions in 
several of those known to activate STAT6 signaling. Further reductions were seen in transcripts 
of cytokines that promote Th2 at the expense of Th1 responses; the latter are typically associated 
with potent CD8+T cell responses. The membrane bound form of FAP reshapes extracellular 
matrix components, which in turn affects leukocyte/macrophages adhesion and migration. 
Reduction of FAP would thus be expected to remodel the composition of the tumor infiltrates and 
thereby the cytokine/chemokine milieu. Furthermore, factor secreted by FAP+ stromal cells can 
activate other cells of the TME, thus depleting FAP+ cells may affect the secretion of inflammatory 
factors by other cell populations. Indeed my data show that most of the factor-producing 
transcripts that changed upon FAP vaccination originated from tumor infiltrating leukocytes and 
CD14+ cells.  
   Elimination of FAP+ cells and the resulting reductions in numbers and functions of ISCs 
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within tumors are associated with better preservation of MAA-specific CD8+ TIL frequencies and 
improvement of their functions. In addition, levels of MROS decreased in MAA-specific CD8+TILs 
accompanied by lower expression of the co-inhibitor PD-1. PD-1 signaling causes a gradual loss 
of CD8+T cell functions and eventually cell death (324,325). This is in part mediated by blockade 
of the Akt/mTOR pathway, which promotes glucose uptake, glycolysis and anabolic pathways. 
Within a hypoxic TME access to glycolysis may be especially crucial, as the alternative pathway 
of energy production, i.e., OXPHOS, requires O2. As has been described tumors commonly lack 
glucose due to its consumption by tumor cells [24] and presumably the tumor stroma. As remains 
to be investigated in more depth, it is feasible that depletion of FAP+ cells and reductions in ISCs 
affects metabolic pathways used by tumor cells and other cells within the TME and thereby 
increases the amount of glucose that is available to CD8+T cells. Access to glucose in turn would 
reduce T cell metabolic stress and decrease PD-1 expression (200), while promoting their 
proliferation and effector functions (192,197). I view decreased expression of PD-1 on vaccine-
induced CD8+ TILs as a major benefit of FAP-vaccination, as blockade of PD-1 signaling by anti-
PD-L1 or anti-PD-1 checkpoint inhibitors are showing remarkable success in delaying 
progression of fatal solid tumors in human patients (326,327).  
   In summary, data presented here demonstrate that combining a traditional cancer 
vaccine with a vaccine that selectively targets FAP+ fibroblasts reduces tumor progression and 
even achieves cures in mouse melanoma models. Reduction of numbers and functions of tumor-
infiltrating ISCs due to changes in the tumors’ cytokine milieu and decreased STAT6 signaling in 
ISCs was identified as one of the underlying mechanism. Depletion of FAP+ cells and reductions 
in numbers and functions of ISCs lead to better preservation of vaccine-induced CD8+TIL 
functions. This is linked to decreased MROS and PD-1 levels signaling changes in the T cells’ 
metabolism.   
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MATERIALS AND METHODS 
	
Animal experiments 
Female C57BL/6 mice (6-8 weeks) were purchased from the National Cancer Institute (NCI) and 
housed at the Wistar Institute Animal Facility. Tyr::CreER BrafCA/+ Ptenlox/lox transgenic mice were 
a generous gift from Dr. Xiaowei (George) Xu of the University of Pennsylvania (Philadelphia, 
PA). Experimental procedures were conducted following approved protocols. For C57BL/6 tumor 
challenge experiments B16BrafV600E tumor cells were given subcutaneously (s.c.) into the right 
flank at 5x104 cells/mouse. In transgenic mice, tumors were induced by applying 4-
hydroxyltamoxifen (4-HT, Sigma, MO) to the shaved right flank at 4ug/mouse/day for three 
consecutive days. Tumor growth was monitored by measuring the perpendicular diameter of 
tumors every other day. Mice were euthanized once the diameter of tumor exceeded 1-1.5 cm. 
For combined vaccination experiments, AdC68-gDMelapoly was given at a dose of 1010 virus 
particles [vp] and AdC68-mFAP or AdC68gD vectors were given at the dose of 9x1010 vp. Vectors 
were diluted in phosphate buffered saline (PBS). For control groups, each mouse received 1011 
vp of the AdC68gD vector. In single vaccination experiment, the AdC68-mFAP vector was given 
at 1011 vp per mouse. All vectors were given intramuscularly (i.m.). For T cell depletion assay, 
mice were challenged on day 0 with B16 tumor cells and vaccinated on day 3 with the AdC68-
mFAP vector. Anti-CD8 (53-6.7) or anti-CD4 (GK1.5) or both antibodies (BioXCell, West 
Lebanon, NH) were given intraperitoneally at 0.3mg/mouse on day 0, 2 and 4 after tumor 
challenge. 
  
Cell lines 
B16BrafV600E cells (gift from Dr. M Herlyn, Wistar Institute), referred to as B16, were produced by 
transducing B16.F10 cells with lentiviral vector pLU-EF1a-mCherry expressing mouse BrafV600E. 
These cells rather than wild-type B16F10 cells were use as my vaccine carries the mutated Braf 
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epitope. Ad vectors were grown in HEK 293 cells. Cells were grown in Dulbecco’s Modified 
Eagles medium (DMEM) with 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin.  
 
Ad vector production 
The molecular clone of pAdC68-mFAP vector was constructed by digesting the pcDNA:mFAP 
vector (gift from Dr. E Puré, University of Pennsylvania) with ApaLI and ligating the mFAP insert 
into the pShuttle vector.  The insert of mFAP from the pShuttle-mFAP vector was transferred to 
the molecular clone of AdC68 through I-CeuI, PI-SceI and PvuI digestion. Construction, rescue, 
purification, titration and quality control of AdC68 vectors have been described previously(308).  
 
Western blotting 
HEK 293 cells were grown in 6-well plates until they reached 70-80% confluency.  Medium was 
replaced with 1ml serum-free DMEM and different doses of Ad vectors from 109-1011 vps were 
added to each well and incubated for two hours before 1ml of 10% FBS DMEM was added. 
AdC68-gD vector-transduced HEK 293 cells served as negative control. Cells were harvested 48 
hours later, washed twice with cold PBS and lysed in RIPA buffer (Invitrogen, Grand Island, NY) 
with protease inhibitor (Roche, Indianapolis, IN). Protein samples were separated with 4-15% 
SDS-PAGE and transferred to a PVDF membrane. After blocking and washing, the membrane 
was incubated with primary sheep anti-FAP antibody (0.5ug/ml, R&D, Minneapolis, MN, AF3715) 
diluted with 5% milk and 0.1% Tween 20 in PBS overnight at 4°C. Secondary anti-sheep HRP 
antibody was used for protein detection. b-actin was probed as loading control as described 
before(328).  
 
Enzyme-linked immunosorbent assay (ELISA) 
To measure FAP-specific antibody titers in AdC68-mFAP vaccinated C57BL/6 mice sera were 
collected in two-weekly intervals after vaccination. Briefly, ELISA plates were coated at 4°C 
overnight with mouse FAP (200ng/well, gift from Dr. J D Cheng, Fox Chase Cancer Center, 
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Philadelphia, PA) diluted in coating buffer (0.1M NaHCO3, pH 9.6).  Plates were washed with 
PBS/0.05% Tween- 20 and blocked using PBS with 10% BSA overnight. Serum samples were 
serially diluted in triplicates and incubated in wells for 2 hours at room temperature. Sheep anti-
FAP antibody (Abcam, Cambridge, MA) was serially diluted as standard. After washing bound 
IgG was detected with alkaline phosphatase (AP) conjugated-goat anti-mouse secondary 
antibody for serum samples and AP-Donkey anti-sheep secondary antibody for the antibody 
standard (both from Abcam). A phosphatase substrate (Sigma, St. Louis, MO) dissolved in DEA 
buffer was added and absorbance was read about 20 minutes later at 405nm using an 
absorbance reader (ELx800, BioTek, Winooski, VT). Serum antibody titers were determined 
based on standard curves from each plate and are expressed as mg/ml.  
 
Tissue procession 
Lymphocyte isolation from spleen and tumors has been described previously (308). To prepare 
single cell suspensions, tumors were cut into <2mm small pieces and digested in 1mg/ml 
Collagenase/Dispase (Sigma) and 1mg/ml DNAse I (Roche) dissolved in Roswell Park Memorial 
Institute (RPMI) for 30-60mins on a shaker. 10mM EDTA was added after digestion, and single 
cells were prepared by mechanical mincing with metal-mesh sieves. Cells were then passed 
through a 70mm cell strainer.  
 
Antibody staining, flow cytometry and cell sorting 
For intracellular cytokine staining, ~106 lymphocytes were stimulated with peptides or peptide 
pools (5mg/ml/peptide) and Golgiplug (Fisher Scientific, Waltham, MA 1.5mg/ml) dissolved in 
DMEM with 2%FBS for 5-6 hours at 37°C. (FAP peptides: FAP1: YSYTATYYI, FAP2: 
IQYLCWSPV, FAP3: LAYVYQNNI, FAP4: YVYQNNIYL, FAP5: SSWEYYASI, FAP6: 
RALTLKDIL, FAP7: YDLQNGEFV, FAP8: FAVNWITYL, FAP9: KALVNAQVD, FAP10: 
IAYSYYGDG, FAP11: TAVRKFIEM, FAP12: LTFWYKMIL, FAP13: SSDYYFSWL, FAP14: 
SQNHLYTHM, FAP15: IYSERFMGL, FAP16: HLYTHMTHF. MAA peptides: mTrp-1455-463: 
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TAPDNLGYA, mTrp-1481-489: IAVVAALLL, mTrp-2522-529: YAEDYEEL, hTp-2180-188: SVYDFFVWL, 
hTrp-2343-357: STFSFRNAL, mTrp-2363-371: SQVMNLHNL, hgp10025-33: KVPRNQDWL, mBraf594-602: 
FGLANEKSI). A rabies virus glycoprotein peptide was used as negative control. After stimulation 
cells were stained as described previously (243,308). Cells were stained with Amcyan fluorescent 
reactive dye (Life technologies, Carlsbad, CA), anti-CD8-Alexa700 or –Brilliant violet (BV) 605 
and CD44-FITC or -PercpCy5.5. For intracellular cytokine staining cells were stained with 
antibodies to IFN-g(APC or BV421), TNF-a (PE-Cy7, Biolegend, San Diego, California), 
granzyme B (APC, Life Technologies) and perforin (PE, eBioscience, San Diego, CA) as 
described (328). For Trp-1455 tetramer staining, cells were stained with PE-labeled Trp-1-specific 
MHC class I (H-2Db) tetramer with TAPDNLGYM peptide (NIAID tetramer facility, Atlanta, GA) 
together with other surface markers including anti-CD8, CD44, and PD-1-BV605 (all from 
Biolegend, San Diego, CA). For mitochondrial membrane potential (MMP) and mitochondrial 
reactive oxygen species (MROS) staining, cells were stained with DioC6 (40nM) and Mitosox red 
(5mM, Life technologies) for 30mins at 37°C before surface markers staining. For staining of 
other cell populations from tumors, single cell suspensions were blocked with CD16/CD32 Fc 
receptor blocking antibody (BD Pharmingen, San Jose, CA) for 30 mins at 4°C. Cells were further 
stained with either sheep anti-FAP antibody (10µg/ml, R&D, AF3715) or normal sheep IgG 
control antibody (R&D) at 4°C for 1 hour. After washing cells were stained with donkey anti-sheep 
APC-conjugated secondary antibody for 30 minutes together with anti-CD3-Pacblue, CD14-
PercpCy5.5, CD19-FITC, Gr-1-PE, CD11b-PE-Cy7, CD206-BV605, F4/80-Alexa700, Sca-1-PE-
Cy7 and CD90.2-FITC (all from Biolegend). For staining of immunosuppressive functions tumor-
derived cells were first stained with CellRox green (5mm) for 30 mins at 37°C. After washing, 
cells were stained with surface markers for 30 mins at 4°C. Cells were then fixed and 
permeabilized with fixation/permeabilization buffer (Becton Dickinson, Franklin Lanes, NJ) for 30 
mins on ice, followed by staining with rabbit polyclonal antibody to iNOS (10mg/ml, Abcam) in 1x 
permwash buffer (Becton Dickinson) for 30mins on ice. Normal rabbit IgG (R&D) was used as 
isotype control. Following washing cells were further stained with Alexa647-goat anti rabbit 
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secondary antibody (1:2000, Life Technologies) and Arginase1 PE (R&D) for 30 min at 4°C. To 
measure expression of phosphorylated STAT, cells were first fixed with pre-warmed Fix Buffer I 
(pre-warmed to37°C, Fisher) for 10 mins at 37°C. After washing with cell staining buffer 
(Biolegend), cells were stained with surface markers and permeabilized with PermBuffer III (pre-
chilled to -20°C, Fisher) for 30 min at 4°C. Cells were washed twice with cell staining buffer and 
stained with STAT1(pY701) PercpCy5.5, STAT3(pS727) Alexa647 and STAT6(pY641) antibodies 
(all from Fisher) diluted in cell staining buffer for 60mins at room temperature. Cells were 
analyzed by an LSRII (BD Bioscience). Data were analyzed with FlowJo (TreeStar, Ashland, OR).  
 
In vivo cell lysis assay 
C57BL/6 mice were vaccinated with either AdC68-gD or AdC68-mFAP vectors. Two weeks later 
splenocytes from naïve syngeneic mice were plated at 107 cells/100ul and pulsed with FAP 
peptides 1,5,7,8,9 (these peptides represents FAP-derived CD8+T cell epitopes with high 
immunogenicity in C57/Bl6 mice), or a control peptide from the rabies glycoprotein at 5mg/ml for 
each peptide at 37°C for 2 hours. Following washing cells pulsed with FAP peptides were labeled 
with carboxyfluorescein succinimidyl ester (CFSE, Life technologies) at 2mM, while cells pulsed 
with the control peptide were labeled with CFSE at 0.2mM. Two cell populations were mixed at 
1:1 ratio and a total of 2x107 cells were transferred into mice vaccinated with either vector through 
tail vein injection. 16 hours later, splenocytes were isolated from recipient mice and live single 
cells were analyzed by flow cytometry for expression of CFSE. Loss of CFSEhi cells pulsed with 
FAP peptides was used as a measure of specific lysis. Percentage of cell lysis was calculated 
using the following formula: (1-(%CFSElo cells in control vaccinated mice/%CFSEhi cells in control 
vaccinated mice)/(%CFSElo cells in FAP vaccinated mice/%CFSEhi cells in FAP vaccinated mice)) 
x100. 
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Gene expression analysis 
For the analyses of transcripts from whole tumors, mice were perfused immediately after 
euthanasia with PBS and heparin (10units/ml). The tumors were cut into small pieces, stabilized 
with RNAlater RNA stabilization reagent (Qiagen, Valencia, CA) and stored at -80°C until 
processed for RNA isolation. To analyze transcripts in different tumor cell subsets, single cell 
suspensions were prepared and stained as described above. Cells were sorted (Mono Astrios, 
Beckman Coulter, Jersey City, NJ) on ice into RNAprotect cell reagent (Qiagen). RNA was 
isolated using RNeasy plus mini kit (Qiagen) and RNA concentration was determined by 
Nanodrop (Thermo Scientific, Waltham, MA). Reverse transcription was performed using the high 
capacity cDNA reverse transcription kit (Life Technologies) and relative quantitative real-time 
PCR was performed using Fast SYBR Green master mix and 7500 Fast Real-time PCR system 
(Life Technologies). All primers (listed below) were designed by Vector NTI. GAPDH is used as 
the internal control. The following primers were used (forward followed by reverse): CCL2: 5'-
TGCTGACCCCAAGAAGAAATG-3', 5'-TGAAGACCTTAGGGCAGATGCAG-3'; CCL5: 5'-
AGCTGCCCTCACCATCCTC-3', 5'-AGCGCGAGGGAGAGGTAGG-3'; CCL22: 5'-
ACTCCTGGTGGCTCTCGTCC-3', 5'-TGGCAGAGGGTGACGGATGTA-3'; CXCL10:  5'-
AAGGACGGTCCGCTGCAAC-3', 5'-TGATCTCAACACGTGGGCAGG-3'; CXCL12: 5'-
TCGCCAGAGCCAACGTCAAG-3', 5'-TCGGGTCAATGCACACTTGTCTG-3'; IL-4: 5'-
AACCCCCAGCATGTTGTCATCC-3', 5'-TGGCGTCCCTTCTCCTGTGAC-3'; IL-6: 5'-
ACAAAGCCAGAGTCCTTCAGAGAG-3', 5'TTGGAAATTGGGGTAGGAAGG-3'; IL-10: 5'-
AAGGTGTCTACAAGGCCATGAATG-3', 5'-TGTCTAGGTCCTGGAGTCCAGC-3'; IL-13: 5'-
TGCTTGCCTTGGTGGTCTCG-3', 5'-TGCCGTTGCACAGGGGAGTC-3'; TGF-b: 5'-
TACGTCAGACATTCGGGAAGC-3', 5'-TTCAGCCACTGCCGTACAAC-3'; GM-CSF: 5'-
ACCCACCCGCTCACCCATC-3', 5'-TCTTCAGGCGGGTCTGCACAC-3'; SCF: 5'-
ACCAAGGAGATCTGCGGGAATC-3', 5'-ACATCCATCCCGGCGACATAG-3', GAPDH: 5'-
TGCCCCCATGTTTGTGATGG-3', 5'-AATGCCAAAGTTGTCATGGATGACC-3'. 
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MDSC in vitro co-culture assay 
Gr-1hiCD11b+MO-MDSCs, Gr-1intCD11b+PMN-MDSCs and CD206+F4/80+ TAMs from spleens of 
mice bearing 1 month-old BrafCA/+Ptenlox/lox transgenic tumors or B16 tumors were sorted into 
RPMI medium. CD8+T cells were purified from spleens of naive C57BL/6 mice by negative 
selection using magnetic beads (MACS, Stemcell Technologies, Vanc ouver, Canada). For 
inhibition assays, following isolation CD8+T cells were labeled with celltrace violet dye (1mM, Life 
Technologies, Carlsbad, CA) at 37°C for 20 min. MDSCs or TAMs (8x104 cells/well) and CD8+T 
cells (4x105 cells/well) were plated at a 1:5 ratio into wells of a 96-well plate pre-coated with anti-
CD3 antibody (5mg/ml, 4°C overnight, BD Bioscience, Minneapolis, MN) in RPMI medium (Life 
Technologies) supplemented with 10% FBS (Life Technologies), 20mM HEPES, 2mM Glutamax, 
1mM sodium pyruvate, 0.05mM 2-mercaptoethanol and 1% penicillin-streptomycin. Anti-CD28 
antibody (1mg/ml, BD Bioscience) and mouse IL-2 (20U/ml, Roche) were added to each well. 
Stimulated CD8+T cell without MDSCs/TAMs served as positive controls, while CD8+T cells 
cultured without activators were used as negative controls. MROS and PD-1 levels on T cells as 
well as T cell proliferation were analyzed on day 5 of culture by antibody staining and flow 
cytometry. T cell proliferation data are shown as Proliferation index (PI), i.e., the average number 
of divisions using the formula:  
 ni  is the cell number of the i-the generation (i=1,2,3,…., N). 
 
Statistical analyses 
Significance of differences between 2 populations was calculated by Student’s t test; significance 
of differences among multiple populations was calculated by one-way or two-way ANOVA using 
GraphPad Prism 6. Type I errors were corrected for multiple comparisons using the Holm-Sidak 
method. Overall responses over time were calculated by area under the curve (AUC) analysis for 
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each animal followed by student’s t test comparing AUC values. Differences in survival were 
calculated by Log-rank Mantel-Cox test. Significance was set at p-values of or below 0.05.
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Chapter 4 
 
 
Enhancing CD8+T cell fatty acid catabolism within a 
metabolically challenging tumor microenvironment 
increases the efficacy of melanoma immunotherapy 
 
 
 
 
ABSTRACT 
	
Metabolism plays an important role in modulating T cell effector functions. However, how tumor-
infiltrating T lymphocytes (TILs) adapt to the metabolic constrains within the tumor 
microenvironment (TME) and how this in turn affects their ability to combat tumor progression 
remains poorly understood. Using a mouse melanoma model, we report that metabolic 
challenges due to lack of glucose (Glu) combined with hypoxia within the TME impairs CD8+TILs 
functions. When simultaneously subjected to hypoglycemia and hypoxia, CD8+TILs enhance 
catabolism of fatty acids (FAs) including ketone bodies, which partially preserves their effector 
functions. Pre-conditioning CD8+TILs to increase FA catabolism further improves their ability to 
slow tumor progression although PD-1 expression concomitantly increases. PD-1 checkpoint 
blockade delays tumor progression without changing TIL metabolism or functions. It synergizes 
with metabolic reprogramming of T cells to achieve superior antitumor efficacy. Overall our data 
show that metabolic interventions may improve the efficacy of cancer immunotherapy.  
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Portions of this chapter were adapted from: 
Zhang Y, Liu L, Kurupati R, Zhou XY, Hudaihed A, Filisio F, Giles-Davis W, Rabinowitz JD and Ertl HC. 
Enhancing CD8+T cell fatty acid catabolism within a metabolically challenging tumor microenvironment 
increases the efficacy of melanoma immunotherapy. Manuscript under revision. 
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INTRODUCTION 
	
   Despite recent progress in cancer immunotherapy (329,330), cures remain rare even 
for highly immunogenic tumors such as melanomas. Adoptive transfer of ex vivo expanded TILs 
may affect regression of large melanomas (331). Nevertheless, traditional vaccines that aim to 
induce such T cells have largely been ineffective (332). Exhaustion of tumor antigen (TA)-specific 
CD8+T cells (333,334), which is characterized by their enhanced expression of co-inhibitors, 
decreased levels of the transcription factor T-bet and loss of effector functions following chronic 
antigen stimulation has been implicated to cause failures of active immunotherapy for solid 
tumors (7,(335). Treatments with immune checkpoint inhibitors partially rescue TIL functions and 
have yielded promising results in cancer patients (326).  
   The TME poses significant metabolic challenges to TILs due to disorganized 
vascularization, presence of toxic products derived from tumor and stromal cells and lack of 
nutrients and oxygen (O2) (245). TILs require energy to eliminate tumor cells. Upon activation T 
cells enhance energy production through glycolysis (246), which is less efficient than OXPHOS 
but provides building blocks for biomass formation and cell proliferation. Tumor cells also use 
glycolysis (247), which may lead to Glu depletion within the TME (192,197). T cells with limited 
access to Glu have to rely on OXPHOS to produce energy. Although many substances including 
FAs can fuel OXPHOS, it requires O2, which can become limiting within tumors due to insufficient 
blood supply (248). TILs therefore face dual metabolic jeopardy, which I hypothesize drives their 
functional exhaustion and thereby impairs the efficacy of cancer immunotherapy.  
   Here I study the effects of metabolic challenges within the TME on CD8+TILs functions 
in a mouse melanoma model. Melanoma-bearing mice were immunized with a mixture of 
vaccines that induce CD8+T cells specific for melanoma-associated antigens (MAAs) and an 
unrelated tumor antigen (TA), i.e., E7 of human papilloma virus (HPV)-16. Both MAA- and 
bystander E7-specific CD8+TILs increase co-inhibitor expression and lose functions, contesting 
the notion that high and sustained antigenic stimulation is solely liable for TIL exhaustion (336), 
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although it may contribute by increasing the energy demand of CD8+T cells that encounter their 
cognate antigen. Both CD8+TIL subsets increasingly experience metabolic stress due to 
restricted O2 and Glu supply during tumor progression. As shown with vaccine-induced CD8+TILs 
and in vitro activated polyclonal CD8+T cells, hypoxia through hypoxia-induced factor (HIF)-
1a increases co-inhibitor LAG-3 expression and impairs CD8+T cell functions. Limited Glu supply 
enhances co-inhibitor PD-1 expression, reduces effector functions and increases FA catabolism 
of CD8+T cells; the latter is further enhanced when cells are simultaneously subjected to hypoxia.  
I show that CD8+TILs in late stage tumors increasingly depend on FA catabolism fueled by FA 
uptake and triacylglycerol (TG) turnover to meet their energy demand, which increases PD-1 
expression but preserves some effector functions. PD-1 blockade fails to affect CD8+TILs 
metabolism or effector functions; it could reduce tumor growth in a T cell independent manner. 
Finally, promoting the TILs’ ability to utilize FAs increases their ability to delay tumor progression.  
   My findings show that hypoglycemia and hypoxia plays a critical role in driving the 
metabolic reprograming and functional exhaustion of CD8+TILs. They further indicate that 
metabolic interventions that increase FA catabolism by CD8+TILs in a Glu-deprived TME improve 
the efficacy of cancer immunotherapy.     
RESULTS 
	
CD8+T cells become functionally impaired within the TME independent of recognition of 
their cognate antigen  
  To test if the fate of CD8+TILs is linked to continued recognition of antigen within 
tumors, I used two vaccines in a transplantable mouse melanoma model. One, termed AdC68gD-
Melapoly (308) (Figure 4-1), is an adenovirus (Ad)-based vaccine that elicits robust MAA-specific 
CD8+T cell responses, most notably to the Trp-1455-463 epitope; the other, termed AdC68-gDE7 
(243), stimulates bystander CD8+T cells to E7. 
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Figure 4-1: AdC68-gDMelapoly vaccine design.  
 
Figure 4-1: AdC68-gDMelapoly vaccine design. Illustration of the transgene construct expressed by 
adenoviral vector AdC68-gDMelapoly: The Melapoly sequence is composed of an ER signal sequence (ER 
ss) followed by a pan DR epitope (PADRE), three CD4+T cell epitopes from human (h) Trp-2, and eight 
CD8+T cell epitopes from human or mouse (m)Trp-2, mTrp-1, hgp100 and mBrafV600E.  The Melapoly gene 
was fused into gD following amino acid 269. TMR, transmembrane domain; HVEM, herpes simplex entry 
mediator.  
	
					I vaccinated mice bearing 3-day old tumors and normal mice with AdC68-gDMelapoly 
mixed with AdC68-gDE7. Mice received the combined vaccine treatment show significantly 
delayed tumor progression compared to the group vaccinated with control AdC68-gD vector only 
(Figure 4-2A). I chose to analyze vaccine-induced CD8+TILs from 2-week small tumors and 1-
month advanced tumors. Both vaccine-induced Trp-1- and E7-specific CD8+T cells accumulate 
within tumors, where they contract more rapidly than in the periphery (Figure 4-2B). This is 
especially pronounced for Trp-1-specific CD8+TILs although they unlike E7-specific CD8+TILs 
proliferate within tumors. However their proliferation declines over time (Figure 4-2C) despite 
continued presence of Trp-1 antigen (not shown). 
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Figure 4-2: Vaccine-induced CD8+TILs independent of chronic antigen stimulation become 
functionally impaired within TME. 
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Figure 4-2: Vaccine-induced CD8+TILs independent of chronic antigen stimulation become 
functionally impaired within TME. (A) B16 tumor growth curves in mice received either control vector 
(circle) or AdC68-gDMelapoly with AdC68-gDE7 vectors (square) three days post tumor tumor challenge 
(control group: n=6; vaccine group: n=14). (B) Trp-1-and E7-specific CD8+T cell responses in spleen (Spl) 
and tumors of mice that had or had not been challenged 3 days before vaccination with B16BrafV600E cells 
(n=10 mice/group). Numbers of tetramer (tet)+CD8+ T cells per 106 live cells with mean and standard errors 
of me an (SEM) are shown. (C) BrdU was given one day before euthanasia for 24 hours on days 9, 19 or 29 
after vaccination. Figure shows % of BrdU incorporation into Trp-1- and E7-specific CD8+T cells of mice that 
had been challenged with B16BrafV600E cells 3 days before vaccination (n=5 mice/group). 
				
				Trp-1-specific CD8+T cells from early and, to a more pronounced extent, late-stage tumors 
increase expression of PD-1 and LAG-3 (Figure 4-2D). Enhanced expression of both co-
inhibitors on TILs from small ~ 2 week-old tumors may reflect preferential recruitment of highly 
activated CD8+T cells. Nevertheless, additional increases of co-inhibitors over time combined with 
declining production of effector molecules, such as lytic enzymes and interferon (IFN)-
γ as well as reduced polyfunction in 1-month tumors (Figure 4-2E), suggests that Trp-1-specific 
CD8+TILs differentiate towards exhaustion. Although E7-specific CD8+TILs neither encounter 
their cognate antigen nor proliferate within the tumors, they also augment expression of co-
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inhibitors (Figure 4-2C,D) and lose effector functions and polyfunction in 1-month tumors (Figure 
4-2E). Importantly, the decrease in effector functions of CD8+TILs in 1-month tumors is not due to 
their differentiation towards memory T cells, as my analysis show that levels of differentiation 
markers on/in vaccine-induced CD8+TILs regardless of their antigen specificity remain 
comparable (Figure 4-2F). Lack of memory formation of CD8+ T cells induced by Ad vectors has 
been reported previously (77) and reflects that these vectors persist in a transcriptionally active 
form at low levels in activated CD8+ T cells. This in turn provides antigen for continuous activation 
of the transgene product-specific T cells. Levels of antigens are very modest so that T cells do 
not differentiate towards exhaustion but rather remain at the effector/effector memory stage.  
Overall, these data demonstrate that within tumors factors other than chronic stimulation 
contribute to the functional impairments of CD8+TILs.  
 
 
Figure 4-2. 
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     Metabolic stress is known to dictate cellular fate (337-339)and could potentially affect 
functions and survival of vaccine-induced CD8+TILs independent of their antigen specificity. My 
data show that both Trp-1-and E7-specific CD8+TILs gradually lose mitochondrial membrane 
potential (MMP) (Figure 4-3A), which is essential for proton gradient formation that drives ATP 
production. They also develop increased levels of mitochondrial reactive oxygen species (MROS) 
during tumor progression. MMPloMROShi Trp-1- and to a lesser extend E7-specific CD8+TILs 
become prevalent in late stage tumors (Figure 4-3B), while corresponding CD8+T cells from 
spleens remain largely MMPhiMROSlo. Overall these data suggest that vaccine-induced CD8+TILs 
experience intensifying metabolic stress within growing tumors. 
Figure 4-3: Vaccine-induced CD8+TILs experience enhanced metabolic stress within TME. 
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Figure 4-3: Vaccine-induced CD8+TILs experience enhanced metabolic stress within TME. (A) MFI 
(mean-SEM) of MMP and MROS in Trp-1- and E7-specific CD8+T cells from spleens and tumors harvested 
2 weeks or 1 month after challenge (n=5 mice/group). (B) Quadrant gating of frequencies of Trp-1-and E7-
specific CD8+T cells with high or low stains for MMP and MROS (n=5 mice/group). Representative flow plots 
show samples from mice bearing 1 month-old tumors. For (B) (-) - not significant or (*) - significant are 
arranged so that the 1st shows differences between MMPloMROSlo cells, the 2nd between MMPloMROShi 
cells, the 3rd between MMPhiMROShi cells and the 4th between MMPhiMROSlo cells.   
Hypoxia through HIF-1α  increases LAG-3 expression and reduces T cell functions   
    Solid tumors commonly lack O2. My data show that Trp-1- and E7-specific CD8+TILs 
within the TME increasingly experience hypoxia during tumor progression as shown by enhanced 
expressions of HIF-1α, a transcription factor that stabilizes under hypoxia, and its downstream 
target Glut1, which facilitates Glu uptake, in/on vaccine-induced CD8+TILs from late-stage 
(Figure 4-3C) but not small week 2 tumors (data not shown).  
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Figure 4-3. (C) MFI (mean-SEM) of HIF-1α and Glut1 expression in/on Trp-1-and E7-specific CD8+T cells 
from spleens and tumors of mice bearing 1 month-old tumors (n=5 mice/group). Histograms: HIF-1α and 
Glut1 levels in representative samples from spleen (open) and tumor (grey). *p<=0.05, **p<=0.01, *** 
p<=0.001, **** p<=0.0001.  
 
     To test the effect of hypoxia, I stimulated CD8+T cells in vitro for 4 days in regular Glu-
rich medium under normoxia (21% O2) or subjected them to hypoxia (1% O2) for the last 16 hours 
of culture (Figure 4-4A). Hypoxia affects T cell stimulation as evidenced by reduced blast 
formation (Figure 4-4B). Activated CD8+T cells under hypoxia increase expression of HIF-1α and 
Glut1 (Figure 4-4C). They become metabolically stressed as evidenced by decreases in MMP 
and rises in MROS, leading to an increase in the proportion of MMPloMROShi CD8+T cells (Figure 
4-4D) reminiscent of the mitochondrial metabolic profile of vaccine-induced TILs in late-stage 
tumors.  
Figure 4-4: Hypoxia affects CD8+T cell metabolism, differentiation and functions.  
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Figure 4-4: Hypoxia affects CD8+T cell metabolism, differentiation and functions. (A) Cartoon 
illustrates my experimental design where cells were stimulated continuously for 96 hours. To assess the 
effect of hypoxia cells were moved to a 1% O2 chamber for the last 16 hours.  (B) Blast formation; 
normalized % of live CD8+T cells forming blasts by day 4 of culture under hypoxia (H, light grey) compared 
to those cultured under normoxia (N, black) using protocol shown in A (n=6 samples/group, representative 
of more than  experiments). (C) Normalized MFI values for HIF-1α and Glut1 expression in/on CD8+T cells 
under normoxia, N or hypoxia, H (n=5 samples/group, representative of 4 experiments). * on top of each bar 
indicates significant differences compared to Glu, N. (D) Left: Normalized MFI of MMP and MROS. Right: 
Quadrants gating for MMP over MROS stains (n=5 samples/group, representative of >5 experiments). 
 
    Hypoxia reduces PD-1 but augments LAG-3 expression (Figure 4-4E), suggesting that 
PD-1 declines and LAG-3 increases under conditions that promote glycolysis such as through 
HIF-1α signaling. CD8+T cells cultured under hypoxia reduce T-bet expression (Figure 4-4F), 
decrease production of effector molecules and lose polyfunctionality (Figure 4-4G).  
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Figure 4-4. (E) Normalized MFI of PD-1, LAG-3 and (F) T-bet expression. (G) Left: Production of individual 
functions under hypoxia with data normalized to those under normoxia. Right: Functions of CD8+T cells 
shown as % of CD8+CD44+T cells producing 3, 2 or 1 factors and their representative flow plots. Production 
of IFN-γ, granzyme B (GzmB) and perforin were measured. * within () on top of the bars indicate differences 
in % of total function and * outside of () indicates differences in proportions of cells producing 1-3 functions 
(bottom to top). Numbers on flow plots indicates % of cells positive for IFN-γ, granzyme B or perforin. (E-G) 
n=5 samples/condition, representative of more than 5 experiments. 
 
    A different previously described protocol25 (Figure 4-4H), in which CD8+T cells upon 
the initial activation are rested in IL-2 prior to hypoxia, has no effect on blast formation (Figure 4-
4I) or PD-1 levels, although LAG-3 expression increases (Figure 4-4J) and T-bet levels decrease 
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(Figure 4-4K). Granzyme B (GzmB) production increases while production of other effector 
molecules and polyfunctionality decline (Figure 4-4L). As vaccine-induced CD8+T cells are 
unlikely to rest before infiltrating tumors, I used the protocol of continuous CD8+T cell activation 
for subsequent hypoxia experiments.  
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Figure 4-4. (H) Alternative protocol tests the eff ct of hypoxia on relatively resting CD8+T cells. T cells were 
stimulated for 48 hours and then switched to IL-2 containing medium without antibodies to CD3 or CD28. 
The effect of hypoxia was assessed by subjecting cells cultured in IL-2 to 1% O2 for the last 36 hours. (I) 
Blast formation; normalized % of live CD8+T cells forming blasts under hypoxia compared to those cultured 
under normoxia using protocol shown in H. (J) Normalized expression of PD-1, LAG-3 and (K) T-bet on/in 
cells kept under hypoxia (white) compared to those cultured under normoxia (dark grey) using protocol h. (l) 
Left: Normalized production of individual functions by CD8+T cells cultured under hypoxia compared to those 
cultured under normoxia, using protocol H. Right: % of cells over all CD44+CD8+ cells positive for 1-3 
functions. * are arranged according to colors with significance for 1 function at the bottom. (I-L) n=6 
samples/condition, representative of 2 experiments.  
   HIF-1α correlates with expression of LAG-3 on TILs or CD8+T cells subjected to 
hypoxia (Figure 4-5A). To determine whether HIF-1α directly promotes LAG-3 expression and 
whether this affects CD8+T cell functions, I knocked down HIF-1α transcripts by transducing 
CD8+T cells with lentivectors that express either short-hairpin (sh)RNA to silence HIF-1α or a 
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control sequence, together with a Thy1.1 selection marker (Figure 4-5B). HIF-1α silencing 
reduces expression of HIF-1α in CD8+T cells stimulated in vitro under hypoxia (Figure 4-5C), 
concomitantly decreases LAG-3 but not PD-1 (Figure 4-5D) and improves production of 
granzyme B and IFN-γ (Figure 4-5E).   
Figure 4-5: Hypoxia-induced HIF-1α  directly drives co-inhibitor LAG-3 expression and 
impairs effector functions of activated CD8+T cells in vitro. 
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Figure 4-5: Hypoxia-induced HIF-1α  directly drives co-inhibitor LAG-3 expression and impairs 
effector functions of activated CD8+T cells in vitro. (A) Pearson correlation between MFI values of HIF-
1α and LAG-3 expression in/on TILs or in vitro activated CD8+T cells that were subjected to hypoxia. 
Correlation coefficient r and p values are shown on top of the graphs. Each dot represents one sample 
(n=17 for TILs samples, n=16 for in vitro samples, data were pooled from 2 independent experiments). (B) 
Flow plots illustrates the levels of Thy1.1 expression upon transduction of CD8+T cells with a control 
lentivector expressing eGFP or the HIF-1α shRNA lentivector expressing Thy1.1 as a selection marker. (C) 
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Left: MFI values of HIF-1α expression in activated CD8+T cells transduced with control vector (light grey) or 
HIF-1α shRNA vector (dark grey) and then cultured under hypoxia. Representative histogram is shown next 
to the bars (open: control group, grey: HIF-1α shRNA group). Right: Level of HIF-1α knock-down 
determined by testing transduced bead-enriched Thy1.1+CD8+T cells for HIF-1α transcripts by real-time 
PCR. Data shown as HIF-1α transcripts levels in cells transduced with HIF-1α shRNA normalized to those 
transduced with control RNA. (D) MFI values of PD-1 and LAG-3 expression on activated CD8+T cells 
transduced with control or HIF-1α shRNA vector and then cultured under hypoxia. Representative 
histograms are shown next to the bars (open: control group, grey: HIF-1α shRNA group). (E) % of 
CD44+CD8+T cells transduced with control or HIF-1α shRNA vector cultured under hypoxia producing 
individual factors. Representative flow plots on the right show quadrant gating for IFN-γ over granzyme B or 
perforin. (C-E) n=5 samples/group, representative of 2 experiments.  samples were pooled from n=30 mice 
for each experiment. *p<=0.05, **p<=0.01, *** p<=0.001, **** p<=0.0001. 
 
   To study whether HIF-1α contributes to the CD8+TILs’ co-inhibitor expression and loss 
of functions, I activated enriched CD8+T cells in vitro and, after transduction with control or HIF-
1α shRNA-expressing lentivectors, transferred them into tumor-bearing, AdC68-gDMelapoly-
vaccinated mice (Figure 4-6A). I analyzed the transferred T cells ~3 weeks later (Figure 4-6B) 
using tumor samples from mice bearing similar sized tumors.  
Figure 4-6: HIF-1α  knock down reduces LAG-3 expression and improves MAA-specific 
CD8+T cell functions in the TME. 
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Figure 4-6: HIF-1α  knock down reduces LAG-3 expression and improves MAA-specific CD8+T cell 
functions in the TME. (A) Experimental set up for in vivo study. Enriched CD8+T cells were transduced with 
lentivectors expressing control or HIF-1α targeting shRNA and Thy1.1 and transferred intravenously (i.v.) 
into Thy1.2+ mice. Recipient mice at the time had been challenged with tumor cells 5 days earlier and they 
had been vaccinated with AdC68-gDMelapoly 2 days earlier. (B) Gating strategy for lentivector transduced 
Trp-1-specific CD8+TILs. Trp-1-specific Thy1.1+CD8+T cells were recovered from tumors 2 weeks after 
transfer. Cells from tumors were first gated on mononuclear cells, singlets, live cells and CD8+T cells. They 
were further gated on Thy1.1+ cells and Trp-1-tetramer+CD44+ cells. 
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   Knocking down HIF-1α (Figure 4-6C) reduces the Trp-1-specific CD8+TILs’ expression 
of LAG-3 without affecting PD-1 (Figure 4-6D) and significantly improves the MAA-specific TILs’ 
frequencies and functions (Figure 4-6E). Production of perforin increases upon HIF-1α-silencing 
in vivo but not in vitro, which may reflect that other conditions such as differences in supply of 
nutrients contribute to the effect of hypoxia on activated CD8+T cells. These data suggest that 
hypoxia through increased HIF-1α signaling directly enhances LAG-3 expression and dampens 
effector functions of CD8+TILs. They further suggest that a HIF-1α-driven metabolic switch to 
glycolysis might be counterproductive for T cell functions within an O2 and Glu-depleted TME. 
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Figure 4-6. (C-D) Upper panel: MFI values of HIF-1α (C) and co-inhibitors PD-1 and LAG-3 (D) expression 
in/on Trp-1-specific CD8+TILs transduced with control (Co RNA) or HIF-1α shRNA (shRNA) vector. Lower 
panel show representative histograms: control vector transduced samples (empty), HIF-1α shRNA vector 
transduced samples (grey). (E) Left: % of MAA-specific CD8+TILs transduced with either control or HIF-
1α shRNA expressing vector producing individual factors; Right: % of lentivector transduced cells in each 
group producing 3,2 and 1 factor. * within () indicates difference in sum of responses, * out of () left to right: 
difference in having 3, 2, 1 functions.  (C-E) n=6 mice/group, data are representative of 2 experiments. 
*p<=0.05, **p<=0.01, *** p<=0.001, **** p<=0.0001.  
 
Activated CD8+T cells subjected to Glu and O2 deprivation enhance FA catabolism 
    Not only O2 but also the supply of Glu declines during tumor progression within the 
TME presumably due to its consumption by tumor cells (Figure 4-7A). To investigate the 
collective effects of Glu and O2 restrictions, enriched CD8+T cells were stimulated in vitro in Glu 
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medium with 2-deoxy-D-glucose (2-DG), a competitive inhibitor of glycolysis, or Glu was replaced 
with galactose (Gal). Cells were cultured under normoxia or short-term hypoxia. The extracellular 
acidification rate (ECAR), a measure of glycolysis, declines in T cells cultured with 2-DG or Gal. 
The O2 consumption rate (OCR), a measure of OXPHOS, decreases with 2-DG but increases 
with Gal. CD8+T cells activated under either condition show increases in the OCR/ECAR ratio, 
suggesting a switch towards energy production through OXPHOS (Figure 4-7B). 
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Figure 4-7: Effects of glucose limitation on metabolism, differentiation and effector functions of 
activated CD8+T cells in vitro subjected to normoxia or short-term hypoxia. When indicated (D in Y-
axis title) values are normalized to those obtained with Glu, N set at 100 (black dotted lines). The red 
dashed lines show results for cells cultured in Glu and subjected to hypoxia (H) normalized to those cultured 
in Glu and under normoxia. (A) Glu concentration in plasma or interstitial fluid of 2 week- and 1 month-old 
tumors (n=5 mice/group, representative of 2 experiments). (B) Normalized OCR, ECAR and the OCR to 
ECAR ratios at baseline for CD8+T cells stimulated in Glu with 2-DG or medium supplumented with Gal 
instead of Glu for 4 days. Data are normalized to those obtained with cells kept in Glu-rich medium set at 
100 (n=5 samples/group with 3 repeated measures/sample, representative of 3 experiments).   
 
 
   Cells cultured with 2-DG or Gal compared to those grown with Glu express more PD-1 
regardless of O2 supply, suggesting a link between use of OXPHOS and high PD-1 expression 
(Figure 4-7C). Compared to cells cultured with Glu those grown with limited access to Glu under 
normoxia decrease T-bet expression (Figure 4-7D) and lose functions including polyfunctionality 
(Figure 4-7E). Intriguingly, functions of CD8+T cells without access to Glu are better preserved if 
cells are also subjected to hypoxia (Figure 4-7E).  
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Figure 4-7. (C) Normalized MFI values and representative histograms for PD-1 expression on CD8+T cells 
activated in different Glu-restricted medium under normoxia (black) or hypoxia (grey) (n=5 
samples/condition, representative of more than 5 experiments). Numbers next to histograms indicate MFI 
values. (D) Normalized MFI values of T-bet (n=5 samples/group, representative of 3 experiments). (E) Left: 
% of cells producing 3, 2 and 1 factors over all CD44+CD8+ T cells cultured under different conditions. 
Middle: Same data as left illustrating differences in % of cells producing 3, 2 and 1 factors in Glu+2-DG or 
Gal medium compared to those of cells in Glu medium with the corresponding O2 supply. Statistics on each 
bar indicates difference in % of cells producing 3, 2 and 1 function (bottom to top).  Right: representative 
flow plots show IFN-γ and granzyme B production (n=5 samples/group, representative of 3 experiments). 
F G
 
Figure 4-7. (F) Cartoon indicates roles of different factors that were analyzed at the transcriptional level. (G) 
Table summarizes functions, names and abbreviations of the analyzed factors. 
     These data suggest that under hypoxia cells with limited supply of Glu may more 
readily switch to alternative metabolic pathways to support their energy demand. 
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    To study the metabolic pathways used by CD8+T cells with limited Glu and O2 supply 
in vitro or within the TME, I measured expression levels of transcripts for factors that participate in 
nutrient consumption and energy production by comparative quantitative (q)PCR  (Figure 4-8A, 
Figure 4-7F,G). Upon short-term hypoxia CD8+T cells stimulated with limited access to Glu 
compared to those stimulated in Glu-rich medium decrease transcripts for enzymes of glycolysis 
and the tricarboxylic acid (TCA) cycle, ROS detoxification and the electron transport chain (ETC); 
while transcripts for FA uptake, TG turnover, peroxisomal and mitochondrial FA oxidization (FAO) 
increase. This pattern is closely mirrored by Trp-1- and E7-specific CD8+TILs from late-stage 
tumors compared to those from small 2 week-old tumors, indicating that metabolically stressed 
CD8+T cells increasingly rely on FA catabolism to produce energy. Changes in transcripts during 
tumor progression are not driven by differentiation of TILs towards a more resting stage, as they 
are distinct from differences in vaccine-induced splenic CD8+T cells tested at 3 months compared 
to those tested at 2 weeks after vaccination (Figure 4-8B).  
Figure 4-8. Limited access to Glu and oxygen forces activated CD8+T cells to enhance FA 
catabolism in vitro. 
Transcripts, in vitro and TILs ex vivo
low       high low       high
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Figure 4-8: Limited access to Glu and oxygen within TME forces activated CD8+T cells to enhance FA 
catabolism. (A) Relative transcripts levels: CD8+T cells stimulated in Gal or Glu+2-DG vs. Glu medium 
under hypoxia. Or: Trp-1- and E7-specific CD8+TILs from 1-month tumors vs. those from 2-week tumors. 
Color code compares the changes in transcripts levels between in vivo and in vitro samples. Yellow: similar; 
green: opposite; orange: mixed. (B) Relative transcripts levels of Trp-1-or E7-specific CD8+T splenocytes 
collected 3-months vs. 2 weeks after vaccination. (A, B) n=5 mice/group.  
    Consistent with increased transcript levels of factors involved in FA metabolism, 
CD8+T cells grown with limited access to Glu under normoxia or hypoxia significantly increase FA 
uptake (Figure 4-8C) and enhance oxidation of endogenous and exogenous FAs (Figure 4-8D). 
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Figure 4-8. (C) Uptake of Bodipy FL C16  (fluoresent free fatty acid) by cells cultured in Glu (red) or Gal (dark 
grey) media under normoxia (N) or hypoxia (H). Histograms show Bodipy uptake in representative samples 
subjected to hypoxia (n=5 samples/condition, representative of two experiments, n=25 mice were pooled for 
each experiment). (D) Basal OCR due to consumption of exogenous (brown bars) and endogenous (yellow 
bars) FAs by CD8+ T cells stimulated in v tro in Glu or Gal media (n=3 samples/condition with 3 repeated 
measures/sample, representative of two experiments, n=15 mice were pooled for each condition in every 
experiment). 
    To directly measure effects of Glu and O2 deprivation on FA catabolism of CD8+T cells, 
my collaborator performed liquid chromatography-mass spectrometry (LC-MS)-based metabolic 
analyses. Metabolites involved in FA mitochondrial transport and oxidation, i.e., acetylcarnitine, 
palmitoylcarnitine and the ketone body 3-hydroxybutyrate, increase in cells stimulated in vitro in 
Gal medium and this is exacerbated under hypoxia (Figure 4-8E). 13C6-Glu/Gal or 13C16-palmitate 
isotope tracing (Figure 4-8F) show that CD8+T cells activated in Glu medium and short-term 
hypoxia or in medium with limited access to Glu under normoxia or hypoxia compared to those 
activated in Glu medium under normoxia show reduced presence of carbohydrate-derived 13C in 
TCA cycle metabolites (Figure 4-8G), but significantly higher 13C16-palmitate-derived carbon 
incorporation into acetyl-CoA and TCA cycle metabolites (Figure 4-8H). Cells stimulated under 
hypoxia show significantly higher percentages of 13C16-palmitate-derived acetyl-CoA than those 
cultured in the same medium under normoxia, suggesting that cells further increase FAO under 
hypoxia. 
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Figure 4-8. (E) Relative intensity of FAO-related metabolites in CD8+Tcells stimulated for 4 days in vitro 
under different conditions normalized to those of cells cultured under Glu, Normoxia. Normoxia: black; 
Hypoxia: light grey. (F) 13C6-Glu/Gal or 13C16-palmitate-derived 13C cycling into metabolites of glycolysis or 
TCA cycle. (G) Normalized contribution of 13C6-Glu/Gal-derived 13C carbon and (H) 13C16-palmitate-derived 
13C-carbon to metabolites of the TCA cycle in cells cultured under different conditions compared to those 
cultured under Glu, Normoxia (set as 100). Data are shown as mean values of relative % of labeling with 
SEM. * on top of each bar indicates significant differences compared to cells cultured under Glu, N. (E, G, H) 
n=6 samples/condition, representative of 2 experiments. n=30 mice were pooled for each experiment. 
*p<=0.05, **p<=0.01, *** p<=0.001, **** p<=0.0001. 
   Next I studied the metabolism of activated CD8+T cells directly in vivo by stable isotope 
tracing. Mice bearing 3-day tumors were vaccinated with mixtures of AdC68-gDMelapoly and 
AdC68-gDE7.  Two weeks or one-month later mice were given 13C6-Glu and levels of glycolysis 
metabolites and 13C incorporation into TCA cycle intermediates were analyzed in CD44+CD8+T 
cells from spleen and tumors (Figure 4-9A). The need for sufficient cell numbers precluded an 
analysis of vaccine-induced CD8+T cells. The intensity of glycolysis intermediates glucose-6-
phosphate (G6P) and 3-phosphoglycerate (3PG) in TILs declines during tumor progression 
(Figure 4-9B), indicating reduced glycolysis. The contribution of 13C-Glu-derived carbon to TCA 
cycle intermediates declines comparing CD44+CD8+T cells from late to early stage tumors or from 
tumors to spleens (Figure 4-9C), confirming that TILs decrease Glu catabolism. 
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Figure 4-9: Activated CD8+T cells within metabolically challenging TME enhance FA 
catabolism. 
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Figure 4-9: Activated CD8+T cells within metabolically challenging TME enhance FA catabolism. (A) 
Experimental design for 13C6-Glu in vivo tracing. (B) Relative intensity of glycolysis metabolites in 
CD44+CD8+TILs from 1-month tumors normalized to those from 2-week tumors (n=2 pooled samples/group, 
30 mice/sample). (C) Normalized 13C6- Glu contribution to TCA cycle metabolites in CD44+CD8+TILs from 1-
month tumors compared to those from spleens (n=2 pooled splenocytes samples; n=1 pooled TILs sample, 
pooled from 60 mice).   
I further performed 13C16-palmitate tracing in mice bearing 2-week or 1-month tumors (Figure 4-
9D). The intensities of acylcarnitine species, the ketone bodies 3-hydroxylbutyrate and 
acetoacetate increase in TILs during tumor progression (Figure 4-9E).  Moreover, the 
contribution of 13C16-palmitate-dervied 13C to TCA metabolites becomes higher in CD44+CD8+T 
cells from 1-month tumors compared to those from 2-week tumors or 1-month spleens (Figure 4-
9F), supporting the TILs’ enhanced reliance on FA catabolism during tumor progression. In 
splenic CD44+CD8+T cells tested at different time points after vaccination, 13C16-palmitate-derived 
carbon incorporation into TCA cycle metabolites remains stable or decreases over time. 
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Figure 4-9. (D) Experimental design for 13C16-palmitate in vivo tracing. (E) Relative intensity of FA 
metabolites in CD44+CD8+TILs from 2 wk- or 1 mo-old tumors. (F) Normalized 13C16- palmitate contribution 
to TCA cycle metabolites in CD44+CD8+T cells from 1-mo vs. 2-wk tumors (left) or 1-mo tumors vs. 1-mon 
spleens (middle) or spleens at 1 mo vs. 2 wk after tumor challenge (right). Experiments were conducted 
twice with 2-3 pooled samples collected from ~ 30 mice/sample/experiment. Data are shown as mean 
values. 
CD62L and CD127 expression are markedly lower on CD44+CD8+TILs from 1-month compared 
to those from 2-week tumors (Figure 4-9G), confirming the enhanced FA catabolism by late-
stage CD8+TILs is not reflective of their differentiation towards memory. The metabolic switch of 
TILs towards FA catabolism is facilitated by high abundance of different free FA species within 
the melanoma interstitial fluid (Figure 4-9H), enhanced uptake of FAs (Figure 4-9I) and 
increased expression of the FA oxidation (FAO) rate-limiting enzyme Cpt1a (Figure 4-9J) in 
vaccine-induced CD8+T cells from late stage tumors.  
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Figure 4-9. (G) Histograms for memory cell markers expression on CD44+CD8+T cells isolated from 
different tissues and at time points. (H) Relative intensity of free FA species in the tumor interstitial fluid 
shown as ratio of results obtained from 1-mo over 2-wk tumors (n=2-3 samples/group). (I) Uptake of 
BODIPY C16 tested directly ex vivo and representative histograms. (J) MFI for Cpt1a and representative 
histograms. (I-J) n=5/group. 
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Treatment with anti-PD-1 slows tumor progression without changing CD8+ TILs’ 
metabolism or functions 
In clinical trials checkpoint inhibitors such as monoclonal antibodies (mAb) to PD-1 can 
delay tumor progression (54). As in my model CD8+TILs increase PD-1 expression over time, I 
tested if treatment with anti-PD-1 mAb affects their metabolism or functions. Mice were 
challenged with tumor cells, vaccinated 3 days later, and starting 10 days after vaccination 
treated with anti-PD-1 mAb or isotype control. Within 1-month tumors, anti-PD-1 treatment 
reduces staining for PD-1 and enhances pAkt levels on/in vaccine-induced CD8+TILs (Figure 4-
10A) (340)without affecting their differentiation status (Figure 4-10B). 
Figure 4-10. Metabolism and effector functions of CD8+TILs are independent of PD-1. 
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Figure 4-10. Metabolism and effector functions of CD8+TILs are independent of PD-1. Vaccinated 
tumor-bearing mice were treated with isotype control (Iso) or anti-PD-1 antibody (α-PD-1) every 3rd day. (A) 
MFI of PD-1 and pAkt on/in specific CD8+TILs at 1 mo after tumor challenge. (B) MFI of markers on/in 
specific CD8+TILs from 1-mo tumors. (A,B) n=5-7 mice/group, shown as mean-SEM.  
 
PD-1 blockade neither dramatically affects the FA or Glu catabolism of CD44+CD8+TILs (Figure 
4-10C-E) nor improves effector functions of vaccine-induced CD8+TILs (Figure 4-10F). It does 
effectively delay tumor progression in vaccinated as well as unvaccinated or even immune-
deficient NSG mice, which lack T, B and natural killer cells (Figure 4-10G), suggesting that PD-1 
checkpoint blockade delays tumor progression in a T cell-independent manner.  
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Figure 4-10. (C) Normalized 13C16-palmitate contribution to TCA cycle metabolites in CD44+CD8+T cells 
from α-PD-1 treated compared to iso-treated 1-mo tumors. (D) Intensity of ketone bodies in CD44+CD8+T 
cells from 1-mo tumors. (E) Normalized 13C6-Glu contribution to TCA cycle metabolites in CD44+CD8+T cells 
from 1-mo tumors. (C-E) n=2-3 samples/group, shown as mean values. Pooled from 20-30 mice/sample. (F) 
Frequencies of specific CD8+TILs from 1-mo tumors of mice treated with iso or α-PD-1 producing 3, 2 or 1 
factors (n=11-15 mice/group), shown as mean-SEM. (G) Tumor growth in mice that received iso or α-PD-1, 
shown as mean tumor volume +/- SEM (n=4-13mice/group). Arrows under x-axis: red (vaccine); black 
(antibody treatment).   
   Recent studies show that anti-PD-1 treatment decreases tumor progression by 
reducing mTOR signaling in PD-1+ melanoma cells(341). As mTOR signaling increases the T 
cells’ Glu metabolism(338), I tested whether anti-PD-1 mAbs reduce the tumor cells’ Glu 
metabolism and thereby delay their growth. In all three models anti-PD-1 treatment increases Glu 
content within the tumors’ interstitial fluid (Figure 4-11A). Cells from B16BrafV600E tumors of NSG 
mice upon anti-PD-1 treatment increase incorporation of Glu-derived carbons into metabolites of 
the TCA cycle or the purine synthesis pathway, indicating that PD-1 blockade actually increases 
their use of Glu for both catabolic and anabolic reactions (Figure 4-11B-C).  In summary, in our 
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model PD-1 signaling has no major effects on metabolism or functions of CD8+TILs. Anti-PD-1 
treatment could reduce tumor progression in a T cell independent manner.  
Figure 4-11. Anti-PD-1 treatment increases Glu concentration in the tumor interstitial fluid 
and the tumor cells’ Glu metabolism. 
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Figure 4-11. Anti-PD-1 treatment increases Glu concentration in the tumor interstitial fluid and the 
tumor cells’ Glu metabolism. (A) Glu concentration in the tumor interstitial fluid from the indicated mice 
that had received the isotype control (Iso) or the anti-PD-1 antibody (α-PD-1). (B) Cartoon illustrates the 
13C6-glucose metabolism of tumor cells using catabolic pathway by contributing two 13C carbons to citrate 
and TCA cycle intermediate a-ketoglutarate, or using anabolic pathway by contributing three 13C carbons to 
oxaloacetate and citrate and the purine synthesis pathway intermediate AICAR. (C) Results for 13C6-Glu 
tracing of cells isolated from day 20 tumors of NSG mice. Incorporation of 2 and 3 carbons are shown 
indicating the use of Glu for catabolic or anabolic downstream reactions. Data are shown as mean-SEM. 
 
Enhanced reliance on FA catabolism is essential to maintain functions of CD8+T cells 
    To further assess the impact of FA catabolism on CD8+T cell differentiation, I 
stimulated CD8+T cells in presence of fenofibrate (FF), an agonist of PPARα that increases FA 
catabolism, or etomoxir (Eto), an irreversible inhibitor of Cpt1 that decreases mitochondrial FAO 
(Figure 4-12A). In vitro FF-treated cells stimulated in Glu or Gal medium compared to diluent-
treated cells increase FAO as shown by their enhanced transcripts of factors involved in FA 
catabolism (Figure 4-12B) and increased FA uptake (Figure 4-12C). CD8+T cells stimulated in 
either Glu or Gal medium decrease OCR in presence of Eto (Figure 4-12D), confirming the 
drug’s inhibitory effect on FAO. OCR declines more in cells cultured with Gal and Eto, and further 
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decreases when cells are also subjected to hypoxia, again confirming the cells’ increased 
reliance on FAO when Glu and O2 are limited.  
Figure 4-12: Increased FA catabolism enhances PD-1 expression and effector functions of 
metabolically stressed CD8+TILs in vitro.  
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Figure 4-12: Increased FA catabolism enhances PD-1 expression and effector functions of 
metabolically stressed CD8+TILs in vitro. (A) Drugs targeting different pathways of FA catabolism. Red 
lines: inhibition; blue: agonist activity. (B) Heatmap shows transcripts levels of enzymes involved in FA 
metabolism in CD8+T cells stimulated in vitro in Glu or Gal medium with short-term hypoxia (H) comparing 
samples treated with FF to those treated with diluent (n=5 samples/condition, representative of 2 
experiments, n=20 mice were pooled for each experiment). (C) Bodipy C16 uptake by CD8+T cells stimulated 
in vitro in Glu or Gal and subjected to short-term hypoxia with the addition of FF (light grey) compared to 
those of cells cultured under same condition with the addition of diluent (dark grey). * above bars indicates 
significant differences between cells treated with FF and diluent; histograms on the right show 
representative samples (n=5 samples/condition, representative of 2 experiments, n=20 mice were pooled for 
each experiment). (D) Relative basal OCR of CD8+T cells cultured with Eto in Glu or Gal medium under 
normoxia (N) or hypoxia (H) normalized to cells cultured with diluent under same condition. * above each bar 
indicate significant differences between Eto-and diluent-treated cells. Lines with stars above show 
differences between the connected samples (n=3 samples/condition with 3 repeated measures/sample, 
representative of 2 experiments, n=20 mice were pooled for each experiment).   
 
    Under hypoxia PD-1 increases with addition of FF but decreases in presence of Eto 
(Figure 4-12E). FF increases while Eto decreases functions and polyfunctionality of CD8+T cell 
cultured with limited access to Glu and O2 (Figure 4-12F). These results show that enhanced FA 
catabolism promotes effector functions of metabolically stressed CD8+T cells, although it 
increases PD-1 expression. 
As shown in Figure 4-8A T cells experiencing metabolic stress in vitro and TILs from 
late-stage tumors increase transcripts of enzymes participating in TG turnover. To assess if 
CD8+T cells under metabolically challenging conditions mobilize TGs to fuel FAO and OXPHOS, I 
added Orlistat (OS), an inhibitor of the lipolysis enzyme lipa, or Amidepsine A (AmA), an inhibitor 
of the TG synthesis enzymes Dgat1 and Dgat2, to CD8+T cells stimulated under different 
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conditions (Figure 4-12A). Basal OCR decreases in CD8+T cells cultured with either drug in Glu 
(Figure 4-12G) or Gal medium (data not shown) under short-term hypoxia, suggesting that TG 
turnover provides fuels for OXPHOS. Under hypoxia PD-1 decreases with addition of OS 
regardless of other culture conditions and with addition of AmA to Gal medium (Figure 4-12E). 
AmA and to a lesser degree OS decrease functions of T cells cultured in Gal medium and 
subjected to hypoxia (Figure 4-12F). These data indicate that activated CD8+T cells under 
hypoxia use substrates from TG turnover for OXPHOS, as OCR decreases in presence of AmA 
or OS. However TGs are not essential for effector functions of activated CD8+T cells unless cells 
are concomitantly subjected to hypoglycemia.   
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Figure 4-12. (E) Left: Effect of FA metabolism manipulating drugs on PD-1 expression of CD8+T cells 
stimulated in Glu (red) or Gal (dark grey) medium and subjected to hypoxia (n=5 samples/group, 
representative of  at least 3 experiments, n=20 mice were pooled for each experiment). Data are shown as 
MFI values (mean with SEM) with drug treat ent normalized to those of cells treated with the vehicle control 
(set at 100, dashed line) * on top of bars indicates significant differences between cells treated with drug and 
vehicle. Right: Histograms of PD-1 expression on representative samples. (F) Normalized % of cells 
producing 3, 2 or 1 factors. Functions of cells treated with each drug are normalized to those of cells treated 
with diluent (set at 300, dashed line; n=5 samples/group, representative of 3 experiments, n=20 mice were 
pooled for each experiment). * within (): significant difference of total responses between cells treated with 
drug and vehicle. * outside of (): significant differences in % of 1,2 and 3 (bottom to top) factor-producing 
cells between samples treated with drug and those treated with diluent. Representative flow plots show 
levels of IFN-g and granzyme B production. (G) Relative basal OCR of CD8+T cells cultured with OS or AmA 
normalized to cells cultured with diluent in Glu medium under hypoxia (n=6 samples/condition, 
representative of 2 experiments, n=20 mice were pooled for each experiment). * above each bar indicate 
significant differences between drug  and diluent-treated cells. 
 
  To assess how increased FA catabolism affects CD8+TIL functions, I vaccinated 
CD90.2+ mice congenic for CD45, and treated them for 3 weeks daily with FF (CD45.1 mice) or 
diluent (CD45.2 mice). Splenocytes from these mice were mixed at a 1:1 ratio of Trp-1-specific 
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CD8+T cells from the 2 donors and transferred into CD90.1+ recipient mice, which had been 
challenged with tumor cells and vaccinated 3 days later. Cells were transferred 2 days after 
vaccination (Figure 4-13A).  
Figure 4-13. Promoting FA catabolism improves CD8+TIL functions without reducing PD-1 
expression. 
A
 
Figure 4-13. Promoting FA catabolism improves CD8+TIL functions without reducing PD-1 
expression. (A) Experimental setup of the in vivo study. 
Immediately before transfer FF- and diluent- treated Trp-1- and E7-specific CD8+T cells 
from donor mice show comparable expression of CD62L, CD127, KLRG1 and FoxO1, indicating 
that FF does not affect memory formation (Figure 4-13B). FF-treated cells show increased 
expression of PD-1 and T-bet, suggestive of a higher activation status. FF treatment does not 
significantly enhance frequencies or functions of vaccine-induced CD8+T cells (Figure 4-13C). 
FF-treated splenocytes before transfer show enhanced OCR, which is blocked by Eto indicating 
that FF conditions vaccine-induced CD8+T cells to enhance FAO (Figure 4-13D).  
	
	
128	
 
Figure 4-13. (B) MFI 
of markers on/in 
donor CD8+T cells 
from mice treated with 
diluent (Dil.) or FF 
before transfer. (C) 
Functions of CD8+T 
cells from spleens of 
donor mice treated 
with Dil. or FF before 
transfer as % of cells 
producing 3, 2 and 1 
factors (B-C, n=8-
10/group). (D) Basal 
OCR of CD8+T cells 
from spleens of donor 
mice fed with Dil. or 
FF.  Some samples 
were incubated with 
Eto (n=5-6 
mice/group). 
Donor-derived vaccine-induced CD8+TILs were analyzed 3 weeks after transfer (Figure 
4-13E). Compared to diluent-treated TILs of donor origin, FF-treated donor-derived 
CD44+CD8+TILs show enhanced levels of transcripts for factors involved in FA catabolism 
(Figure 4-13F). Both Trp-1- and E7-specific FF donor-derived CD8+TILs show a trend towards 
increased PD-1 expression (Figure 4-13G). Frequencies and functions of FF-treated, vaccine-
induced CD8+TILs of donor origin are significantly higher compared to those of controls (Figure 
4-13H). Upon transfer of splenocytes from FF- or diluent-treated mice into separate cohorts of 
tumor-bearing mice, the former significantly delays tumor growth (Figure 4-13I). Collectively 
these data confirm that enhanced FA catabolism improves antitumor functions of CD8+TILs.  
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Figure 4-13. (E) Flow plots of donor and host CD8+T cells isolated from tumors of recipient mice. (F) 
Transcript levels in CD8+TILs derived from FF-treated compared to those from Dil.-treated donors (n=3-4 
samples/group). (G) MFI of PD-1 on Dil.- or FF-treated donor CD8+TILs (n=6/group). (H) % specific 
CD8+TILs from Dil.- or FF-treated donors producing 3, 2, or 1 factors. (-) or (*) on top of each bar indicates 
significant differences in sum of the responses.  * from bottom to top: differences in producing 1, 2 or 3 
factors. (I) Tumor weight 2 wk after cell transfer (n=5/group). 
 
 To test if FF-induced PD-1 increases affect FF-treated CD8+TIL functions, I fed 
vaccinated donor mice with FF or diluent daily for three weeks and then upon transfer into 
separate tumor-bearing mice treated the recipients with anti-PD-1 or isotype control antibodies 
(Figure 4-13J). Both FF treatment of donors and anti-PD-1 treatment of recipients strongly delay 
tumor progression (Figure 4-13K). Moreover, they act synergistically and together completely 
prevent tumor outgrowth in more than 30% of the vaccinated mice (Figure 4-13K and not 
shown).  
Figure 4-13. (J) 
Experimental design of 
PD-1 blockade combined 
with transfer of FF- or 
Dil.-treated T cells. (K) 
Tumor progression in 
mice that received either 
FF- or Dil.-treated cells 
and either iso or α-PD-1 
treatment after cell 
transfer. n=6-7/group.  
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Anti-PD-1 treatment reduces PD-1 staining on donor cells and this is not affected by FF 
(Figure 4-13L). It only has subtle effects on frequencies and functions of MAA-specific CD8+TILs 
derived from either set of donor mice (Figure 4-13M). PD-1 blockade significantly increases 
frequencies of monofunctional E7-specific CD8+TILs derived from FF treated donors. This effect 
may partially reflect the smaller tumor sizes of a-PD-1 treated mice, which might rescue the 
bystander T cell functions more easily than those of MAA-specific CD8+TILs. 
 
Figure 4-13. 
(L) PD-1 
expression on 
donor-derived 
FF- or Dil.-
treated 
CD8+TILs 
recovered from 
recipients 
treated with iso 
or a-PD-1. (M) 
Functions of 
donor-derived 
CD8+TILs from mice that received different treatments. * from left to right: differences in producing 1, 2 or 3 
factors. (L-M), n=6-7/group. Data are shown as mean with SEM. 
 
Inhibiting FA catabolism by knocking out PPAR-α  decreases PD-1 expression and CD8+T 
cell functions under metabolically stressed condition 
    To further study whether FA catabolism maintains functions of metabolically stressed 
CD8+T cells, I stimulated CD8+T cells from PPARα KO mice in vitro and compared them to those 
from wildtype (wt) mice. Transcripts for most factors involved in the TCA cycle and lipid 
catabolism are higher in PPARα KO compared to wt CD8+T cells when stimulated in Glu medium 
and under hypoxia; this profile reverses in cells cultured in Gal medium and low O2, suggesting 
that knocking out PPARα significantly decreases lipid catabolism of CD8+T cells cultured without 
Glu (Figure 4-14A). PPARα KO compared to wt CD8+T cells express lower levels of PD-1 when 
cultured with Gal-medium regardless of O2 levels (Figure 4-14B). PPARα KO CD8+T cell 
functions are lower compared to those of wt CD8+T cells cultured under the same conditions 
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(Figure 4-14C), suggesting that FA catabolism is required to maintain effector functions of CD8+T 
with limited access to Glu.  
Figure 4-14. Activated PPAR-α  KO CD8+T cells with reduced FA catabolism decreased PD-
1 expression and effector functions under metabolically challenging conditions in vitro. 
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Figure 4-14: Activated PPAR-a KO CD8+T cells with reduced FA catabolism decreased PD-1 
expression and effector functions under metabolically challenging conditions in vitro. (A) Heatmap 
compares mRNA transcripts of enzymes involved in FA metabolism in CD8+T cells from PPAR-a KO mice to 
those from wt mice stimulated in vitro in Glu or Gal medium and subjected to hypoxia. (B, C) Data are 
normalized to results obtained with wt cells cultured under the same conditions and set at 100 (for h) or 300 
(for i) (dashed line). (B) Normalized MFI values of PD-1 expression on PPAR-a KO CD8+T cells cultured 
under different conditions. * Indicates significant difference between wt and PPAR-a KO CD8+T cells. (C) 
Normalized % of PPAR-a KO CD8+T cells cells producing 3, 2 and 1 factors. * Indicates significant 
difference between wt and PPAR-a KO CD8+T cells. Statistics on top of each bar follow the same rule 
described in Figure 4-4G. Flow plots show factor-producing wt vs. PPAR-a KO CD8+T cells cultured in Gal 
medium under hypoxia. (A-C) n=5 samples/condition, representative of 2 experiments. n=6 wt or PPARa KO 
mice were pooled for each experiment. *p<=0.05, **p<=0.01, *** p<=0.001, **** p<=0.0001. 
    To further explore the effect of FA catabolism on vaccine-induced TILs, I used an 
adoptive transfer system, in which splenocytes from PPARα KO and wt CD45 congenic mice 
were co-transferred 3 weeks after vaccination into tumor-bearing and vaccinated recipient mice 
(Figure 4-15A).   
Figure 4-15: Decreasing FA 
catabolism reduces PD-1 
expression and effector 
functions of metabolically 
stressed CD8+TILs. (A) Cartoon 
show experimental setup for 
studying the impact of knocking out 
PPAR-α on the performance of 
vaccine-induced CD8+TILs within 
TME. 
 
A
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   Prior to transfer, functions and polyfunctionality of Trp-1-specific CD8+T cells are similar 
between the two groups, while E7-specfic CD8+T cells are less abundant and polyfunctional in 
PPARα KO mice (Figure 4-15B). This may reflect that strength of TcR signaling, which is lower 
for the E7 epitope, affects to what degree and at what time after activation cells rely on FAO. 
Expression of CD127 is comparable between the two T cell subsets immediately before transfer, 
indicating no major differences in memory formation (Figure 4-15C).  
 
 
Figure 4-15. (B) Functions of Trp-1- and E7-
specific CD8+ T cells from spleens of wt and 
PPAR-a KO mice as % of cells producing 3, 2 
and 1 factors right before transfer (n=7 
mice/group). (C) Histogram shows CD127 
expression on donor Trp-1-specific CD8+T cells 
from spleens before transfer. 
    
     
 
CD44+CD8+TILs originated from PPARα KO donors as compared to those from wt 
donors collected from recipient mice 3 weeks after transfer show a transcriptional profile similar to 
that of PPARα KO vs. wt CD8+T cells cultured in vitro in Gal medium under hypoxia (Figure 4-
15A), indicating reduced FA catabolism by PPARα KO CD8+TILs (Figure 4-15D). Both Trp-1-and 
E7-specifc PPARα KO CD8+TILs show lower levels of PD-1 expression (Figure 4-15E) 
concomitant with decreases in frequencies and functions including polyfunctionality (Figure 4-
15F). Collectively these data confirm that FA catabolism promotes PD-1 expression but preserves 
CD8+T cell effector functions upon metabolic stress.   
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Figure 4-15. (D) Heatmap compares transcripts of FA catabolism enzymes in CD44+ CD8+TILs derived from 
PPAR-a KO and wt donor mice (n=5 mice/group). (E) MFI of PD-1 expression on wt and PPAR-a KO donor 
Trp-1-and E7-specific CD8+TILs. (F) % of Trp-1- and E7-specific CD8+TILs from the two groups of donor 
mice producing 3, 2 and 1 factors. (E, F) n=6 mice/group. * within (): difference in sum of responses.* 
outside of (): differences in each proportion of cells between wt and PPAR-a KO donor derived TILs with 1-3 
functions (bottom to top). Flow plots illustrate functions of donor-derived Trp-1-and E7-specific CD8+TILs 
from each group. Data are representative of 2 experiments.  
	
DISCUSSION 
	
Within the TME CD8+T cells experience hypoxia and have to compete for nutrients 
especially Glu, which tumor cells consume to fuel glycolysis. Cells can compensate for lack of Glu 
by switching from glycolysis to OXPHOS using alternative nutrients such as FAs. Recent studies 
report that hypoglycemia within the TME impairs CD8+T cells functions and reduces the efficacy 
of active immunotherapy (192,197). My results show that metabolic challenges within the TME 
impair the performance of CD8+TILs including bystander TILs, although TA-specific CD8+TILs 
tend to be more affected presumably for they continue to receive stimulatory signals and may 
penetrate more deeply into tumors where nutrients and O2 are especially limiting.  
Solid tumors develop areas of hypoxia, which activates the HIF-1α pathway in cells of the 
TME. HIF-1a expression also rises upon T cell activation (342). In my study HIF-1α increases in 
both MAA-specific and bystander CD8+TILs, pointing towards hypoxia as the underlying cause. 
The effect of hypoxia on CD8+T cells is controversial. Some studies show that O2 is required for T 
cell effector functions (343). Others using protocols in which CD8+ T cells were subjected to 
hypoxia during a resting period report that hypoxia increases functions (342,344). My data agree 
with the former as they show reduced HIF-1α signaling improves CD8+TIL frequencies and 
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functions, indicating that when Glu is limiting, promoting glycolysis and inhibiting OXPHOS by 
HIF-1α becomes detrimental to CD8+TILs. LAG-3, which according to our data is regulated by 
HIF-1α, inhibits T cell expansion and effector functions (345). The LAG-3 locus has several HIF-
1α response elements ([A/G]CGTA) (346), which may influence LAG-3 expression under 
hypoxia.  
Hypoxia and hypoglycemia send opposing metabolic signals. The former promotes 
glycolysis while the latter forces cells to use OXPHOS, which can be fueled by various nutrients 
but requires O2. Cancer cells increase de novo lipogenesis (347) and recruit adipose progenitor 
cells (210). Accordingly in my model the abundance of free FA species increases during tumor 
progression. My data show that CD8+TILs cope with lack of Glu and O2 by augmenting FA uptake 
and FA catabolism to gain energy through OXPHOS. However, even with this metabolic switch 
CD8+TILs show loss of functions, which can be improved by further promoting lipid metabolism by 
FF.  
High expression of PD-1 is viewed to signal CD8+T cell exhaustion and loss of effector 
functions.  My results suggest that high PD-1 expression is not inevitably linked to impaired T cell 
functions. When activated CD8+T cells are exposed to hypoxia, decreased PD-1 expression is 
associated with impaired functions. In contrast, FF-treated CD8+T cells show a trend towards 
increased PD-1 expressions but their functions improve.  PD-1 signaling inhibits TCR- and CD28-
mediated activation of the PI3K/Akt/mTOR pathway, which in turn decreases glycolysis(267) and 
promotes lipolysis and FAO (348). I speculate that enhanced PD-1 signaling in CD8+TILs is 
beneficial by facilitating their metabolic switch within a Glu-poor TME. In my model blockade of 
PD-1 after the initial phase of T cell activation affects neither effector functions nor metabolism of 
TILs although overall Glu concentrations within the tumors increase. These results differ from 
those of a recent study in a mouse sarcoma model, which reports improved glycolysis and IFN-
γ production by CD8+TILs treated with anti-PD-1 during their initial activation (192). I assume that 
these apparently opposing results reflect intrinsic differences in tumor models or in T cells 
induced by vaccination or through stimulation by tumor-derived antigens. Alternatively, 
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differences in timing of treatment may affect the result. PD-1 blockade during the initial stages of 
T cell activation may allow them to better compete for Glu within a TME; once TILs have switched 
to FA catabolism they remain committed to this pathway regardless of PD-1 signaling.   
Anti-PD-1 treatment delays tumor progression in our model. Some of my data suggest 
that anti-PD-1 may promote MAA-specific CD8+T cell infiltration into tumors (not shown). 
However, as anti-PD-1 treatment also delays tumor progression in immune-deficient mice, I 
assume that it acts directly on tumor cells, tumor stromal cells or immunosuppressive cells within 
the TME. A recent study suggests that anti-PD-1 may reduce proliferation of PD-1+ tumor cells by 
blocking mTOR signaling (341). This mode of action of PD-1 blockade will only affect PD-1+ 
tumor cells. As in my study the melanoma cells isolated from tumors grown in vivo express very 
low levels of PD-1 (data not shown); I view it as unlikely that they are directly affected by PD-1 
blockade. Immunosuppressive cells express high levels of PD-1 (not shown) and PD-1 blockade 
may impair their ability to promote tumorigenesis (309). Melanoma cells express PD-L1 (not 
shown) and back-signaling through this ligand increases the tumor cells’ resistance to Fas- or 
CD8+T cell-mediated apoptosis (349). Anti-PD-1 treatment could thus promote tumor cell death 
by enhancing their susceptibility to apoptosis or, in immunocompetent mice, indirectly improve 
TIL functions by increasing the tumor cells’ susceptibility to lytic enzymes. Either mechanism 
could delay tumor growth and thus enhance levels of Glu within the TME. Although the additional 
Glu could fuel proliferation of tumor cells this would be counterbalanced by their increased death 
rates. 
Energy production through FAO rather than glycolysis comes at a price; more O2 is 
needed to generate equivalent amounts of ATP and ROS production increases. Generating 
energy through FAO within a hypoxic TME may thus not be the only method by which CD8+TILs 
maintain their functions. Ketone bodies are highly efficient fuels that require less O2 (350) and 
previous studies showed that they serve as the preferred energy source for cells of the nervous 
system subjected to hypoxia and hypoglycemia (215). Ketone bodies could be synthesized and 
secreted by other cells (351), or they could be produced by TILs directly as suggested by 
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increased transcript levels of Bdh1, a key enzyme in ketone body metabolism. My data show that 
CD8+TILs show pronounced increases in the intensities of ketone bodies acetoacetate and 3-
hydroxybutyrate during tumor progression. I would also like to point out that levels of O2 differ 
within a tumor and that TILs can randomly migrate within the TME (218). TILs could use FAO and 
ketone bodies alternatively depending on surrounding O2 levels to maintain their effector 
functions and prolong their survival. 
As suggested by my results, metabolic reprogramming of CD8+T cells to increase energy 
production through FA catabolism prior to adoptive cell transfer might enhance the overall 
efficacy of cell therapy in patients with some types of cancers, especially those characterized by 
low Glu content like melanomas. In agreement, other studies show that memory CD8+T cells, 
which prefer FAO and OXPHOS for energy production, are better at slowing tumor progression 
than effector cells (205,208). In contrast, others report that increasing the TILs’ ability to use 
glycolysis improves their antitumor effect (192). Which metabolic manipulations are most suited to 
improve TIL-mediated tumor regression will likely depend on the nature of the tumor. Those with 
sufficient levels of Glu may benefit from CD8+T cells with high glycolytic potential, while tumors 
with a hypoglycemic TME may best be combated by CD8+T cells that favor FA catabolism.   
In summary, my results show that metabolic challenges within the TME have profound 
impacts on CD8+TILs. It forces CD8+TILs to increasingly gain energy through FA catabolism, 
including consumption of ketone bodies, which partially preserves their functions and may 
improve their survival. Promoting the CD8+ TILs’ propensity to use FAO combined with PD-1 
signaling blockade further improves treatment outcome. These results invite further investigations 
to assess if the outcome of cancer immunotherapy can be improved by adding metabolic 
manipulations to current treatment strategies.  
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MATERIALS AND METHODS 
	
Mice and animal experiments 
Female C57Bl/6, B6.SJL-PtprcaPepcb/BoyJ (B6 CD45.1+), B6.PL-Thy1a/CyJ (B6 CD90.1+) and 
B6. 129S4-Pparatm1Gonz/J (B6 PPAR-α KO) mice (6-8 weeks) were purchased from the National 
Cancer Institute (NCI) or the Jackson Laboratories and housed at the Wistar Institute Animal 
Facility. Procedures were conducted following approved protocols by the Wistar Institutional 
animal care and use committee (IACUC). Groups of 5-80 C57BL/6 mice were vaccinated 
intramuscularly (i.m.) with AdC68 vectors (1010 virus particles [vp] for AdC68-gDMelapoly; 1011 vp 
for AdC68-gDE7) diluted in PBS. B16BrafV600E cells (5x104 cells/mouse) diluted in PBS were 
inoculated subcutaneously (s.c.) into the right flank of mice. Tumor growth was monitored by 
measuring the perpendicular diameters of tumors every two days. Tumor volume was calculated 
using the formula: tumor volume = ((tumor width)^2 x tumor length)/2. Depending on size early 
stage tumors were harvested 10-14 days after challenge (referred to as 2 weeks) while late stage 
tumors were harvested 4-5 weeks after challenge (referred to as 1 month). For PD-1 blockade 
antibody treatment, mice received either 0.2mg rat anti-PD-1 antibody (29F. 1A12, most kindly 
provided by Dr. G. Freeman, Dana Farber Cancer Center, Boston, MA) or isotype control 
antibody (rat IgG2a, BioXcell) via intraperitoneal injection (i.p.) every two days, starting 10 days 
after vaccination. Tumor growth was measured every other day. For in vivo treatment FF 
(100mg/kg/day, Sigma) was first diluted in DMSO and then further diluted in PBS and given by 
oral gavage daily for 3 weeks. Control mice received diluent at the same volume. For adoptive 
transfer experiments, 1x107 in vitro activated CD8+T cells transduced with lentivectors were 
injected intravenously (i.v.) into recipient mice. For FF/control treated splenocytes or wild 
type/PPAR-α KO splenocytes co-transfer experiments, splenocytes containing 105 Trp-1455 
tetramer+CD8+T cells from each group were mixed and transferred into CD90.1+ recipient mice 
through tail vein i.v. injection.  
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Cell lines 
The B16BrafV600E cell line (kindly provided by Dr. M Herlyn, Wistar Institute, Philadelphia, PA) was 
derived from B16.F10 cells by transduction with the lentivector pLU-EF1a-mCherry expressing 
mouse BrafV600E. HEK 293 cells were used to propagate vaccine vectors. 293T cells were used to 
produce lentivectors. Cells were grown in Dulbecco’s Modified Eagles medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS). Both HEK293 cells and 293T cells were 
obtained from ADCC. All cell lines were authenticated by morphology, biological characteristics 
and growth kinetics in vitro. The B16BrafV600E cell line was further authenticated by its tumor-
forming kinetics in C57BL/6 mice. All cell lines were tested mycoplasma-free. For each 
experiment cells were used within 4 weeks after resuscitation.   
Construction of recombinant adenovirus and lentivectors  
Molecular construction, rescue, purification and titration of AdC68-gDMelapoly and AdC68-gDE7 
vectors have been described(308). Briefly, gDMelapoly or gDE7 construct was inserted into E1-
deleted AdC68 viral molecular clone using I-CeuI and PI-SceI sites. The constructed plasmids 
were used to transfect 293 cells by calcium phosphate (Invitrogen). Cells containing adenoviral 
vectors were harvest 7-10 days later upon plague formation. Virus was further propagated on 293 
cells by serial infection and harvested by three cycles of freeze-thawing. Cell-free supernatant 
from the third cycle of thawing was used for virus purification by Caesium chloride density 
ultracentrifugation. For production of lentivectors, five pLKO.1 lentivectors containing short hairpin 
RNAs (shRNAs) targeting different regions of HIF-1α or lentivector expressing control RNA were 
obtained from The RNAi Consortium. The selection marker Thy1.1 was cloned from the pLKO.3-
Thy1.1 lentivector (Addgene plasmid#14749) into each of the shRNA lentivectors. Lentivectors 
were generated using the 2nd generation lentivector package system (Addgene) by transfecting 
293T cells with the packaging plasmid PsPAX2, the envelope plasmid PMD2.G and each of the 
shRNA-Thy1.1-expressing insert plasmids at a ratio of 3:1:1. Supernatants were collected 48 and 
72 hours post transfection. Lentivectors were concentrated by ultracentrifugation at 20,000rpm, 
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4°C for 2 hours. Vector pellets were incubated with PBS on ice for at least 2 hours before 
resuspension. The lentivector that showed the most pronounced reduction of HIF-1α transcripts 
in transduced cells was used for further studies. 
In vitro stimulation of CD8+T cells and drug treatments 
CD8+T cells from pooled spleens of naive C57Bl/6 mice (20-30 mice/experiment) were enriched 
by negative selection using magnetic beads (MACS, STEMCELL Technologies). Enriched CD8+T 
cells were activated for 4 days in 6-well plates pre-coated with antibodies to CD3 (5µg/ml) and 
CD28 (1µg/mL) (BD Bioscience). For some samples, cells were transferred for the last 16 hours 
to a hypoxia chamber. To study the impact of hypoxia on resting CD8+T cells, enriched CD8+T 
cells were stimulated for 48 hours under normoxia. Cells were then washed off the plates and 
replated in fresh medium with 100U/ml human IL-2 for 96 hours, followed by culture in normoxia 
or hypoxia with IL-2 for another 36 hours before analysis. Cells were cultured in Roswell Park 
Memorial Institute (RPMI) medium without Glu (Life Technologies) supplemented with Glu 
(10mM) or Gal (10mM), 10% dialyzed FBS (Life Technologies), 20mM HEPES, 2mM Glutamax, 
1mM sodium pyruvate, 0.05mM 2-mercaptoethanol and 1% penicillin-streptomycin. Hypoxia 
experiments were performed in a Thermo Napco series 8000WJ CO2 incubator equipped with 
nitrogen tank for O2 replacement. O2 level was kept at 1% during CD8+T cells hypoxia culture for 
time periods indicated in each assay. Drugs and corresponding vehicle controls were added as 
follows:  2-deoxy-D-glucose (2-DG, 2mM, Sigma) or Fenofibrate (FF, 50µM, Sigma) for the entire 
culture period; Etomoxir (Eto, 200µM, Sigma), Amidepsine A (AmA, 20µM, Santa Cruz), or 
Orlistat (OS, 100µM, Sigma) for the last 48 hours. DMSO concentrations were kept below 0.2% 
for all culture conditions.  
Lentivector transduction of CD8+T cells 
For in vitro experiments, 4x106 enriched CD8+T cells were stimulated as described above for 24-
28 hours. Freshly concentrated lentivectors were spin-inoculated into activated CD8+T cells 
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supplemented with polybrene (6µg/ml, Santa Cruz) at 2000rpm, 32°C for 2 hours. Cells were 
washed 20 hours after transduction, transferred to new CD3 antibody pre-coated plates and 
stimulated for another 40 hours in medium supplemented with anti-CD28 and human IL-2 
(100U/ml, Roche) under normoxia or switched to hypoxia. Lentivector-transduced CD8+T cells 
were identified by surface staining for Thy1.1 and were analyzed with a BD LSRII. For in vivo 
experiments, cells were washed 20 hours after lentivector transduction and cultured for an 
additional 48 hours in Glu medium supplemented with human IL-2 (100U/ml).  
Isolation of lymphocytes from mice 
PBMCs and splenocytes were harvested as described (Zhang & Ertl, 2014). Briefly, blood 
samples were collected by retro-orbital puncture and PBMCs were isolated by Histopaque 
(Sigma) gradient. Spleens were harvested and single cell suspension was generated by mincing 
with mesh screen in Leibovitz’s L15 medium and passing through 70µm filter (Fisher Scientific). 
For both samples red blood cells were lysed by 1x RBC lysis buffer (eBioscience). To obtain 
tumor-infiltrating lymphocytes, tumors were harvested, cut into small fragments and treated with 
2mg/ml collagenase P, 1mg/ml DNase I (all from Roche) and 2% FBS (Tissue Culture 
Biologicals) in Hank’s balanced salt solution (HBSS,1X, Thermo Fisher Scientific) under agitation 
for 1 hour. Tumor fragments were homogenized, filtrated through 70µm strainers and 
lymphocytes were purified by Percoll-gradient centrifugation and washed with DMEM 
supplemented with 10% FBS. Pre-experiments were conducted to ensure that this treatment did 
not affect any of the markers that were tested. 
Antibodies, staining and flow cytometry 
Cells were stained with a PE-labeled Trp-1-specific MHC class I (H-2Db) tetramer carrying the 
TAPDNLGYM peptide and an Alexa647-labeled HPV-16 E7-specific MHC class I (H-2Db) 
tetramer carrying the RAHYNIVTTF peptide (obtained from the NIAID Tetramer Facility). 
Lymphocytes were stained with anti-CD8-PerCPCy5.5 (Cat. #100734) or -Alexa700 (Cat. 
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#126618), CD4-PercpCy5.5 (Cat. #100434), CD44-PacBlue (Cat. #103020), LAG-3-APC (Cat. 
#125210) or -PercpCy5.5 (Cat. #125212), KLRGI-FITC (Cat. #138410), PD-1-PE/Cy7 (Cat. 
#329918) or -Brilliant violet (BV) 605 (Cat. #135220) (all from Biolegend), 2B4-FITC (eBio244F4, 
eBioscience) and Amcyan fluorescent reactive dye (Cat. #L34957, Life Technologies). For 
mitochondrial metabolic markers analysis, cells were stained with Mitosox Red (Cat. #M36008, 
5µM, MROS) and DioC6 (Cat. #D-273, 40nM, MMP, Life Technologies) at 37°C for 30 minutes. 
For fatty acid uptake experiments, cells stimulated under different conditions in vitro or isolated 
from spleen and tumors of mice bearing 2 weeks or 1 month-old tumors were immediately 
incubated with 1µM BODIPY FL C16 (Cat. #D-3821, Life Technologies) for 30 mins at 37°C. Cells 
were washed twice with cold PBS before surface staining. For Cpt1a staining, cells were stained 
for surface markers followed by permeabilization with transcription factor buffer set (BD 
pharmingen, San Diego, CA). Cells were then stained with anti-Cpt1a antibody-Alexa488 (Cat. 
#ab171449) or mouse IgG2b isotype control antibody-Alexa488 (Cat. #ab171465, both from 
abcam) at 5µg/ml in 1x permwash for 45 mins at 4°C. For staining of T-bet, cells were first 
stained for surface markers, then fixed and permeabilized with Foxp3/Transcription factor staining 
buffer and stained with T-bet-PE/Cy7 (eBio4B10, all from eBioscience). For intracellular cytokine 
staining (ICS) of ex vivo lymphocytes, ~106 cells per samples were cultured in DMEM containing 
2% FBS and Golgiplug (Fisher Scientific, 1.5µl/ml) for 6 hours with either a peptide pool (5ug/ml 
for each peptide) including all CD8+T cell epitopes expressed by gDMelapoly (mTrp-1455-463: 
TAPDNLGYA, mTrp-1481-489: IAVVAALLL, mTrp-2522-529: YAEDYEEL, hTp-2180-188: SVYDFFVWL, 
hTrp-2343-357: STFSFRNAL, mTrp-2363-371: SQVMNLHNL, hgp10025-33: KVPRNQDWL, mBraf
 
594-
602: FGLANEKSI) or the E7 peptide: RAHYNIVTTF (all from Genescript). A rabies virus 
glycoprotein peptide was used as a negative control. For ICS performed with CD8+T cells 
stimulated in vitro, ~106 cells were transferred to 96 well plates in the original medium and 
stimulated with PMA (500ng/ml), ionomycin (20µg/ml) and Golgiplug for 4 hours under either 
normoxia or hypoxia. Staining was conducted as described before18. Cells were stained with 
antibodies to IFN-γ-APC (Cat. #554413) or -BV421 (Cat. #505830, both from Biolegend), 
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granzyme B-APC (Cat. #MHGB05, Life Technologies) and perforin-PE (Cat. #eBioOMAK-D, 
eBioscience). Cells were analyzed by an LSRII (BD Biosciences) and data were analyzed with 
FlowJo (TreeStar).  
BrdU proliferation assay 
Mice were intraperitoneally injected with 1.5-2mg/mouse of BrdU solution and fed water-
containing BrdU at a concentration of 0.8mg/ml for 24 hours before the assays. They were 
euthanized and lymphocyte samples were analyzed for BrdU incorporation. Cells were first 
stained for surface markers, and then for intranuclear BrdU incorporation using anti-BrdU-FTIC 
antibody (Cat. #51-33284X, 10µM/sample) according to the manufacture’s instruction (BD 
Bioscience).  
HIF-1α  and Glut1 staining 
For ex vivo assays mice were perfused immediately after euthanasia with PBS and heparin 
(10units/ml) and then with 1mM cobalt (II) chloride.6H2O (CoCl2, EMD Millipore) diluted in PBS. 
For both ex vivo and in vitro experiments, lymphocytes isolation and staining before fixation were 
performed in medium containing 200µM CoCl2. For staining, lymphocytes were first blocked with 
10% normal goat serum (Life Technologies) for 30 minutes at room temperature and then stained 
with anti-Glut1 primary antibody (Cat. #ab40084) or mouse IgG2a isotype control antibody (Cat. 
#ab17019, abcam) at 1µg/106 cells for 60 minutes at room temperature. Cells were washed and 
stained with PacBlue labeled-goat anti-mouse secondary antibody (Cat. #P31582, 1:2000 
dilution, Life Technologies) together with antibodies to other cell surface markers for 30 minutes.  
Cells were fixed, permeabilized, and stained for HIF-1α  with anti-HIF-1α-Alexa700 antibody (Cat. 
#IC1935N, R&D) using the FoxP3 buffer set (eBioscience). 
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Extracellular Flux Analysis and FAO assay 
OCR and ECAR for CD8+T cells stimulated under different conditions were measured with XF24 
and XF96 Extracellular Flux Analyzers (Seahorse Bioscience). Hypoxia samples were prepared 
in a hypoxia chamber under 1% O2. Dead cells were removed by dead cell removal kit using 
MACS and live cells were pre-incubated with 100µM cobalt chloride before being removed from 
the hypoxia chamber and entered into the Seahorse analyzer. In experiments to determine the 
contribution of fatty acid oxidation (FAO) to OCR, 200mM etomoxir (Eto) was added 15 minutes 
before the Seahorse analysis. Briefly after repeated measures of basal respiration and lactate 
production, 1µM OM was added to measure ATP leakage and glycolytic capacity of the cells. 
1.5µM FCCP was then added to measure maximal respiration followed by addition of 100nM 
Rotenone and 1µM Antimycin A to determine spare respiratory capacity and then 100mM 2-DG 
to determine glycolytic reserve. For measuring oxidation of exogenous and endogenous FAs, 
cells activated in either Glu or Gal medium for 3 days were washed and transferred to substrate-
limited Glu or Gal media for overnight stimulation. Substrate limited media contained 0.5 mM Glu 
or Gal, 1mM GlutaMAX, 0.5mM carnitine (all form Sigma) and 1% dialyzed FBS. Samples were 
treated with either Eto or vehicle control 15 minutes before the assay. Palmitate: BSA or BSA was 
added just before the assay. The contributions of FAO to OCR was calculated as follows: Basal 
respiration due to exogenous FA oxidation= (Basal Palm:BSA-Eto OCR rate – basal BSA-Eto 
OCR rate) - OCR due to uncoupling by FFA; OCR due to uncoupling by FFA= after OM injection, 
Palm:BSA-Eto OCR rate - BSA-Eto rate.  Basal OCR due to endogenous FAs consumption = 
basal BSA-Eto OCR rate - basal BSA+Eto OCR rate. 
Lipid and Glucose concentration measurement in tumor interstitial fluid 
Tumors interstitial fluid was collected as described(352). Free FA species concentrations were 
determined by LC-MS. Absolute concentration of Glu was measured by LC-MS upon adding 13C6-
Glu as the internal standard.  
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Isotopic labeling in vitro for metabolomics analysis.  
For 13C6-Glu/Gal tracing in vitro, cells were cultured from the onset of the assays in Glu-free 
RPMI medium with 10mM 13C6-Glu/Gal (Sigma) for 4 days. For 13C16-palmitate tracing in vitro, 
cells were stimulated for 3 days in Glu or Gal medium. On the night of day 3, some samples were 
transferred to 1% O2 for overnight culture. 13C16-palmitate (Sigma) was first dissolved in 100% 
ethanol at 200mM and conjugate to fatty acid-free BSA (Sigma) at a 5:1 molar ratio to a final 
concentration of 8mM-13C16-palmitate-BSA by vortexing at 37°C for 3-4 hours with sonication.  On 
day 4, samples were pelleted and replated in fresh medium with 10% delipidated FBS (Cocalico 
Biologicals) and 400µM 13C16-palmitate-BSA. Hypoxia samples were returned to 1% O2. All 
samples were cultured for another 4 hour. Dead cells were removed by MACS. Samples were 
pelleted at 4000rpm for 5 minutes.  All collection procedures were conducted at 4°C. Cell 
numbers in each sample were determined. Metabolism was quenched and metabolites were 
extracted by adding 1 ml -80°C 80:20 methanol: water per million cells. After 20 min of incubation 
on dry ice, samples were centrifuged at 10000 g for 5 min. Insoluble pellets were re-extracted 
with 1 ml -80°C 80: 20 methanol: water on dry ice. The supernatants from two rounds of 
extraction were combined, dried under N2, resuspended in 1 ml water per million cells. 
Metabolites were normalized to cell number.  
Isotope labeling in vivo.   
Tumor-bearing mice were fasted for 16 hours. 13C6-Glu (Cambridge) diluted in PBS was given i.p. 
to mice at 2g/kg. Spleens and tumors were collected 30 minutes later. 13C16-potassium palmitate 
was conjugated to FA-free BSA (6:1 molar ratio) and given to mice at ~0.35g/kg by oral gavage. 
1-hour later 13C16-palmitate-BSA was given i.v. at 125mg/kg. Spleens and tumors were collected 
30 mins later and cells were isolated on ice. Tumor samples were weighed and flash frozen in 
liquid nitrogen. CD8+CD44+T cells from pooled samples were stained and sorted at 4°C. 
Metabolites were extracted with -80°C 80: 20 methanol: water, dried under N2 and resuspended 
in water at 100mg tissue/ml or 106 cells/100ml. Metabolites were normalized to cell number. 
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Contribution of 13C to TCA cycle metabolites was calculated as [(m+1)*1+… (m+n)*n] / 
{[(m+0)+…+(m+n)]*n}*100%, where m+0 is the normalized signal intensity of a metabolite in 12C 
form, m+n indicates normalized signal intensity for each form of 13C labeled metabolite, n 
indicates the total number of 13C carbon atoms in that metabolite.  
LC-MS Instrumentation and method development.  
Glycolytic and TCA metabolites were analyzed by reversed-phase ion-pairing chromatography 
coupled with negative-mode electrospray-ionization high-resolution mass spectrometer on a 
stand-alone orbitrap (Thermo Scientific)(353). Carnitine species were analyzed by reversed-
phase ion pairing chromatography coupled with positive-mode electrospray-ionization on a Q 
Exactive hybrid quadrupole-orbitrap mass spectrometer (Thermo Scientific); Liquid 
chromatography separation was achieved on a Poroshell 120 Bonus-RP column (2.1 mm ×150 
mm, 2.7 µm particle size, Agilent). The total run time is 25 min, with a flow rate of 50 µl/min from 
0 min to 12 min and 200µl/min from 12 min to 25 min. Solvent A is 98: 2 water: acetonitrile with 
10 mM amino acetate and 0.1% acetic acid; solvent B is acetonitrile. The gradient is 0-70 % B in 
12 min. All isotope labeling patterns were corrected for natural 13C-abundance.  
Gene expression analysis 
Lymphocytes were isolated from spleens and tumors of mice (tumor-bearing or normal) at 
different time points and stained with dyes and antibodies to live cells, CD8+, CD44+ and the Trp-
1 and E7 tetramers. For co-adoptive transfer experiments, CD8+CD44+T donor cells of different 
origin were recovered from spleen and tumors of recipient mice three weeks later by antibodies 
staining and sorting. Trp-1 or E7 tet+CD44+CD8+T cells were sorted (Mono Astrios, Beckman 
Coulter) on ice into RNAprotect cell reagents (QIAGEN). In vitro cultured CD8+T cell samples 
were processed on ice to remove dead cells using manual cell separation columns and Mini/Midi 
MACS separators (Miltenyi Biotec). For lentivector transduction assays, transduced cells were 
further purified based on Thy1.1 expression using MACS. RNA was isolated from purified cells 
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using RNeasy Mini kits (Qiagen) and RNA concentrations were determined using Nanodrop 
(Thermo Scientific). cDNAs were obtained by reverse transcription using the high capacity cDNA 
reverse transcription kit (Life Technologies). Relative quantitative real-time PCR analyses were 
performed with Fast SYBR Green master mix using 7500 Fast Real-Time PCR system (Life 
Technologies). GAPDH or β-2 microglobulin were used as internal controls yielding comparable 
results. Primers (Table 4-1) for all tested transcripts were designed by Vector NTI.  Differences in 
transcripts expression levels are visualized in heatmaps. Values were log transformed to show 
ratios of differences. Color scale was set as -2 (lower expression, deep blue) to 2 (higher 
expression, deep red). 
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Metabolic pathways
Gene name 
(Forward-F and 
Reverse-R) Primer sequences
mGLUT1-F TGTGGGAGGAGCAGTGCTCG
mGLUT1-R TGGGCTCTCCGTAGCGGTG
mHK2-F TGATCGCCTGCTTATTCACGG
mHK2-R ACCGCCTAGAAATCTCCAGAAGG
mPGK1-F ATGTCGCTTTCCAACAAGCTG
mPGK1-R TGGCTCCATTGTCCAAGCAG
mIDH3a-F TGGGTGTCCAAGGTCTCTCG
mIDH3a-R TCTGGGCCAATTCCATCTCC
mMDH2-F TTGGGCAACCCCTTTCACTC
mMDH2-R TGTGACTCAGATCTGCTGCCAC
mPPARα-F AGCCCCATCTGTCCTCTCTCC
mPPARα-R TCCAGAGCTCTCCTCACCGATG
mSLC27A4-F TGAGTTTGTGGGTCTGTGGCTAGG
mSLC27A4-R AAGACAGTGGCGCAGGGCATC
mSLC27A2-F TGCTGCTGCTGCCTCTGCTG
mSLC27A2-R AGGATGGTACGCACGGGTCG
mDGAT1-F ACCTGGCCACAATCATCTGCTTC
mDGAT1-R TTGGCCTTGACCCTTCGCTG
mDGAT2-F AGCATCCTCTCAGCCCTCCAAG
mDGAT2-R TAGCACCAGGAAGGATAGGACC
mPNPLA2-F TTCCCGAGGGAGACCAAGTG
mPNPLA2-R TGCCGAGGCTCCGTAGATG
mLIPA-F TGCTTTCTCGGGTGCCCAC
mLIPA-R TCCTCACCAGGATATCCCCAG
mACAA1a-F TCCGCTAGGTTCCCGCAGG
mACAA1a-R ACAGAAGCTCGTCGGGGGTG
mEHHADH-F AAAGTTCGCAAAGGGCAAGG
mEHHADH-R TCGCCCAGCTTCACAGAGC
mACOX1-F TCCCGATCTGCGCAAGGAG
mACOX1-R TGTTCTCCGGACTACCATCCAAG
mHSD17B4-F TTGTGAACGACTTAGGAGGGGAC
mHSD17B4-R AAATGTGTCCAGTGCCGTCTTC
mACADVL-F ACCCTCTCCTCTGATGCTTCCAC
mACADVL-R TGAGCACAGATGGGTATGGGAAC
mACADM-F AAGCAGGAGCCCGGATTAGG
mACADM-R TCCCCGCTTTTGTCATATTCC
mBDH1-F TCGCCATACTGCATCACCAAG
mBDH1-R TGCCAGGTTCCACCACACTG
mNOX1-F AGAAATTCTTGGGACTGCCTTGG
mNOX1-R TGCCCCTCAAGAAGGACAGC
mSOD1-F ACAGGATTAACTGAAGGCCAGC
mSOD1-R TTGCCCAGGTCTCCAACATG
mCAT-F TGACATGGTCTGGGACTTCTGG
mCAT-R AGCCATTCATGTGCCGGTG
mCOX5B-F ACCCGCTCCATGGCTTCTG
mCOX5B-R AGTCCCTTCTGTGCTGCTATCATG
Glucose	metabolism
Peroxisomal	FAO
Ketone	body	metabolism
Lipid	metabolism	regulaion,	
FAs	uptake,	TG	synthesis	and	
lipolysis	and	FA	synthesis
Mitochondrial	FAO
ROS	production/detoxification	
and	Electron	transport	chain	
(ETC)
 
Table 4-1: List of primers for receptors and enzymes measured in chapter 4.  
Statistical analysis 
I chose sample size based on pilot experiments and literature reports in the filed. No 
randomization or blinding was done in the experiments and there were no inclusion/exclusion 
criteria. The statistics were performed based on the properties of data distribution, variation, and 
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biological questions asked. D’Agostino-Pearson omnibus normality test were ran for each data 
set. The variations were similar between the groups that were statistically compared. Significance 
of differences between 2 populations was calculated by two-tailed Student’s t test; Multiple t-test 
with Holm-Sidak correction was performed for multiple 2-group comparisons within the same 
graph. Significance of differences among multiple populations was calculated by one-way or two-
way ANOVA using GraphPad Prism 6. Data were shown as mean value with standard error of the 
mean (SEM). Significance was set at p-values of or below 0.05. Type I errors were corrected for 
multiple comparisons using the Holm-Sidak method.  
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Chapter 5 
 
DISCUSSION 
 
 
SIGNIFICANCE		
	
     Despite the significant breakthroughs made in recent years in the field of cancer 
immunotherapy, metastatic melanoma still represents one of the most life-threatening diseases 
that require urgent attention. Resistance or only transient responses to the current available 
therapeutic agents, including BRAF and MEK inhibitors, anti-PD-1/PD-L1 antibodies, anti-CTLA-4 
antibody and adoptive cell transfer (ACT), is observed in the majority of melanoma patients. 
Continuous efforts to develop more effective treatment strategies for metastatic melanoma and 
other cancers are therefore essential and this is the major goal of my thesis.  
    Cancer immunotherapy aims to attack foreign or self-tumor antigens (TAs) through the 
immune system. Among various players of the immune system that may exert antitumor 
functions, CD8+T lymphocytes are the most promising candidates with potent tumoricidal 
potential. The T cell receptors (TCR) have high diversity; upon stimulation T cells vigorously 
proliferate and acquire direct cytolytic functions. Eliciting and maintaining robust TA-specific 
CD8+T cell responses is the major focus of numerous preclinical and clinical cancer 
immunotherapeutic studies, including cancer vaccine design and investigations of ACT and 
immunoinhibitory ligand blockade strategies.  
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     However, as repeatedly stated throughout this thesis, there are many limitations 
related to the use of CD8+T cells within the highly immunosuppressive tumor microenvironment 
(TME), which render the current therapeutic approaches largely ineffective in most patients with 
advanced cancers. First and foremost, tumors are a heterogeneous mass that contains a variety 
of cell types including fibroblasts, endothelial cells and immune inflammatory cells, i.e. myeloid-
derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells 
(Tregs) (354). Most of these cells could suppress effective CD8+T cell functions through secretion 
of inhibitory cytokines such as IL-10 and TGF-β or enzymes such as arginase, iNOS and 
IDO (355-357). In addition, stromal fibroblasts, macrophages and tumor cells express ligands for 
co-inhibitors, such as PD-L1, HVEM and CD80/CD86, which inhibit cytotoxic CD8+T cell functions 
through interaction with PD-1, BTLA and CTLA-4, respectively. Moreover, It is well established 
that effector CD8+T cells gradually differentiate towards functional impairment within TME, a 
phenomena referred to as T cell exhaustion. Although chronic antigen stimulation is traditionally 
viewed as the cardinal cause of T cell functional exhaustion, our studies among other recent 
findings strongly suggest that the stressful metabolic conditions within the TME greatly contribute 
to the loss of functions of CD8+ effector T cells. TA-specific tumor-filtrating CD8+T cells, upon 
recognizing antigens within the TME, will become highly activated and energy demanding. 
Effector T cells enhance both glycolysis and mitochondrial OXPHOS to produce ATP, which 
require sufficient glucose (Glu) and oxygen supply. As the TME is poorly vascularized and tumor 
cells competitively consume Glu to fuel their own proliferation, CD8+TILs have limited access to 
both Glu and oxygen. These metabolic challenges and reduced ATP production of CD8+TILs 
have been shown to temper their antitumor functions (192,358). Overcoming any one of these 
metabolic obstacles could potentially improve the therapeutic efficacy of melanoma 
immunotherapy and benefit patients in the clinic, which is the overarching goal of my dissertation.  
    Numerous studies aim to block inhibitory factors within the TME and combine it with 
strategies to boost functions of TA-targeting effector CD8+T cell. Such studies conducted in both 
animal models and melanoma patients have yielded some promising results.  FDA-approved 
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immune checkpoint inhibitors, given either individually or in combination, have exhibited objective 
clinical responses in 30-40% of patients with metastatic melanoma (54). In addition, preliminary 
studies suggest that targeting T-cell immunoglobulin and mucin-domain containing (TIM)-3 
achieved similar therapeutic efficacy compared to that of PD-1 pathway blockade in preclinical 
cancer models, while combining TIM-3 with PD-1 blockade further delayed tumor 
growth(359,360). Combining checkpoint inhibitors with vaccines or ACT has also been 
investigated. Adding gp100 vaccine to ipilimumab did not provide additional benefits for 
melanoma patients in a phase III clinical trial (13), while in animal models it has been 
demonstrated that combining anti-PD-1/PDL1 antibodies with ACT could generate optimal effects 
against melanoma (361). However, as checkpoint inhibitors globally target inhibitory ligands 
expressed in the immune system of cancer patients, their application carries the risk of inducing 
severe autoimmune diseases or other adverse effects. Novel approach that could locally target 
the upregulated inhibitory pathways in TA-specific CD8+T cells may therefore result in more 
desirable effects. In chapter 2 this concept has been investigated in detail.  
     Tumor stromal fibroblasts promote tumorigenesis and suppress immune cell functions 
through various mechanisms (127). Depleting FAP+ fibroblasts within the TME through genetic 
depletion, vaccine approaches or ACT have reduced tumor growth in a number of cancer types 
(122,124,131,362). It was shown that depleting FAP+ fibroblasts could shift the polarization of T 
cells from a T helper 2 (Th2) to a Th1 phenotype, improve CD8+T cell infiltration and functions 
and reduce immunosuppressive cells (ISCs) in the TME (363). However, whether combining 
FAP-targeting vaccine with tumor-cell targeting vaccine can further shift the immune balance 
within the TME and affect ISCs functions have never been studied before. More importantly, as 
depleting FAP+ fibroblasts and ISCs may lift the metabolic challenges within TME, it is important 
to understand whether this strategy could potentially reduce the metabolic stress of TA-specific 
CD8+TILs and thereby augment their antitumor functions. These questions are systemically 
addressed in chapter 3.  
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      Last but not least, the metabolic status of immune cells and its contribution to immune 
cell functions in different disease settings have become the focus of intense investigations in 
recent years (364,365). Within the TME, it was shown that Glu deprivation due to its consumption 
by tumor cells dampens the glycolytic capacity of effector T cells and reduces their ability to 
produce IFN-γ. Moreover, restoring Glu supply or increasing the CD8+T cells’ ability to use 
glycolysis could partially restore their antitumor functions (192,197). However, the impact of other 
metabolic constrains on CD8+TILs are still poorly understood. For example, the limited blood 
supply provides inadequate oxygen to CD8+TILs that penetrate deeply into the TME, which could 
negatively affect the TILs’ ability to use mitochondrial OXPHOS for energy production. How 
hypoxia affects effector functions of CD8+TILs especially if combined with Glu deprivation is 
unknown. In addition, the TME contains abundant lipids of various species and lactate produced 
by tumor cells and stroma cells, which may modulate the nutrients uptake and metabolic 
pathways used by CD8+TILs as well as their effector functions. Investigating these issues could 
facilitate the development of novel metabolic intervention strategies for CD8+T cells, which may 
improve their antitumor performance within the TME and prolong the survival of patients with 
metastatic cancer. This topic is studied at length in chapter 4.  
	
CONCLUSIONS AND FUTURE DIRECTIONS  
	
I. Blocking the immunoinhibitory pathway: 
    To study whether blockade of immunoinhibitory signaling in vaccine-induced TA-
specific CD8+T cells during priming could enhance their antitumor functions, I focused on the 
BTLA/CD160-HVEM pathway and designed the cancer vaccine to express melanoma-associated 
antigens (MAAs) within HSV gD, which competitively blocks BTLA/CD160 interacting with HVEM. 
Interactions between the HVEM cysteine-rich domain (CRD)1 region on antigen presenting cells 
and melanoma cells with BTLA/CD160 on T cells inhibits T cell activation and might also lead to 
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their functional impairment within the TME. HSV gD  binds its N-terminus loop to the CRD1 and 
CRD2 regions of HVEM that overlap with the BTLA binding site; gD has higher binding affinity, 
therefore blocking HVEM-BTLA interaction (261,276,366) (Figure 5-1).  
CRD1
CRD2
CRD3
CRD4
N terminus
N terminus
N terminus
N terminus
C terminus
C terminus
C terminus
C terminus
HVEM HVEM
HSV1 gD
BTLA
ba
BTLA
BTLA
HSV1 gD LIGHT
HVEM
Germinal centre
Structures located in 
peripheral lymphoid tissues 
such as the spleen. They 
are sites of B-cell proliferation 
and selection of clones that 
produce antigen-specific 
antibodies of higher affinity.
LIGHT was originally described to be transiently 
induced to high levels in T cells following activa-
tion10,28–30. LIGHT is also highly expressed by immature 
DCs, but is downregulated on maturation with LPS or 
CD40 (REF. 31). B cells do not seem to express LIGHT 
in vivo. However, stimulation of B cells with LIGHT and 
CD40L together can synergize to induce the expression 
of LIGHT on B cells4,21,32 (FIG. 3).
Naive T cells express high levels of HVEM, but 
expression decreases during activation, with high levels 
being re-expressed at the end of the activation phase21,28. 
Blocking the interaction of LIGHT with HVEM during 
T-cell activation using HVEM-specific antibodies or 
HVEM–Fc fusion proteins prevents HVEM downregu-
lation, indicating that interaction of LIGHT with HVEM 
can directly signal a decrease in HVEM expression33,34. 
However, sustained LIGHT expression by T cells might 
be insufficient for a continued decrease in HVEM expres-
sion, as mice transgenic for T-cell expression of human 
LIGHT maintain high levels of HVEM. But these results 
should be interpreted with caution, because the trans-
genic cells might not express enough LIGHT, or there 
might be a weaker affinity between the two molecules to 
downregulate HVEM35. Mouse B cells express low levels 
of HVEM, whereas naive and memory human B cells 
express high levels of HVEM32–34. HVEM expression by 
human B cells is reduced after stimulation with LIGHT, 
and is undetectable on germinal centre B cells32. Finally, 
HVEM expression on immature DCs is decreased follow-
ing engagement with exogenous LIGHT, with or without 
DC activation through CD40L29. So, in general, naive 
or resting cells seem to express high levels of HVEM, 
whereas activated cells are HVEMlow/null as a result of 
the direct interaction of LIGHT with HVEM. However, 
which cell types present LIGHT to these activated T cells, 
B cells and DCs in vivo is not clear (FIG. 3). 
Mechanisms of inhibitor receptor activity
As a receptor whose ligation provides an inhibitory signal 
for the T cell, BTLA joins two other inhibitory receptors 
expressed by T cells: CTLA4 and PD1. In contrast to the 
co-stimulatory receptors CD28 and ICOS, co-ligation of 
these inhibitory receptors with the TCR blocks T-cell pro-
liferation and effector function. The signalling pathways 
and the pattern of expression of these receptors differ, 
reflecting their role in T cells during different stages of 
the immune response. CTLA4 regulates naive T-cell acti-
vation, PD1 becomes expressed on activated T cells, and 
BTLA is expressed on both naive and activated T cells, 
potentially regulating all phases of T-cell activation. 
Mechanisms by which CTLA4 and PD1 inhibit T-cell 
activation. Despite considerable analysis, how ligation 
of CTLA4 inhibits T-cell activation has still not been 
entirely resolved, but probably involves both the seques-
tration of B7 molecules away from CD28, as well as the 
Figure 2 | Molecular modelling of herpesvirus-entry mediator and its ligands. a | Structural comparison of the 
herpesvirus-entry mediator (HVEM), herpes simplex virus type 1 glycoprotein D (HSV1 gD) and B- and T-lymphocyte 
attenuator (BTLA) complexes. Left panel shows a model of human HVEM bound to HSV1 gD. Right panel shows human 
HVEM bound to human BTLA. In both complexes, HVEM is represented as a space-filled model spanning cysteine-rich 
domains (CRDs) 1 to 3. Both HSV1 gD and BTLA use a structurally similar short β-strand to bind HVEM (yellow). Residues 
on HVEM that have atoms within 4 Å of the interface are coloured: red indicates contacts shared between HSV1 gD and 
BTLA, cyan denotes HSV1 gD-specific contacts, and magenta represents BTLA-specific contacts. Structural data taken 
from REFS 18,24. b | Model of HVEM complexes at the cell surface. LIGHT self-associates into a non-covalent homotrimer 
(yellow) similar to other tumour-necrosis factor (TNF) family members. How HVEM binds LIGHT is not known, but, by 
analogy with the structure of TNF receptor 1 when bound to TNFβ14, it is thought that LIGHT contacts HVEM (grey) 
primarily through an elongated surface that spans CRD2 and CRD3. The contact region on HVEM (red), which is shared 
between HSV1 gD and BTLA, is exposed in this model. The areas of HVEM’s surface that contact HSV1 gD or BTLA are 
colour coded as in part a. It remains to be determined whether BTLA interacts with HVEM in trans on an adjacent cell, 
or in cis on the same cell. C terminus, carboxy terminus; N terminus, amino terminus.
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Figure 5-1. Molecular modeling of HVEM and its binding with HSV1 gD or BTLA. (Left) Model of HVEM 
is shown binding to HSV1 gD or BTLA through its cysteine-rich domain. Red indicates contacts shared 
beween HSV1 gD and BTLA. (Right) Model of HVEM interacts with its ligands on cell surface. Fi ure is 
adapted from Murphy K.M., Nelson C.A. and Sedy JR. N ture immunology. 2006. 
 
       Although our labor tory has hown that v ccines expressing ntigens as fusion 
proteins within HSV gD can induce markedly enhanced antigen-specific T cell responses 
especially in aged mice (263) or tumor-bearing mice (244), whether adjuvanting a cancer vaccine 
with gD could affect T cell differ ntiatio  and fu ctions within the TME had not been studied. In 
my project, I fused eight CD8+T cell epitopes derived from four MAAs and four MAA-associated 
CD4+T cell epitopes within gD to d termin  whether blocking the BTLA/CD160-HVEM signaling 
during T cell priming could improve their antitumor functions within tumors.  
    I chose to design a lye itope cancer vaccine in order to reduce the chance of 
immune escape, as tumor cells are capable of evading the immune pressure exerted by vaccine-
induced immune re ponses due to the advantageo s growth of antigen-loss variants or non
targeted subpopulations. In designing the polyepitope vaccine, I used several strategies in order 
to enhance MAA-specific T cell respon es. For xampl , among the 8 MAA-derived CD8+T cell 
epitopes, 4 of them (mTrp-1455, mTrp-1481, mTrp-1522 and murine BrafV600E) bear amino acid 
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mutations at the MHC anchor positions. This allows for the induction of significantly higher 
frequencies of CD8+T cells that could recognize the original Trp-1 or Braf epitopes presented on 
B16 tumor cells. In addition, one epitope of human gp100 protein is included. This also facilitates 
the generation of more robust T cell responses against gp100 that could recognize mouse gp100. 
In addition, I included the mouse Ig k signal sequence at the 5’ end of the construct to facilitate 
processing of CTL epitopes in the endoplasmic reticulum (ER). The universal T helper cell 
epitope PARDE, which is highly immunogenic in C57BL/6 mouse, is incorporated to potentiate 
CD8+T cell responses. Moreover, I designed spacer sequences (Alanine and Tyrosine) between 
each CD4+ and CD8+ T cell epitope basing on the processing results generated by several 
softwares, i.e. IEBD analysis, PAPROC in silico prediction, Netchop 3.1, to ensure better 
processing and presentation of each epitope by proteasome and enzymes (i.e. ERAP1) within the 
ER.  
    The polyepitope constructs, termed Melapoly, with or without gD induce dominant 
CD8+T cell responses to the Trp-1455 epitope, the responses to other 7 epitopes are subdominant 
and develop with a delay. However, the gD adjuvanted vaccine only significantly enhances 
frequencies of functional CD8+T cells specific to the subdominant epitopes compared to those 
induced by AdC68-Melapoly vaccine alone starting at about 4 weeks after vaccination. This 
difference persists and becomes more significant at later time points (up until 26 weeks after 
vaccination as we monitored). In contrast, frequencies of functional Trp-1-specific CD8+T cells are 
similar between the two vaccine groups throughout the 26 weeks. It is well known that many of 
the immunogenic TAs are self-antigens, which means that high-avidity T cells against these 
antigens have undergone thymic clonal deletion and most TA-specific T cell populations available 
for priming in the body are of low avidity (367). Therefore the fact that gD adjuvant selectively 
benefit low avidity T cells make it a valuable candidate for cancer vaccines.  
     When estimating the efficacy of the gD adjuvanted vaccine in delaying tumor 
progression, I used the B16BrafV600E transplantable tumor model in both pre- and post-tumor 
challenge vaccination experiments. The gD adjuvanted vaccine yields significantly better tumor 
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protection compared to the non-gD vaccine in both systems, although it works more effectively if 
given prior to tumor challenge.  Importantly, we showed that when the vaccine is given 3 days 
after tumor challenge, the survival advantage generated by the gD adjuvanted vaccine is not 
solely linked to the magnitude of MAA-specific CD8+T cell responses. In mice with comparable 
frequencies of function+ MAA-specific CD8+T cells, those that received the gD adjuvanted vaccine 
show prolonged survival. Detailed analysis indicates that MAA-specific CD8+TILs elicited by the 
gD vaccine show significantly reduced expression of co-inhibitors,  i.e., PD-1, LAG-3 or 2B4 alone 
or in combinations, compared to those generated by the non-gD vector. As I showed that high 
expression of co-inhibitors corresponds with weaker functions, specifically reduced cytokine 
secretion and lower T-bet levels in MAA-specific CD8+TILs, the reduced expression of co-
inhibitors on gD-adjuvanted vector induced CD8+TILs suggests their improved functional profile, 
although this was not measured directly. How blocking BTLA-HVEM interactions during T cell 
activation affects their differentiation and functional performance within the TME is still unknown. I 
assume that suppressing the immunoinhibitory BTLA-HVEM pathway during MAA-specific T cell 
priming by HSV gD boosts their activation status, which makes them more resistant to functional 
impairments within the TME. However the precise mechanism is not well studied and is an area 
that should be investigated further. It will also be interesting to study whether blocking other 
immunoinhibitory signaling during T cell priming or activation will further enhance the TILs 
antitumor activities.  
 
II. Depleting immunosuppressive FAP+ tumor stroma:  
    To explore other approaches that could further diminish the functional impairment of 
vaccine-induced TA-specific CD8+TILs, I constructed the tumor stroma targeting AdC68-mFAP 
vaccine that depletes the FAP+ tumor stroma cells in solid tumors and combined it with the tumor 
cell targeting AdC68-gDMelapoly vaccine. The combination strategy strongly delays melanoma 
progression as I demonstrated in two tumor models, the transplantable B16BrafV600E  tumors and 
the clinically more relevant inducible tumor model with transgenic Tyr::CreER BrafCA/+Ptenlox/lox 
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mice. The latter mice develop metastatic melanoma within 7-10 days upon applying 4-
hydorxytamoxifen to the skin, and the mechanism of melanoma development in these mice 
closely mimicked the disease progression in patients with metastatic melanoma. FAP+ cell 
staining in tumors show that most FAP+ cells are CD45 negative with high expression of 
mesenchymal stromal cell markers CD90 and Sca-1. Although the inducible BrafCA/+Ptenlox/lox 
tumors contain significantly more FAP+ cells compared to those in B16 BrafV600E tumors, the FAP+ 
targeting vaccine works equally well in both tumor models in terms of delaying tumor growth 
compared to the groups of mice that received only the control AdC68-gD vector. This is 
associated with CD8+T cell mediated depletion of FAP+ stromal cells in both tumor models. 
Moreover, adding the FAP vaccine to the tumor cell targeting gDMelapoly vector further reduces 
the abundance of FAP+ stromal cells compared to those of mice received the FAP vaccine or 
gDMelapoly vaccine alone, which also translates into further delay in tumor growth.  
    The strong correlation between reduced FAP+ stroma cell numbers and delayed tumor 
growth confirms that FAP+ tumor stromal fibroblasts support tumor growth. Indeed, my studies in 
both tumor models suggest that depleting FAP+ cells reduces the number of Gr-1hi and Gr-1int 
MDSCs in the TME, this effect is more dramatic when the FAP vector is given together with the 
gDMelapoly vector. Furthermore, MDSCs and TAMs from tumors of mice that received the 
combination treatment show reduced immunosuppressive functions in terms of iNOS and Arg1 
production compared to those from mice that received only the tumor cell targeting vaccine. 
Further analysis suggests that this is associated with reduced presence of immune inflammatory 
and inhibitory cytokines IL-4, IL-10, TGF-β, as well as certain chemokines such as CCL5 and 
CCL22 in the TME and diminished pSTAT6 signaling in MDSCs and TAMs. Although I did not 
analyze the direct cause of reduced frequencies and suppressive functions and MDSCs/TAMs in 
tumors upon FAP+ stromal cell depletion, my data strongly suggest that depleting FAP+ cells 
alters the cytokine/chemokine milieu within the TME. As IL-4 and IL-13 are the main upstream 
cytokines that activate the JAK-STA6 pathway, the decreased levels of IL-4 in the tumor may be 
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one of the key factors that reduce pSTAT6 signaling in ISCs and thereby blunt their suppressive 
functions.  
     My data also for the first time indicate that the presence of ISCs enhances 
mitochondrial metabolic stress and co-inhibitor PD-1 expression on activated CD8+T cells in vitro. 
Depleting FAP+ cell in vivo also reduces the metabolic stress and PD-1 expression of MAA-
specific CD8+TILs and enhances their frequencies and polyfunctions. It is tempting to speculate 
that FAP+ cell depletion lifts the metabolic stress of CD8+TILs partially through reducing the 
abundance of ISCs within tumors. It will be interesting to study the mechanism of how ISCs 
potentiate the metabolic stress of CD8+T cells in vitro or in the TME. It is possible that ISCs 
compete with effector T cells for key nutrients, i.e. glucose and glutamine that are essential for 
their energy demand. Within tumors the presence of stromal cells, which could recruit other 
inflammatory cells and endothelial cells, may further increase competition for nutrients and create 
a more metabolically challenging environment for the tumor-infiltrating effector T cells. Moreover, 
my data indicate a strong correlation between enhanced MROS levels with increased PD-1 
expression on activated CD8+T cells in vitro and in the TME. As upregulation of co-inhibitor PD-1 
usually signals T cell functional impairment in advanced tumors, it is important to understand 
whether enhanced metabolic stress could directly upregulate PD-1 expression. My studies of T 
cell metabolism in the TME described in chapter 4 show that lack of Glu, which enhance 
mitochondrial OXPHOS and reduces glycolysis for energy production by activated CD8+T cells, 
increases MROS accumulation and co-inhibitor PD-1 expression in/on these cells. Whether FAP+ 
stroma cells exert such effect on CD8+TILs directly or indirectly through ISCs is still an issue that 
requires further investigation.  
      Compared to vaccines targeting tumor antigens for destruction, the FAP vaccine has 
broader applicability as FAP protein is universally expressed on fibroblasts in many types of 
cancers. In addition, the abundance of FAP+ stromal fibroblasts differs by cancer type, i.e. 
pancreatic cancer and colon cancer may possess more FAP+ stromal cells than melanoma 
(122,368,369). In the future it will be important to assess the efficacy of the FAP vaccine in 
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delaying tumor progression in other types of cancer, either by itself or in combination with tumor-
cell targeting vaccines.  
 
III. Manipulating the metabolism of CD8+TILs: 
     To determine the factors that contribute to the functional impairment of vaccine-
induced T cells within the TME, I vaccinated B16-tumor bearing mice with both AdC68-
gDMelapoly and AdC68-gDE7 vectors, which induce both MAA- and E7-specific CD8+T cells. T 
cells of the latter specificity do not recognize antigens within the TME; therefore I could ask the 
question whether constant antigen stimulation is required for the ‘functional exhaustion’ of 
activated CD8+TILs. Interestingly my data show that even without exposure to their cognate 
antigens, E7 T cells enhance co-inhibitors PD-1 and LAG-3 expression and lose function within 
tumor during tumor progression, which is very, similar to the changes I observed with MAA-
specific T cells. These data strongly factors other than chronic antigen stimulation within the TME 
profoundly affect the functions of activated TILs.  
     It is becoming increasingly clear that the metabolic status of immune cells has an 
important impact on their differentiation and functions. My preliminary data show that compared to 
small 2-week tumors, more advanced tumors contain significantly low levels of glucose and 
oxygen, which I hypothesize could impair the energy production of activated CD8+TILs through 
both glycolysis and mitochondrial OXPHOS and enhance their metabolic stress. Indeed, analysis 
of mitochondrial metabolic markers suggests that both MAA- and E7-specific CD8+TILs in 1-
month tumors possess much lower mitochondrial membrane potential (MMP). In addition they 
show strong accumulation of mitochondrial reactive oxygen species (MROS), a toxic OXPHOS 
by-product, compared to those in 2-week small tumors. Together these data suggest that both 
vaccine-induced T cell subsets develop mitochondrial dysfunctions within metabolically 
challenging TME, which may affect their effector functions and antitumor activity.  
    Therefore I studied the impact of hypoxia and glucose limitation on activated CD8+T 
cell metabolism and functions both in vitro and directly ex vivo. My data suggest that hypoxia 
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through HIF-1α signaling pathway impairs effector functions of activated CD8+T cells and directly 
drives co-inhibitor LAG-3 upregulation both in vitro and in the TME. My results also imply that 
promoting glycolysis of CD8+TILs, i.e. such as through hypoxia-induced HIF-1α signaling within a 
Glu-depleted TME is detrimental to their functions. However these data are in conflict with some 
published studies, which showed that HIF-1α increases the effector functions of CD8+T cells 
using Von Hippel-Lindau (VHL) or Prolyl Hydroxylase Domain (PHD) Knockout (KO) cells or mice 
(187). VHL and PHD are O2-sensing enzymes that target HIF for degradation under normoxia. 
VHL or PHD KO cells possess stabilized HIF-1α expression from the onset of CD8+T cell priming 
and activation, which is clearly different from my system where tumor-infiltrating CD8+T cells 
experience hypoxia and enhance HIF-1α signaling after their activation in the O2-replete 
periphery lymph nodes. Therefore I suspect that the enhanced HIF-1α activity from the onset of T 
cell activation may affect other signaling pathways in these cells and modulate their effector 
functions through different mechanisms, which could explain the discrepancy between their data 
and my finding of the function-dampening effect of hypoxia-induced HIF1α within the TME.  
      To study the effect of Glu deprivation on CD8+T cells, I stimulated enriched CD8+T 
cells in vitro in medium supplemented with 2-DG or Galactose (Gal) instead of Glu. Both 
conditions force the activated CD8+T cells to rely more on the mitochondrial OXPHOS pathway 
for energy production. This in turn leads to significantly increased co-inhibitor PD-1 expression on 
these T cells. Interestingly, my data show that although hypoxia by itself reduced PD-1 levels on 
activated CD8+T cells, lack of Glu combined with hypoxia still significantly enhances PD-1 
compared to cells cultured with Glu under normoxia, which may explain why in the TME 
CD8+TILs show upregulated PD-1. Moreover, I observed that although lack of Glu impairs 
functions of CD8+T cells under either normoxic or hypoxic condition, the reduction in functions are 
less significant when cells are cultured under hypoxia with limited Glu compared to those cultured 
under hypoxia with ample supplies of Glu.  Cells actually improve their capacity to produce more 
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than one factor with restricted Glu and O2 supply, suggesting that the loss of effector functions 
can be more easily compensated for under Glu and O2-limited condition.  
Indeed, further metabolic studies confirm that activated CD8+T cells cultured with limited 
access to Glu show increased fatty acid (FA) uptake, triacylglyceride (TAG) turnover and FA 
catabolism including fatty acid oxidation (FAO) and ketone bodies metabolism. This metabolic 
preference is further exacerbated when cells also have limited access to oxygen. My study for the 
first time confirms this metabolic switch of CD8+TILs using 13C-labled Glu and FA stable isotope 
tracing directly in vivo followed by LC-MS based metabolomics analysis. As my data show the 
TME of 1-month advanced tumors contain abundant free FAs of various species. Utilizing FA 
catabolism for energy production could provide CD8+TILs with a survival advantage and may 
protect them from severe and rapid functional loss.  
    As CD8+TILs in advanced tumors increase PD-1 expression, it is important to 
understand whether the metabolic switch to FA catabolism requires the presence of PD-1. If so 
anti-PD-1 treatment would provide a disadvantage for metabolically stressed CD8+TILs, which is 
counterintuitive as this treatment reduces tumor progression. I studied this by treating tumor-
bearing mice that had received the AdC68-gDMelapoly vaccine 10 days earlier with anti-PD-1 or 
isotype antibody every two days until one month after tumor challenge. In vivo 13C-glucose and 
13C-palmitic acid isotope-tracing studies reveal that blocking PD-1 signaling has only subtle effect 
on metabolism of activated CD8+T cells in spleen and tumors. Furthermore, in the two groups of 
mice with similar sized tumors, blocking PD-1 signaling fails to affect the effector functions of 
CD8+TILs. PD-1 blockade delays B16 tumor growth in both vaccinated and unvaccinated 
C57BL/6 mice, the later of which posses very few tumor-infiltrating lymphocytes. Moreover in 
NSG mice that lack T, B and NK cells, PD-1 blockade still strongly delays tumor progression, 
suggesting that this checkpoint inhibitor could exert its antitumor effect independent of T cells. 
These results are consistent with other studies, which show that a portion of B16 tumors express 
PD-1. Blocking PD-1 expressed on tumor cells from interacting with PD-L1 expressed on stromal 
cells or tumor cells reduces the activity of mTOR/pS6 signaling in tumor cells and inhibits 
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tumorigenesis (341), potentially by inhibiting the Glu metabolism in these cells. My preliminary 
studies show that the B16 tumor cells isolated from tumor-bearing mice express very low levels of 
PD-1. Anti-PD-1 treatment actually increases the rate of Glu metabolism in tumor cells, implying 
that it is unlikely that PD-1 blockade delays tumor growth directly through inhibiting the PD-1 
signaling in these cells. In contrast, my study shows that tumor cells as well as ISCs and tumor 
stromal cells show high levels of PD-L1 expression. As anti-PD-1 antibody has been shown to 
back signal through PD-1-PD-L1 interaction to induce the apoptosis of tumor cells, I predict that in 
our system anti-PD-1 treatment may work through PD-L1 expressed on tumor cells or other cells 
in the TME to enhance their death rate, therefore increases the glucose supply within the tumor 
and delays tumor growth. Compared to tumor cells, ISCs and tumor stromal cells also show 
higher levels of PD-1 expression. It is also possible that anti-PD-1 delays tumor progression 
through inhibiting the tumorigenic potential of these cells within the TME.  My preliminary data 
suggest that in vaccinated tumor-bearing mice, those treated with anti-PD-1 show increased total 
and MAA-specific CD8+T cell infiltration into the tumor, indicating that anti-PD-1 may also delay 
tumor growth through increasing the number of tumor-specific T cells within the TME.  
    Finally, I boosted the FA catabolism capacity of activated CD8+T cells in the TME 
using the PPARα agonist fenofibrate prior to T cell adoptive transfer. As expected, CD8+TILs with 
enhanced FA catabolism show far better effector functions in terms of cytokine and lytic enzymes 
production. In addition their ability to delay tumor growth improves. Interestingly fenofibrate-
treated cells show a trend towards enhanced PD-1 expression. To study the relation between PD-
1 and functions in fenofibrate-treated CD8+T cells upon adoptive transfer, I treated recipient mice 
that received either diluent- or fenofibrate-treated CD8+T cells with anti-PD-1 or the isotype 
control starting at five days post adoptive transfer. In mice received isotype antibodies, those that 
received fenofibrate-treated cells show markedly slower tumor progression compared to those 
transferred with diluent-treated cells. In mice received either group of T cells, anti-PD-1 treatment 
strongly delayed tumor growth. Importantly, anti-PD-1 and fenofibrate treatment work in synergy 
and the mice received both treatments show markedly strong delay in tumor growth, with more 
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than 30% of mice completely protected. My data show that PD-1 blockade does not affect effector 
functions of MAA-specific CD8+T cells originated from either diluent- or fenofibrate-treated donor 
mice, which is consistent with the result that anti-PD-1 works in a T cell independent manner. 
Therefore, my study suggest that PD-1 checkpoint inhibitor, which works through tumor cells or 
other cells within the TME, could strongly improve the efficacy of cancer immunotherapy if it is 
given together with metabolic manipulation that optimize the nutrient consumption capacity of 
tumor-specific CD8+T cells.  
My data show that promoting FA catabolism by CD8+TILs cells improves their antitumor 
efficacy. This could be applied to several types of cancer immunotherapy such as adoptive 
transfer of ex vivo expanded TILs or CAR-T cells. It could also be used as an adjuvant for cancer 
vaccines or checkpoint inhibitors. Clearly additional studies are needed to confirm that increasing 
FA catabolism of TILs not only benefits individuals with melanomas but also other types of solid 
cancer, and even more importantly if my results in mouse models apply to human cancer patients. 
 
Below, I list several research questions that are worth pursuing in the future.  
1. Metabolic intervention of T cells for cancer immunotherapy  
a. To determine whether different diets affect nutrients supply (glucose, FAs, glutamine etc.) 
and T cell metabolism within the TME. If so, whether the metabolic changes affect T cell 
functions. This study may provide dietary guidelines for cancer patients, which can help 
improve the efficacy of their cancer immunotherapy.  
b. To study if metabolizing different types of lipids will affect differentiation and effector 
functions of T cells. If some lipid species that are abundant in tumor could promote T cell 
functions, one could design novel strategies to enhance the uptake/usage of this lipid by T 
cells and determine whether antitumor T cell efficacy can be improved.  
c. Exploring novel approaches to promote T cell lipid catabolism prior to their adoptive 
transfer. In my study fenofibrate, a PPAR-α agonist is used. However, more efficient 
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methods, i.e. overexpression of lipid uptake receptor or lipid catabolism enzymes may 
further improve the lipid catabolism, and therefore antitumor functions of CD8+TILs. 
 
2.  Combining other therapeutic approaches with metabolic intervention 
  a.    Checkpoint inhibitors have made significant progresses in recent years. I propose to study 
the effect of each promising checkpoint inhibitor on the metabolism of TA-specific TILs, as 
pushing the metabolism of TILs towards the same direction using other methods may 
achieve similar or even better antitumor efficacy. In addition, I would like to determine 
whether combining different checkpoint inhibitors with metabolic intervention strategies 
could further improve the therapeutic efficacy. And if so, it will be important to understand 
the underlying mechanism.  
   b.  My study has implicated that both tumor stroma and ISCs enhance the metabolic stress of 
active T cells. I would like to further understand how presence of tumor stroma or ICSs 
reprograms the metabolism of TA-specific TILs, and study the combination effect of tumor 
stroma/ISCs depletion with T cell metabolic intervention strategies on tumor growth. 
 
3. Study Immunometabolism of other types of immune cells in TME 
         Besides T cells, metabolic challenges within the TME could potentially affect other immune 
cell populations. Specifically, It is important to understand how metabolism and 
immunosuppressive functions of ISCs are affected in solid tumors. It will be worthwhile to 
study if manipulating the metabolism of ICSs will affect their functions, and exploring new 
metabolic intervention pathways to reduce the inhibitory capacity of ISCs.  
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